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ABSTRACT
Unlike many nicotinic subunits, the a l  nicotinic subunit and the 5-HT3A subunit are 
able to form functional homomeric receptors. Despite sharing this ability, they have 
differences in cell-surface expression in human embryonic kidney (HEK) cells, with 
5HT3A subunits forming a large number of functional receptors, whereas the a l  
subunit forms few or no correctly folded receptors as assayed by radioligand binding 
with [125I]a-BTX. A series of chimeras between a l  and 5HT3A were constructed to 
investigate which domains of the subunits were important for folding and cell 
surface expression. Only chimeras that contained the region from the beginning of 
Ml to the end of M3, and M4 domain of the 5HT3A subunit were able to form 
correctly folded receptors.
The chimeras that gave high levels of radioligand binding were also found to be 
functional using whole-cell patch-clamp recording. Functional characteristics were 
examined, and differences were found in single channel conductance and 
desensitization. Chimeras with the large cytoplasmic loop and the extracellular N- 
terminal region of a l  had larger single channel conductances than the 5HT3A 
receptor, with the inclusion of the a l  large cytoplasmic loop and the N-terminal 
domain increasing the conductance by approximately 10 and 2 fold respectively
Co-expression of a l  with RIC3 (a protein originally identified in C. elegans) in 
HEK cells, results in high levels of cell surface expression. These receptors were 
shown to be functional, with whole cell responses from 20-300 pA. showing fast 
desensitization (time constant of 66±13 ms) and strong inward rectification. RIC3 
was also shown to increase the functional expression of the a8 and the rat a3|32 
nAChRs, which rarely formed detectable functional receptors when expressed alone. 
On co-expression with RIC3 almost all cells expressing a8  responded giving an 
average response of 240 pA, and all cells expressing a3|32 responded giving an 
average response of 99 pA. C. elegans RIC3 has been shown to increase the 
functional expression of the human 5HT3A receptor by 168 %. Human RIC3 had no 
effect on human 5HT3A and in fact decreased the functional expression of the murine 
5HT3A by 59 %.
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CHAPTER 1 
INTRODUCTION
16
1.1 Neurotransmitter receptors
The nicotinic ACh receptors and the 5-hydroxy try ptamine type 3 receptors are the 
focus of this thesis. These two neurotransmitter receptor classes are both ligand- 
gated ion channels. When ligand-gated ion channels are activated by an agonist or 
drug, an ion-permeable transmembrane channel opens, thus transferring a signal 
from outside the cell to within the cell. Nicotinic acetylcholine receptors (nAChRs) 
and 5-hydroxy try ptamine type 3 receptors (5-HT3RS) are oligomeric proteins with 
five membrane-spanning subunits and a conserved cysteine loop in the N-terminal 
extracellular region formed from a disulphide bond between two cysteine residues, at 
positions 126 and 142 for the a  7 nAChR subunit and at 138 and 153 in the 5-HT3A 
subunit. Analysis of the gene sequences of these receptors and others sharing these 
characteristics has shown that they have a common evolutionary ancestor, and thus 
are all part of a large gene super-family (Ortells and Lunt, 1995). The first ligand- 
gated ion channel from this family to be biochemically isolated and studied 
extensively was the Torpedo nAChR (Changeaux et al., 1970). Subsequently, many 
more members of this family have been identified, for example the gamma- 
aminobutyric acid receptors GABAaR and GABAcR, and glycine receptors in 
vertebrates, and 10 nAChRs in Drosophila over 40 nAChRs in C. elegans.
1.1.1 The nicotinic acetylcholine receptors (nAChRs):
There are two types of AChRs, named nicotinic and muscarinic. Nicotinic AChRs 
are ligand-gated ion channels, whereas muscarinic AChRs are G-protein coupled 
receptors. These two types of AChRs were originally distinguished 
pharmacologically by their sensitivity to nicotine (isolated from the tobacco plant) 
and muscarine (isolated from the poisonous mushroom Amanita muscaria) (Dale, 
1914).
1.1.1.1 A short history of Torpedo nAChR
As mentioned above, the first well-characterised ligand-gated ion channel was the 
acetylcholine- (ACh) activated cationic channel protein from the electric organ of the 
ray. (La Torre et al., 1970, Changeux et al, 1970). The electric organs of two 
species of ray, Torpedo {californica and marmorata) and the electric eel 
Electrophorus electricus, contain a very high density of nAChRs that have been
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shown to resemble the nAChR at the neuromuscular junction (Sealock et al., 1982). 
A snake toxin a-bungarotoxin (a-BTX), that was shown to bind and inactivate the 
Torpedo nAChR almost irreversibly (Lee and Chang, 1966), has been used to purify 
large quantities of the Torpedo nAChR protein (Changeux et al., 1970; Miledi et al., 
1971).
The purified Torpedo electric organ receptor has been shown to be made up of four 
different proteins, of molecular weights 40, 48, 62 and 60 kDa (Hucho et al., 1976) 
named a, p, y and 6 respectively. The total molecular weight of the assembled 
nAChR is approximately 250 kDa (Reynolds and Karlin, 1978). The receptor was 
proposed to be pentameric, containing two a, and then one of each of the p, y and 6 
subunits as there appeared to be more a  subunit protein compared to the other 
subunits when separated by electrophoresis (Hucho et al., 1976). Functional 
characterisation of the Torpedo electric organ nAChR was achieved by reconstitution 
of the four subunit proteins in planar lipid bilayers (Labarca et al., 1984) and also by 
injection of the four subunit mRNAs into Xenopus oocytes (Sumikawa et al., 1981, 
Barnard et al., 1982). It was shown properties of this receptor were different to the 
native ACh-activated receptors in oocytes (Kusano et al., 1977), which are 
muscarinic AChRs.
Torpedo nAChR a , p, y and 6 subunits were the first ligand-gated ion channel 
subunits to be cloned (Noda et al., 1982, Claudio et al, 1983, Noda et al., 1983a). 
The nAChR subunits expressed at the neuromuscular junction and in the central 
nervous system of vertebrates and invertebrates have now also been identified and 
cloned. The Torpedo nAChR is still used as a model nAChR, for example 
ultrastructural studies have given us insight into the three-dimensional structure of 
the nAChR at very high resolution (4 A; Unwin et al., 2003). This has not been 
possible for other nAChRs, due to the absence of suitably pure source of receptors.
1.1.1.2 Vertebrate neuromuscular nAChRs
It was known from the 1940s that there were receptors at the skeletal neuromuscular 
junction that responded to ACh (Fatt, 1949). The cDNA sequences of Torpedo 
nAChR subunits were used to isolate homologous proteins in muscle. Mammalian
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a , p, y and 6 were identified (Noda et al., 1983a; Lapolla et al., 1984, Nef et al., 
1984, Tanabe et al., 1984) and a novel subunit was cloned (e) that exhibited close 
sequence similarity to the y subunit (Takai et al., 1985). The 8 subunit and was 
shown to be expressed predominately in the adult form of the vertebrate 
neuromuscular nAChR, whilst the y subunit is only expressed in the foetal form 
(Mishina et al., 1986). These two forms of the muscle nAChR have different 
functional characteristics including greater single channel conductance, greater 
calcium permeability and faster desensitization in receptors containing the 8 subunit 
(Mishina et al, 1986; Villarroel and Sakmann, 1996) thus there is a developmental 
switch that changes the functional characteristics of the muscle nAChR. The muscle 
nAChR was thought to resemble the Torpedo receptor, also having a pentameric 
subunit structure (Sealock et al., 1982).
1.1.1.3 Vertebrate neuronal nAChRs
Nicotinic AChRs are present throughout the central and peripheral nervous systems, 
as demonstrated by nicotine and a-BTX binding (Clarke, 1985; McGehee and Role, 
1995). However, these nAChR are not a homogeneous group of receptors as at the 
neuromuscular junction. It has been shown that the nAChRs activated in 
sympathetic neurones do not bind to a-BTX (Patrick and Stallcup, 1977), and are not 
blocked by a-BTX (Carbonetto et al., 1978). Thus, it was demonstrated that there 
was more than one subtype of nAChR in the nervous system, with some nicotinic 
receptors that, unlike the muscle nAChR, do not bind a-BTX. In fact it has since 
been demonstrated that there is much greater diversity of nAChR subtypes (Sargent,
1993).
Molecular cloning has identified 12 vertebrate neuronal nicotinic subunits (Boulter et 
al., 1985; Boulter et al., 1987; Deneris et al., 1988; Deneris et al., 1989; Wada et al., 
1988; Boulter et al., 1990; Couturier et al. 1990a; Elgoyhen et al., 1994; Elgoyhen et 
al., 2001), and these have been divided into two categories, a  and “non-a” (Boulter 
et al., 1987). The a8  subunit has been identified in chick (Schoepfer et al., 1990), 
but not in any other vertebrates. Subunits are classified as a  subunits by the 
presence of an adjacent pair of cysteine residues in the extracellular amino- (N-) 
terminus, equivalent to Cys192 and Cys193 of the Torpedo nAChR a  subunit. These
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cysteine residues form a disulphide bond and are thought to contribute to the ligand- 
binding domain of the Torpedo nAChR, shown by labelling with a tritiated nicotinic 
ligand (Kao et al., 1984; Kao and Karlin, 1986). The neuronal p subunits do not 
show particular sequence similarity with muscle p subunit compared to the y or 6 , 
and have been referred to as “structural” subunits (Schoepfer et al., 1988), although 
the neuronal p2 and p4 subunits contribute some residues to the ligand binding site 
(Parker et al., 1998, Wang et al., 1998).
1.1.2 5-hydroxytryptamine type 3 receptors (5-HT3Rs)
There are a number of different subtypes of the 5-hydroxy try ptamine receptors (5- 
HT1-7R), however, most of the 5-HT receptor subtypes are G-protein coupled 
receptors and are not discussed in this thesis.
The 5-HT type 3 receptors (5-HT3RS), like the nAChRs, are excitatory cation- 
selective ligand-gated ion channels (Derkach et al., 1989). The 5-HT3A subunit was 
cloned from NCB-20 cells (a murine/hamster hybrid brain cell line; Maricq et al., 
1991). This subunit is able to generate functional homomeric receptors when 
expressed in Xenopus oocytes. A homologous subunit has been cloned in a number 
of other species including rat (Johnson and Heinemann, 1992), human (Belelli et al., 
1995) and guinea pig (Lankiewicz et al., 1998). There is some diversity in 5-HT3R 
subunits generated through alternative splicing. The first cloned murine variant is 
now referred to as the long form, whereas an alternative splice variant (which lacks 6 
amino acids in the intracellular loop) is termed the “short” form (Hope et al., 1993). 
There is no significant difference in function of the short and long forms of the 
murine 5-HT3A receptor (Glitsch et al., 1996) and the only pharmacological 
differences are in the efficacy of 2-methyl-5-hydroxytryptamine (2-Me5-HT) and 
meta-chlorophenylbiguanide (mCPBG) (Niemeyer and Lummis, 1998) and the 
potency of ondansetron (Hope et al., 1993).
5-HT3A subunits, equivalent to the short splice variant identified in mouse, have been 
cloned in rat (Miquel et al., 1995; Isenberg et al., 1993), human (Belelli et al., 1995; 
Miyake et al., 1995) and guinea pig (Lankiewicz et al., 1998). Two additional splice 
variants of the human 5-HT3A subunit have also been identified, but are unable to
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form functional homomeric receptors (Brtiss et al., 2000). However, both the 
truncated splice variant and the long splice variant modify the function of the 
receptor when co-expressed with the short form (Briiss et al, 2000).
Although the 5-HT3A subunit is able to form recombinant homomeric receptors, this 
is not sufficient to explain the properties of some native 5-HT3R.S, even with 
incorporating the splice variants into the receptor (Hussy et al., 1994). More 
recently, additional 5-HT3R subunits have been cloned. The 5-HT3B subunit is 
unable to form functional homomeric receptors, however it can form heteromeric 
receptors with the 5-HT3A subunit (Davies et al., 1999b). This heteromeric receptor 
has different properties to the homomeric receptor (Dubin et al., 1999). The 5-HT3C 
subunit alters the functional response to 5-hydroxytrptamine (5-HT) when co­
expressed with the 5-HT3A subunit (Dubin et al., 2002). Other putative subunits 
have also been cloned (5-HT3D and 5-HT3E, Niesler et al., 2003), but have not been 
well characterized.
1.2 The Structure of nAChRs and 5-HT3Rs
The nAChR and 5-HT3R subunits share structural characteristics that are common to 
the members of the super-family of ligand-gated ion channels to which they belong. 
Both contain an N-terminal signal peptide, which is cleaved to form the mature 
protein. The subunits have a similar overall topology, with a large extracellular N- 
terminal domain, four putative transmembrane domains (M1-M4) and a short 
extracellular carboxy- (C-) terminal domain (Noda, 1983; Maricq et al., 1991), see 
Figure 1.1.
1.2.1 Primary amino-acid sequences and homology
Comparison of the nucleotide sequence of genes within this ligand-gated ion channel 
super-family suggests that all the members originated from a common ancestral gene 
(Ortells and Lunt, 1995), see Figure 1.2. All members of the super-family of ligand- 
gated ion channels, including the nAChR, 5-HT3R and GABAaR subunits, have two 
conserved cysteine residues in the N-terminal region, which forms an important 
disulphide bond. The protein sequence in the N-terminal forms the ligand-binding
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Transmembrane
domains
Ion channel pore
Extracellular
Intracellular
Figure 1.1 The predicted topology o f the nAChR and 5 -HT3R subunits, and 
pentameric structure o f the assembled receptor
(A), The subunits have a large extracellular N-termial domain which contains 
the ligand binding site, the main immunogenic region and sites for N- 
glycosylation. Following the N-terminal domain are four transmembrane (Ml- 
M4) domains and then a short extracellular C-terminal domain. There is a 
large hydrophilic cytoplamsic loop in between M3 and M4, and this contains a 
number of putitive sites for phosphorylation. (B), The receptors are formed of 
five subunits arranged around a central ion channel pore. Adapted from Millar, 
2003.
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Figure 1.2 Evolutionary tree o f the ligand-gated ion channel superfamily. 
Adapted from Ortells and Lunt, 1995. This evolutionary tree was constructed 
from the alignment of the amino acids of ligand-gated ion channels.
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domain and determines the agonist specificity (Eisele et al., 1993) and contains sites 
for asparagine-linked glycosylation (Nomoto et al., 1986; Quirk et al., 2004). The 
large M3-M4 cytoplasmic loop shows the least sequence similarity between 
subunits, and contains several potential sites of phosphorylation (Huganir and 
Greengard, 1990; Lankiewicz et al., 2000). A possible consequence of the 
variability of the large M3-M4 cytoplasmic loop is that intracellular interactions can 
be specific to certain subunits and receptors. This would allow receptors to be 
functionally modulated, trafficked and targeted selectively.
1.2.2 Arrangement and subunit stoichiometry: Pentameric receptors
The Torpedo nAChR contains four subunit proteins, a , p, y and 6 (Hucho et al., 
1976). These subunits form a pentameric receptor with the subunit stoichiometry of 
aya5|3 (Karlin et al., 1983, Pedersen and Cohen, 1990). This native receptor forms 
dimers in the Torpedo membranes that are cross-linked at the 6 subunits (Hamilton 
et al., 1979; DiPaola et al., 1989). The pentameric structure has been confirmed by 
high resolution electron microscopy (Brisson and Unwin, 1985), which showed five 
rod shaped subunits at 25 A resolution, and a pentameric transmembrane region at 
4A resolution (Miyazawa et al., 2003).
A soluble ACh binding protein (AChBP) has been isolated from snail glia and has 
24% sequence similarity with the a  7 subunit, and 20-24% sequence similarity with 
the other nicotinic subunits (Smit et al., 2001). The AChBP forms a soluble 
pentameric transmitter receptor that can suppress cholinergic transmission by 
binding to ACh. The AChBP has been demonstrated to also bind nicotine, d- 
tubocurarine and a-BTX (Brejc et al., 2001). The crystal structure of the AChBP has 
been determined at 2.7 A and shows structural similarity to the extracellular region 
of the Torpedo nAChRs (Brejc et al., 2001). This is a useful tool to predict more 
precisely the position of individual amino acids in the nAChRs and 5-HT3RS. 
Recently the structure of the Torpedo nAChR resolved at 4 A has been refined and 
the structure of the AChBP was compared to that of the a  subunit (Unwin, 2005).
The nAChR in murine skeletal muscle has a similar predicted topology to the 
Torpedo receptor (Sealock, 1982). Once homologous subunits (muscle a,p,y and 6)
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were cloned, sucrose gradient sedimentation showed muscle nAChR had a similar 
apparent molecular weight to the Torpedo receptor, implying that it assembled into a 
oligomer with five subunits. The y subunit is only expressed at high levels in 
embryonic muscle or following denervation. After birth the levels of y decrease and 
instead the homologous s is expressed a high levels selectively by the muscle cell 
nuclei located under the neuromuscular junction. The s subunit replaces the y subunit 
within the pentamer (Mishina et al., 1986).
There is evidence that neuronal nAChRs are also pentameric complexes. Expression 
of cx4p2 receptors containing reporter mutations has been used to estimate the 
number of subunits in each receptor (Cooper et al., 1991). This suggested that there 
were five subunits, and has been confirmed by metabolic labelling of methionine 
residues (Anand et a l,  1991). Elucidating which subunits make up neuronal AChRs 
is complex, as most cells express more that two subunits and evidence suggests that 
more that two subunits may co-assemble (see section 1.4). Two well studied 
heteromeric receptors contain a4  and p2 subunits (Boulter et al., 1987, Schoepfer et 
al., 1988) and a3 and p4 subunits (Duvoisin et a l,  1989; Parker et a l,  1998). These 
combinations are thought to have two a  subunits and three p subunits (Cooper et al., 
1991; Anand et a l, 1991; Boorman et a l, 2000), although other ratios have been 
proposed depending on the expression ratio of the two subunits (Zwart and 
Vijverberg, 1998, Nelson et a l, 2003). Some nAChR subunits are capable of 
forming homomeric receptors (e.g. a l ,  a9; Couturier et al., 1990a, Elgoyhen et a l,
1994) and it has been reported that homomeric a l  receptors have five binding sites 
for the ligand methylycaconitine (MLA) (Palma et a l,  1996a) implying a pentameric 
structure.
The 5-HT3A subunit can also form homomeric receptors (Maricq et a l, 1991). The 
molecular weight of the 5-HT3R is consistent with the receptor being made of up 
five of the 5-HT3A subunits. This receptor has more directly been shown have a 
pentameric structure using electron microscopy with receptors purified from NG1 OS- 
15 cells (Boess et al., 1995). Although the resolution was much lower than studies 
on the Torpedo nAChR, five densities of protein can be seen around a hollow pore. 
The stoichiometry of the heteromeric 5-HT3R is as yet unknown.
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1.2.3 The ligand-binding domain
1.2.3.1 The nAChRs ligand-binding domain
The ligand-binding domain in Torpedo and muscle nAChR has been shown to be at 
two non-equivalent sites (Neubig et al, 1979, Prince and Sine, 1996), and is located 
between the a  and non-a subunits (Pederson and Cohen, 1990, Galzi et a l,  1991, 
Taylor et al. ,2000). The subunit pairs, ay and a 6 , form an a-BTX binding site 
(Kurosaki et al., 1987). Residues from both the a  (Kao et al., 1984, Kao and Karlin, 
1986, Galzi et a l, 1990) and the 8/y subunits (Czajkowski et a l,  1993, Sine, 1993, 
Martin et al., 1996) contribute to the binding site. Electron microscopy of the 
Torpedo nAChRs at 4 A has demonstrated the presence of two cavities in the 
extracellular region that are proposed to form the ligand binding sites (Unwin, 2005).
It has been suggested that heteromeric neuronal receptors contain two a  subunits and 
three (3 subunits ((X2P3) (Cooper et a l, 1991; Anand et a l,  1991; Boorman et a l, 
2000), and would therefore be expected to contain two binding sites, similar to the 
muscle and Torpedo nAChRs. The different affinities of nicotinic ligands observed 
with the a5  verses ay ligand binding sites is similar to that seen with a4|32 versus 
a4(34 binding sites (Parker et al., 1998). Thus the diversity of neuronal nAChR 
subunits means that heterogeneous populations of receptors with varying affinities 
for agonist and antagonists, and varying functional properties, can occur within the 
nervous system. Homomeric nAChRs would be expected to have five ligand 
binding sites, with the same subunit contributing the principal and complimentary 
components (Corringer et al., 2000). It has been reported that recovery of the 
homomeric a l  nAChR from MLA inhibition is best fitted with a five binding site 
model (Palma et a l,  1996). In functional experiments, the Hill coefficient in 
obtained for homomeric receptors {a l or a chimeric receptor) from concentration- 
response curves is usually approximately 2 (Corringer et a l,  1995; Servent et a l,
1997), which implies that activation of the receptor may only require agonist binding 
to two sites within the receptor.
Important amino acids on the principal and complimentary components that are 
involved in binding nicotinic ligands have been identified on the Torpedo nAChR by 
affinity labelling and site directed mutagenesis. These have then been modelled into
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Figure 1.3 Model of the nAChR ligand binding domain.
The pentameric complex of subunits is shown, with two a  and three (3 subunits 
around the central pore. The two binding sites are shown at two a/|3 interfaces. 
The schematic of this interface is enlarged and shows the six loops of amino 
acids that form the ligand binding site. The priciple component of the binding 
site comes from the a  subunit (loops A-C) and the complimentary component 
from the p subunit (loops E and F). Adapted from Iter and Bertrand, 2001
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six loops of amino acids (Corringer et al., 2000), with loops A-C from the a  subunit 
and loops D-F from the 6, ory subunit (Figure 1.3). The residues on the a  subunit 
include Trp86 and Tyr93 in loop A, Trp149 in loop B and Cys192, Cys193 Tyr190 and 
Tyr198 in loop C (Galzi and Changeux, 1995). The residues identified in the a  
subunit are present in the a2, a3, a4, a6, a l  and a8  subunits. The a5 subunit lacks 
conserved tyrosine residues, from loops A and C (Boulter et al., 1990, Couturier et 
al., 1990b), and may actually be a structural non-a subunit (Ramirez-Latorre et al., 
1996, Wang et al., 1996, Kuryatov et al., 2000). The residues on the y or 6 subunits 
include Trp55 ad Trp57 in loop D, Tyr111 and Arg113 in loop E and Asp180 in loop F 
(Chiara et al., 1998; Chiara et al., 1999; Martin et al., 1996). The residues in the D 
loop are conserved in |32, p4, a l  and a8 subunits (Corringer et al., 2000). Mutations 
of residues homologous to those in the six loops show significant changes in the 
apparent affinity of nicotinic agonists and competitive antagonists (Corringer et al., 
2000).
1.2.3.2 The 5 -HT3R ligand-binding domain
The extracellular N-terminal region of the 5-HT3A subunit has been demonstrated to 
contain the ligand-binding domain (Eisele et al., 1993). The ligand-binding domain 
has been proposed to be similar to that of the nAChRs, and residues important for 
serotonergic agonist binding have been predicted on the basis of the known structure 
of the AChBP (described in Section 1.2.2) (Reeves et al., 2003). The residues are 
proposed to be organised in domains equivalent to the loops A-F of the nAChRs 
(Reeves and Lummis, 2002).
Site-directed mutagenesis has been performed on residues in the 5-HT3A subunit 
predicted to be important for ligand binding (Reeves and Lummis, 2002). In loop A,
• 1 TO 1mutation of Glu and Phe altered the binding characteristics of the receptor 
(Boess et al., 1997; Steward et al., 2000). Additionally mutation of Trp121 and Pro123 
resulted in receptors that showed no ligand binding (Spier and Lummis, 2000; Deane 
and Lummis, 2001). In loop B, mutation of Trp183 altered the potency of agonists 
(Spier and Lummis, 2000). The region in 5-HT3A subunit equivalent to the C loop is 
involved in the binding of the serotonergic agonist m-chlorophenylbiguanide 
(mCPBG) (Mochizuki et al., 1999). In loop D, mutation of Trp90, Arg92 and Tyr94
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affect ligand binding (Yan et al., 1999). Finally, in loop E, Tyr141, Tyr143 and Tyr153 
are also involved in ligand binding. The similarity of the 5-HT3A ligand-binding 
domain is illustrated by the mutation of Phe130 to Asn (the equivalent residue in 
Torpedo a  nAChR subunit), which results in a receptor that is activated by ACh 
(Steward et al., 2000).
1.2.4 The channel domain
1.2.4.1 The nAChR ion channel
The nAChRs are permeable to both monovalent and divalent cations (Fucile, 2004). 
The ion channel of the Torpedo nAChR is formed by amino acid residues 
contributed by the transmembrane domains of the a , p, y, 6 subunits (Hucho et al., 
1986). The importance of the M2 sequence for channel properties has been 
demonstrated with chimeras of bovine and Torpedo y subunits, and point mutations 
of the residues within M2 and at each end of the channel (Imoto et al., 1986, Imoto 
et al., 1988; Leonard et al., 1988). This has been confirmed by labelling with non 
competitive blockers such as [ HJchlorpromazine, that bind inside the channel once 
it is opened by agonist. Labelling was detected in 6-Ser262 in M2 (Giraudat et al., 
1986), the homologous residues a-Ser248 and p-Ser254 (Hucho et al., 1986), y-Ser 257 
(Revah et al., 1990), y-Leu260, P-Leu257, and y-Thr253 (Revah et al., 1990). This 
contribution from each subunit forms rings of residues within the channel (Figure 
1.4). The residues which are accessible to labelling by [3H chlorpromazine from 
inside the channel provide evidence for an a-helical structure for M2 (Revah et al., 
1990).
In addition to these polar and non-polar rings of residues there are also three rings of 
negatively charged residues within M2. The Torpedo nAChR residues a-Asp238, a- 
Glu241 and a-Glu262 and the equivalent residues in p,y and 6 form negatively charged 
rings around the lumen of the channel (Figure 1.4; Imoto et al., 1988; Stroud et al.,
1990). These negatively charged rings are thought to attract cations and repel anions 
both from inside and outside the cell. These rings are know as the outer 
(extracellular), intermediate and inner (cytoplasmic) rings (Imoto et al., 1988). 
Equivalent residues have been mutated in the a l  receptor and have been shown to be 
involved in ion channel properties. The a l  subunit can be converted into an anion
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Figure 1.4 A model o f the high affinity binding site for the open channel 
blocker, chlorpromazine.
The M2 amino acids of the P and y subunits are shown in a helical 
conformation. The sphere labelled CPZ represents the space filled by 
chlorpromazine. The filled circles are amino acids labelled by l3Hj-CPZ, 
showing the rings of polar and non-polar residues in the channel. The rings of 
charged resides at either end of M2 (labelled inner, intermediate and outer) are 
also shown. Adapted from Revah et al, 1990.
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channel with the appropriate mutations (Galzi et al., 1992). The removal of a 
negative charge at the Glu237 residue abolishes the normally very high calcium 
permeability of a l  but does not alter the flow of monovalent cations (Bertrand et a l , 
1993). For complete conversion to an anionic channel this negative charge must be 
removed and additional proline residue needs to be added between residues 234-237 
(Galzi et al., 1992, Corringer et al., 1999). This small loop of residues has been 
hypothesized to be a gating region in this receptor (Corringer et al., 1999).
The a l  subunit has been used extensively as a model receptor in a number of 
mutagenesis studies. Because the a l  subunit is able to form homomeric channels, 
mutagenesis of only one cDNA will alter that residue in all five subunits of the 
receptor. The homomeric a l  nAChR is more permeable to calcium than the muscle 
and Torpedo and most other neuronal nAChRs (review Fucile, 2004). The a l  
nAChR has a calcium permeability (fractional current carried by calcium in%, Pf) of 
approximately 10-20 % (Fucile, 2004), which is higher than the calcium permeable 
NMD A receptors. Mutation of a7-Leu247 (homologous to Torpedo y-Leu260) to 
serine or threonine altered ion channel properties, including loss of desensitization 
and rectification, and the proposed addition of another conductance state (Revah et 
al., 1991, Bertrand et al., 1992). It has been suggested that the leucine ring is 
involved in preventing ion permeation in a desensitized state, and mutation to non­
hydrophobic residues results in this state becoming conducting.
The structure of the Torpedo nAChR channel has been visualized with electron 
microscopy (Figure 1.5; Miyazawa et al., 1999, Miyazawa et al., 2003, Unwin, 
2005). High resolution (4 A) images indicate that M2 is a-helical, as are the other 
transmembrane domains. This method also revealed more about the topology of the 
M2 helix and how the protein forms a gate or barrier against ions when shut. The 
M2 helix is about 40 A long and tilts radially inwards from the extracellular region 
until the middle of the membrane where it kinks at a-Leu251. This is the narrowest 
point is at a-Leu and a-Ser , a-Val and a-Phe , which form a hydrophobic 
girdle around the pore that is less than 3.5 A in diameter for about 8A until a - 
Val259. This is too small for the monovalent and divalent cations to pass though 
and thus creates a closed gate. When the receptor is activated the proposed
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Figure 1.5 The 3-dimensional structure of the nAChR, visualized by electron 
microscopy\
(A), Three cross sections views through the Torpedo nAChR at 4.6 A 
resolution, from Miyazawa et al., 1999. (B), Ribbon diagrams of the receptor 
(from the amino-acid sequence fitted to the density map obtained by electron 
microscopy) viewed from the (a) synaptic cleft (b) the plane of the membrane. 
The a-Trp149 is highlighted in yellow, and the subunits in red (a), green (p), 
blue (y) and light blue (6). The purple boxes in (A) and (B) indicate the 
equivalent positioning within the Torpedo subunits of the three arginine 
residues within the 5HT3A subunit which are thought to determine the single 
channel conductance. E, extracellular; I, intracellular. Adapted from Unwin, 
2005.
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mechanism for opening the channel is a rotation of the M2 helix which causes a 
weakening of the hydrophobic forces in the girdle so that it comes apart, widening 
the pore (Unwin, 1993; Auerbach, 2003).
1.2.4.2 The 5-HTjaR ion channel
The 5-HT3R.S are also cationic ion channels (Jackson and Yakel, 1995). Although 
there is no comparable electron microscopy data for the 5-HT3A subunit 
transmembrane domain, it is thought to be very similar to the structure described 
above for the nAChR. The M2 domain has been shown to be a-helical (Reeves et 
al., 2001, Panicker et al., 2002), with a kink in the middle near a lysine residue, 
which is reminiscent of the Torpedo nAChRs (Miyazawa et al., 2003).
There is a high degree of sequence similarity in the M2 domains of the a l  and 5- 
HT3A subunits (approximately 75%). Mutation of the equivalent residue to the a l-  
Leu247 nearly eliminated the rectification seen in the wild type receptor and slows the 
rate of desensitization (Yakel et al., 1993), which is similar to the results of the 
mutation in a l  (Bertrand et al., 1992). The 5-HT3A has three rings of negatively 
charged residues as described for the nAChRs. Similar to the study described above 
for the a l  receptor, the homomeric 5-HT3A receptor can be converted to an anion 
channel by a similar set of mutations (Gunthorpe and Lummis, 2001), but the mutant 
channel also showed differences in apparent affinity for 5-HT and the time course of 
the response. Mutation of only the glutamate residue to an alanine neutralized one 
ring of negative charge at the intracellular region of M2, and made the ion channel 
non-selective (Thompson and Lummis, 2003). Introduction a ring of positive charge 
at the extracellular end of M2 made the ion channel anion selective without largely 
changing other properties of the receptor (Thompson and Lummis, 2003). A 
mutation of an lie294 in M2 decreases the calcium permeability of the 5-HT3A 
receptor (Reeves and Lummis, 2000), which is similar to the results of a mutation in 
a homologous position of the a l  subunit (Bertrand et a l , 1993).
The heteromeric 5-HT3R, with 5-HT3A and 5-HT3B subunits, has a lower calcium 
permeability compared to the homomeric 5-HT3A receptor (Davies et al., 1999b). 
This may be due to the lack of the rings of negatively charged residues in the M2
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domain of the 5-HT3B subunit (Dubin et al., 1999). The heteromeric channel also 
has a larger single-channel conductance, however this has been attributed to residues 
the large cytoplasmic loop of the 5-HT3B subunit rather than the ion channel (Kelley 
et al., 2003). Three arginine residues in the intracellular loop within the amphipathic 
helix (Position shown in Figure 1.5), when mutated to the equivalent residues in the 
5-HT3B subunit, cause the homomeric receptor to have a conductance comparable to 
the heteromeric receptor. These arginine residues are positively charged and may act 
as an electrostatic barrier to positively charged ions trying to flow through the 
receptor on channel opening.
1.3 Folding and assembly, trafficking and targeting of nAChRs 
and 5-HT3R
The ligand-gated ion channels described in the previous sections have a complex 3- 
dimensional structure. To produce the final receptor from a number of linear protein 
sequences, the subunits must fold into the correct membrane spanning topology and 
assemble with other subunits in the correct stoichimetry and arrangement (Green and 
Millar, 1995). This occurs in the endoplasmic reticulum, where the receptor also 
undergoes post-translational modifications before being exported to the plasma 
membrane.
1.3.1 Folding and assembly
Nicotinic receptors assemble slowly and inefficiently (Merlie and Lindstrom, 1983) 
in comparison to other transmembrane proteins. This is thought to be due to 
inaccurate folding of the subunit proteins, which has been monitored by the 
formation of ligand binding sites and conformational epitopes for monoclonal 
antibodies (Merlie and Lindstrom, 1983). It has been shown for the Torpedo 
subunits that correct folding requires interactions with other subunits (Paulson et al.,
1991). It is thought that much of the secondary structures form during synthesis of 
the protein, the formation of the tertiary structure occurs after subunit 
oligomerization (Gething and Sambrook, 1992).
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1.3.1.1 Chaperone proteins and other receptor-associated proteins
Chaperone proteins are thought to be involved in the folding of nAChR subunits, and 
may retain misfolded subunits within the endoplasmic reticulum. The chaperones 
BiP (immunoglobulin binding protein) and calnexin associate with the a , (3 and 
6 subunits of muscle nAChRs and the 5-HT3 receptor subunits (Blount and Merlie, 
1991; Forsayeth et a l , 1992; Gelman et a l , 1995; Keller et a l, 1996; Boyd et a l, 
2002). Co-expression of calnexin with the muscle nAChR subunits enhances 
assembly and surface expression of the receptor (Chang et a l, 1997). The 
chaperone protein 14-3-3r| associates with the a4|32 nAChRs, and co-expression 
with cx4j32 increases steady-state levels of the a4  subunit (Jeanclos et a l, 2001).
In additional to chaperones, other proteins have been demonstrated to affect surface 
expression of nAChR and 5-HT3RS. Rapsyn (43K) is involved in the clustering of 
muscle nAChRs (Froehner et a l,  1991), but not for neuronal nAChRs. Co­
expression of the visinin-like protein-1 (VILIP-1) with a4|32 AChRs caused an up- 
regulation of the surface expression of receptors (Lin et a l 2002). The RIC3 
(resistant to inhibitors of cholinesterase) protein interacts with both nAChR subunits 
and the 5-HT3A subunit (Williams et a l, 2005; Lansdell et a l,  2005; Cheng et a l, 
2005). Human RIC3 has been shown to enhance the correct folding of the a l  
subunit (Williams et a l,  2005; Lansdell et a l,  2005) and also enhance the functional 
expression of heteromeric nAChRs (Lansdell et a l,  2005) and human 5-HT3A 
receptors (Cheng et a l , 2005).
1.3.1.2 Post-translational modifications in folding and assembly
Both the nAChRs and the 5-HT3R subunits have putative sites of phosphorylation 
and N-glycosylation, and it has been demonstrated that post-translational 
modifications can effect receptor expression. Examples with the nAChRs include 
phosphorylation of a4|32 receptors which may be involved in the up-regulation of 
this receptor in HEK cells by nicotine (Gopalakrishnan et a l, 1997), and N- 
glycosylation at specific sites is required to form correctly folded 0x2 (3y 6 receptors in 
Xenopus oocytes (Gehle et a l,  1997). Post-translational modifications also affect 5- 
HT3RS. Receptor stability is affected by the N-glycosylation sites on the 5-HT3R 
subunits (Boyd et a l, 2002), and glycosylation at N 109 on the 5-HT3A subunit has
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been demonstrated to be important for receptor assembly (Quirk et al., 2004). In 
addition to phosphorylation and glycosylation, palmitoylation of assembling a l  
receptors has a role in forming receptors able to bind a-BTX (Drisdel et a l, 2004).
1.3.1.3 Models of nAChR assembly
There are at present two models that describe the assembly of a, (3, y and 6 subunits 
into the nAChR in the endoplasmic reticulum (Wanamaker et al., 2003). The first 
model involves the association mature subunits to form the heterodimers ab  and 
ay, and then the pentameric receptor including the |3 subunit (Blount et a l, 1990). 
This model is not consistent with results obtained with pulse-labelled subunits, and 
the method of solubilisation performed in experiments that support the first model 
may have dissociated subunit complexes (Wanamaker et al., 2003).
In second model the subunits associated in the order: aPy -*apy6—^ P y b  (Green 
and Claudio, 1993). The subunits are not folded into their mature form before 
association with each other. Folding events that bury a disulfide bond loop in the a  
subunit N-terminus occur after its association with p and y, and once this loop is 
buried the trimer apy can bind a-BTX and also form the tetramer aPyb (Green and 
Wanamaker, 1997). The same event then occurs on the p subunit, which allows the 
formation of the pentamer a 2Pyb. However this model is probably too simple, as it 
does not take into account the results that show that ap6  and ayb are able to form a- 
BTX binding sites (Gu et al., 1991) and that ap6  form functional channels (Kurosaki 
et al., 1987). Thus in vivo is it likely to be more complex, with other subunit 
combinations and assembly pathways present to a greater or lesser extent. The 
assembly of neuronal nicotinic and 5-HT3A subunits has not been well characterized. 
It has been shown that a l  only binds a-BTX after forming pentamers (Anand et al., 
1993).
1.3.1.4 Subunit combinations
It has been possible to express functional recombinant receptors with the Torpedo, 
muscle and most neuronal nAChR subunits, with the right combination of subunits. 
The minimum requirment for heteromeric receptors is the subunits needed to make
1 QO 1 Q "1the binding site; at least one a  subunit containing the Cys and Cys residues, and
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another subunit to form the complimetary component of the binding site. Despite 
containing the two adjacent Cys residues a5 cannot form homomeric, or heteromeric 
receptors with only |3 subunits (Boulter et al., 1990; Couturier et a l, 1990b). The a5 
subunit only forms functional receptors with other a  subunit and (3 subunit 
heteromeric combination, such as a3p4 (Wang et al., 1996; Gerzanich et al., 1998).
In contrast to these heteromeric receptor formations, the a l  and a8 subunits form 
functional homomeric receptors in Xenopus oocytes (Couturier et al., 1990a, 
Gerzanich et al., 1994). However, they generally do not form functional receptors in 
a number of cell lines examined (e.g. HEK cells), despite having sufficient protein 
expressed (Cooper and Millar, 1997; Cooper and Millar, 1998; Sweileh et al., 2000). 
In one case a stable HEK cell line expressing functional a l  receptors was established 
(Gopalakrishnan, 1995), however this is likely to be due to this isolate expressing 
factors that other HEK cells lack that enable the a l  subunit to form functional 
receptors (see Chapter 4 Section 4.1). The expression of other nicotinic subunits with 
a l  or a8  in HEK cells made no difference (Cooper and Millar, 1997; Cooper and 
Millar, 1998). The 5-HT3A folds more efficiently that nAChR subunits and forms 
homomeric functional receptors in all the cell lines tested (Hargreaves et al., 1994; 
Cooper and Millar, 1997; Gunthorpe et al., 2000). A chimera constructed from the 
NH2-terminal domain of the a l  subunit and the transmembrane and COOH-terminal 
of 5-HT3A subunit forms functional channels when expressed in oocytes (Eisele et 
al., 1993). When a similar chimera was tested in the cell lines that did not express 
functional a l  receptors (e.g. HEK cells) they did form functional channels with the 
ligand binding properties of the a l  subunit (Cooper and Millar, 1997; Corringer et 
al., 1998). It has been suggested that the a l  subunit cannot form the correct 
conformation in these cell lines for ligand binding (Rakhilin et al., 1999). Thus it 
seems that there are important interactions between parts of the subunit protein 
beyond the extracellular N-terminus that allow the correct folding of the a l  protein.
1.3.2 Trafficking and targeting
Assembled proteins are transported from the endoplasmic reticulum to the plasma 
membrane. To prevent unassembled or incorrectly folded protein leaving the 
endoplasmic reticulum, many receptors have endoplasmic reticulum retention signals
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in their amino acid sequence that are only masked when the subunit is assembled 
into oligomeric complexes (Ma and Jan, 2003). Endoplasmic reticulum retention 
signals have been identified in some nAChR subunits, for example the muscle a  
subunit has a PLYFXXN sequence in Ml that is involved in the retention of the 
subunit in the endoplasmic reticulum (Wang et al., 2002). This motif is conserved in 
all muscle-type nAChR subunits and most neuronal subunits (a2-a6  and |32-p4). A 
retention motif has also been found in the 5-HT3B subunit, in the first cytoplasmic 
loop between Ml and M2, which is sufficient to cause the retention of the 5-HT3A 
subunit when it is transplanted into the homologous region (Boyd et al., 2003). The 
correct folding of the a l  protein may hide a retention motif, and when it misfolds 
and is exposed this may cause less receptor to be transported to the cell surface 
(Rakhilin et al., 1999).
The fact that certain ligand-gated ion channels do not reach the cell surface of a 
specific type of cell could be an important way of regulating the pharmacological 
profile of that cell. For example, as well as the a l  receptor, there have been few 
reports of the heteromeric a 9 a l0  nAChR forming ligand binding sites in cells other 
than oocytes. The a9  subunit forms functional homomeric receptors in a murine 
cochlear cell line (Jaggar et al., 2000). This is not surprising since these a9  and alO 
are not generally found in the CNS or PNS, and one of the few sites of high levels of 
expression are the cochlear hair cells (Elgoyhen et al., 1994; Elgoyhen et al., 2001). 
Thus, cochlear hair cells must presumably express something that permits expression 
of this nAChR.
There have also been studies of subcellular targeting of nAChRs. For example, 
muscle nAChRs are denser at the thickened postjunctional folds of the endplate as 
compared to the non-thickened bottom folds, which are equivalent to the 
extrajunctional regions (Salpeter and Harris, 1983). There is evidence from an in 
vivo study that the long internal loop of the a3 subunit targets the receptors to 
specialized postsynaptic membranes (Williams et al., 1998). The a l  subunit has 
been shown to be targeted to distal locations of the chick sciatic nerve (Roth et al., 
2000), and to the somato-dendritic portion of neurones in the chick nucleus 
semilunaris (Sorenson et al., 2001). The distribution of the splice variant of the a l
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nAChR subunit overlaps with that of the a l  subunit when expressed in cultured rat 
cortical neurones, but is also targeted to distinct areas (Severance and Cuevas, 2004). 
This implies that the differences in sequence allow the subunits be targeted to 
different regions.
1.4 Native neuronal nAChRs and 5-HT3RS
The distribution of nAChR and 5-HT3R subunit mRNA and protein has been 
thoroughly investigated, however the subunit composition of all native receptors is 
as yet unknown. Some work has been done to elucidate the subunit combinations 
that form receptors in native cells, for example, chick ganglion neurons there are 
thought to be only 3 populations of receptors (Conroy and Berg, 1995).
1.4.1 Native nAChR distribution and subtypes
Ligand binding with [3H]ACh and [125I]a-BTX has been investigated in the brain to 
examine the distribution of potential neuronal nAChRs. Both these ligands bound to 
muscle nAChRs but showed a differential pattern of binding in the brain (Clarke et 
al., 1985). This has been shown to be more complex than just two types of neuronal 
nAChRs. This is due to the number of different possible receptors that could contain 
five subunits from a 2 -a l, a 9 ,a l0  and |32-|34 (also cx8 in chick).
In situ hybridisation and immunohistochemistry experiments investigated the 
distribution of specific subunit mRNA and protein and demonstrated the differing 
expression patterns of the nAChR subunits. For example the (32 subunit mRNA is 
widely distributed throughout the brain (Swanson et al., 1987; Paterson and 
Nordberg 2000). In contrast the a2  subunit mRNA is only seen in the 
interpeduncular nucleus (Wada et al., 1988). As there is considerable overlap in the 
expression of many of the subunit mRNA, suggesting that the proteins they encode 
may have the opportunity to come together to form receptors.
1.4.1.1 Subtypes of nAChRs in the Central Nervous System
The cx4 and (32 subunit mRNAs and proteins are widely expressed in the central 
nervous system (Goldman et a l , 1987; Deneris et al., 1988; Swanson et al., 1987).
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They form functional heteromeric receptors when expressed recombinantly (Boulter 
et a l, 1987; Buisson et a l, 1996) with high affinity to nicotine (Connolly et al.,
1992). Immunodepletion experiments in chick brain have shown that a large 
proportion of the epibatidine binding receptors contain a4  and |32 (Conroy and Berg, 
1998). These two subunits probably form the primary site for high affinity nicotine 
binding in the central nervous system (Zoli et al., 1998). Both a4  and (32 knockout 
mice lack high affinity [ H]-nicotine binding sites (Marubio et al., 1999, Picciotto et 
al., 1995).
Additional subunits combine with the a4|32 receptor to form diverse receptors in the 
central nervous system. The a5 subunit has been shown to assemble with a4  
subunits in the brain (Conroy et al., 1992). The (33 and |34 subunits have been shown 
to co-assemble with a4|32 in rat cerebellum (Forsayeth and Kobrin, 1997). 
However, there are also nAChRs that contain no (32 subunit. When the (32 subunit is 
knocked out there are still high affinity [ H]-epibatidine sites in the dorsocaudal 
medulla oblongata, pineal gland and habenula-ventral interpeduncular system, which 
are consistent with the pharmacology of a3(34 (Zoli et al., 1998).
Radioligand binding of [125I]a-BTX in the brain is thought to be due to a l  nAChRs. 
The localization of a l  mRNA has been shown to overlap with [125I]a-BTX binding 
sites (Seguela et al., 1993) and a l  knockout mice lack a-BTX binding. Nicotine 
induced currents in rat hippocampal slices that are blocked by a-BTX and MLA are 
not present in the knockout mice (Orr-Urtreger et al., 1997).
The radioligand [125I]a-BTX also binds to the a8 subunit, however, this subunit has 
only been identified in chick (Schoepfer et al., 1990). The a l  homomeric receptors 
are thought to account for 74% of a-BTX binding sites in chick brain (Keyser et al.,
1993) and 65-70% of a-BTX receptors in the chick optic lobe (Gotti et al., 1994). 
The a 8 homomeric nAChRs are thought to account for 9% of a-BTX binding sites 
in chick brain (Keyser et al., 1993) and heteromeric a7 a8  nAChRs account for 20- 
25% of the a-BTX binding sites in the chick optic lobe (Gotti et al., 1994).
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1.4.1.2 Subtypes of nAChRs in the Peripheral Nervous System
Little or no a4  subunit is expressed in the periphery (Rust et al., 1994). In contrast, 
the a3 and |34 transcripts are highly expressed and thought to be the primary high 
affinity nicotinic receptors in the periphery (Corriveau and Berg, 1993; Mandelzys et 
al., 1994). The a3 subunit has been shown to co-immunoprecipitate with the |34 
subunit in the rat trigeminal ganglion (Flores et al., 1996). Other subunits are 
thought to co-assemble with some a3|34, including a5 and |32 in the chick ciliary 
ganglion (Vernallis et al., 1993; Conroy and Berg, 1995) and the rat trigeminal 
ganglion (Flores et al., 1996). The a6  and |33 subunits were shown to assemble with 
a3|34 in the chick retina (Vailati et al., 2000).
[125I]a-BTX binding sites are seen in cultured sympathetic neurones (Patrick and 
Stallcup, 1977; Carbonetto et al., 1978). The a l  mRNA is highly expressed in the 
rat superior cervical ganglion and adrenal medulla (Rust et al., 1994) and chick 
ciliary ganglion (Corriveau and Berg, 1993). In the chick peripheral nervous system, 
the a l  homomeric receptors are thought to account for only 14% of a-BTX 
receptors in the chick retina whereas the a8 homomeric receptors account for 69% 
(Keyser et al., 1993). The chick retina also has heteromeric a7a8  nAChRs which 
account for 17% of a-BTX receptors (Keyser et al., 1993). Some evidence suggests 
that a l  may assemble with subunits other than a8. In both rat and chick there are 
thought to be at least three subtypes of receptor that may contain the a l  subunit, 
because there are distinct pharmacological subtypes that are sensitive to a-BTX and 
MLA (Yu and Role, 1998b, Cuevas et al., 2000). Possible subunits that could 
assemble with a l  are p2 (Britto et al., 1992) or p3 (Palma et al., 1999). There is 
also a splice variant of the a l  subunit, that forms receptors that have different 
functional and pharmacological properties to the original homomeric a l  receptor 
(Severance et al., 2004). This splice variant has been detected in the peripheral 
nervous system and could account for a-BTX sensitive receptors that have distinct 
properties to the original a l  subunit.
There is the possibility that there are more nAChR subunits to be found and cloned 
in some species, although this is unlikely in humans since the whole genome has 
been sequenced and searched for homologous sequences. In chick ciliary ganglion
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there is a population of nAChRs that are sensitive to a-BTX but have not yet been 
shown to immunoprecipitate any known subunit (Pugh et a l, 1995).
1.4.1.3 The a 9  and a 9 a l0  nAChRs
Responses to ACh have been detected in cochlear hair cells (Art et al., 1984), but 
most AChR subtypes are not expressed there (Hiel et a l, 1996). Only the a9  and 
alO  nAChR subunits are expressed in cochlear hair cells, with their expression 
generally restricted to the peripheral vestibular system (Elgoyhen et a l, 1994; 
Elgoyhen et a l, 2001), although a9  is found in the rat dorsal root ganglion neurones 
(Lips et a l, 2002). The expression pattern of a9  and alO  is not exactly the same and 
a9  is expressed alone in areas such as nasal epithelium (Elgoyhen et a l, 2001).
1.4.2 Native 5-HT3R subtypes and distribution
The 5-HT3R is present in the nervous system in a number of areas including cortical 
areas, olfactory regions, the hippocampus and the amygdala (Kilpatrick et al., 1988; 
Marazziti et a l, 2001). There are two subtypes of 5-HT3RS in the nervous system; 
the homomeric 5-HT3AR and the heteromeric 5-HT3R. The 5-HT3A subunit mRNA 
is expressed in both central and peripheral rat neurones whereas the 5-HT3B subunit 
mRNA is mostly restricted to the peripheral nervous system (Morales and Wang,
2002). There have been reports of 5-HT3B subunit protein in the hippocampus 
(Monk et a l , 2001), and also in cell lines of neuronal origin (Hanna et a l, 2000). 
Thus, there may be a mixture of homomeric and heteromeric receptors in the brain, 
with a larger proportion of homomeric receptors in the CNS. The mRNA of the 5- 
HT3C is found in the adult human brain, however no 5-HT3D and 5-HT3E subunit 
mRNA has been detected in the brain (Niesler et a l , 2003).
1.4.3 Developmental changes in neuronal subunit expression
There are developmental changes in the expression of some of the nAChR subunits. 
For example, in chick ciliary ganglion there is a significant increase in the expression 
of the a5 subunit from embryonic day 8 (E8) to El 8 (Corriveau and Berg, 1993). 
There also is a significant increase in the expression of a3 and a l  subunits from 
postnatal day 1(P1) to P14 in rat superior cervical gangion neurones (Mandelzys et 
a l, 1994).
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1.5 Functional expression of recombinant nAChRs and 5-HT3Rs
The Torpedo nAChR was the first ion channel to be expressed in a heterologous 
system (Barnard et al., 1982). Since then, functional expression has been used to 
examine the pharmacological and functional properties of all the ligand-gated ion 
channels in a variety of expression systems. Xenopus oocytes have been used 
extensively as a model system to express recombinant DNA, and receptor properties 
have been studied using two electrode voltage clamp and patch-clamp recording. 
Many mammalian cell lines have also been used to express receptor subunits, as they 
are more representative of the conditions the native protein encounters. Both patch- 
clamp recording and calcium-influx assays have been used to examine functional 
characteristics. It is important to note that there is variability in functional 
characteristics of the same receptor depending on the cell type it is expressed in, the 
experimental conditions used and the system used to examine function. For 
example, there have been differences noted in functional characteristics of receptors 
expressed in Xenopus oocytes compared to mammalian cells, such as the single­
channel conductance of a l  and cx3|34 nAChRs (Lewis et al., 1997; Section 1.5.3). 
Differences are also observed between patch-clamping and calcium-influx assays. 
When the human 5-HT3B subunit is co-expressed with the human 5-HT3A subunit in 
HEK cells, the E C 5 0  for 5-HT is ten fold greater when 5-HT responses were recorded 
using patch-clamp experiments compared with a calcium-influx assay (see Section 
1.5.1). This could be due to calcium influx assays being more sensitive, or that the 
response to calcium has a different E C 5 0  to the whole cell responses observed.
1.5.1 Agonist potency and efficacy
Agonists to the nAChRs include ACh, nicotine, 1,1-dimethyl-4-phenylpiperazinium 
(DMPP), cytosine, epibatidine, and choline. These have varying binding affinites, 
potencies and efficacies on different nAChR subtypes such as those listed in Section 
1.4. There are also differences between the same receptor subtype in different 
species, for example DMPP has a much lower efficacy of 3% on chick a l  compared 
to 78% on rat a l  (Vazquez and Oswald, 1999).
Choline is a product of the break down of ACh, and is known to have low potency at 
heteromeric receptors such that the physiological concentrations would be
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ineffective. However, it has been shown that choline has a much higher potency at 
the a  7 receptor (Alkondon et a l , 1997) which allows a l  nAChRs to be activated at 
physiological concentrations. This could allow a paracrine method of nAChRs 
activation, and suggests a physiological role for a l  nAChRs in places where there 
are no cholinergic inputs. Nicotine is more potent at a4|32 receptors than other 
subtypes. The EC50 values range from 0.8 (chick, Ramirez-Latorre et a l, 1996) 
to 15 |iM (rat, Fenster 1997) compared to 106 pM for human a3|34 (Gerzanich et a l,
1998).
The agonists of 5-HT3RS include (in rank order of potency for murine 5-HT3A) 
mCPBG > 5-HT > 2-Me-5-HT > PBG (Hope et a l, 1993; Mair et a l, 1998). As 
with nAChRs there are some species differences, for example 2-Me5-HT only has a 
efficacy of 9.1% in murine 5-HT3A as compared to 87% in human 5-HT3A (Hope et 
a l, 1993; Belelli et a l, 1995). The new diversity of the 5-HT3R subunits introduces 
potential control over the function of the 5-HT3R. With the addition of the 5- 
HT3B subunit the heteromeric receptor has different apparent affinities for agonists. 
For example, both 5-HT and 2-Me-5-HT become less potent agonists, but mCPBG 
and 1-PBG become more potent agonists with heteromeric receptors expressed in 
Xenopus oocytes (Davies et a l, 1999b; Dubin et a l,  1999), and a mammalian cell 
line (Stewart et a l, 2003). There was no difference seen in efficacies at the 
homomeric and heteromeric receptors (Dubin et a l,  1999). There are also small 
differences between splice variants of the 5-HT3A subunit. For example, the potency 
and efficacy of mCPBG is greater at the short compared to the long splice variant of 
the murine 5-HT3a subunit (Niemeyer and Lummis, 1998).
1.5.2 Antagonist potency
There are antagonists that show a much higher potency for certain receptor subtypes, 
thus allowing selective antagonism. The a l  and a8  nAChRs are antagonised by low 
concentrations of a-BTX and ML A (Couturier et a l,  1990a; Palma et a l, 1996a; 
Gerzanich et a l,  1994; Gotti et a l, 1994). The toxin a-conotoxin Mil is a selective 
antagonist for a3|32 nAChRs (Cartier et a l, 1996). In comparison d-tubocurarine is 
regarded as a typical competitive antagonist at all the nicotinic receptors. Although 
d-tubocurarine acts as an competitive antagonist at the muscle nAChR, it has been
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demonstrated to open nACh channels in rat myotubes (Trautmann, 1982), thus it 
may be viewed as a very bad agonist, which can occlude the binding site for more 
efficient agonists.
It has been reported that long-term exposure to nicotine can causes persistent 
inactivation of a4(32 and a l  nAChRs when expressed in oocytes (Hsu et al., 1996; 
Olale et a l,  1997). This has been demonstrated for the a4|32 in a mammalian cell 
line (Gentry et al., 2003) however other reports show no long-lasting inactivation 
when a4|32 or a l  were expressed in a mammalian cell line or in native cells (Kawai 
and Berg, 2001; Buisson and Bertrand, 2001). The a3 nAChRs are only 
desensitized by much higher concentrations of nicotine compared to the a4(32 
receptors, and this inactivation is rapidly reversible (Olale et al., 1997).
1.5.3 Rectification
Nicotinic AChRs have been observed to have strong voltage dependency or inward 
rectification (Forster and Bertrand, 1995). In comparison, the homomeric 5-HT3A 
receptor does not display as great a rectification, and the heteromeric 5-HT3A/3B 
receptor shows no rectification at all (Davies et al., 1999b). Mutations in the M2 
region of the a l  subunit have been reported to abolish rectification (Leu 247, Revah et 
al., 1991; Glu237, Forster and Bertrand, 1995).
1.5.4 Desensitization
The characteristics of desensitization vary between the nAChRs (Quick and Lester,
2002). Different subunits alter the desensitization distinctly when they are included 
into the nAChR. This allows a mechanism to vary the length of time the current, 
including calcium ions, is allowed into the cell during exposure to agonist. The 
amount of calcium entering the cell is very important as calcium levels control many 
aspects of cell function such as neurotransmitter release. The a l  and a 8 receptors 
desensitize very quickly with time constants of a few 10s of ms, whereas the a4p2 
desensitizes more slowly, with a time constant of about 1 second (Ragozzino et al.,
1997). In contrast to the homomeric a l  and cx8 receptors, the homomeric a9  
receptor desensitization is very slow and is incomplete even after long agonist 
applications (Elgoyhen et al., 2001). When alO  forms a heteromeric receptors with
45
a9  the desensitization is much faster. The a l  subunit has been reported to associate 
with the 02 subunit and the resulting receptor has a slower rate of desensitization 
(Khiroug et al., 2002). The splice variant of the a l  subunit recently reported forms 
homomeric receptors that also desensitize more slowly (Severance et al., 2004).
The (34 containing nAChRs have even slower kinetics of desensitization than 02 
receptors, which has been attributed to the N-terminal domain of these subunits 
(Bohler et a l , 2001). Residues in the loop B and C region of the ligand-binding 
domain affect the potency of ligands to desensitize the receptor (Corringer et a l ,
1998).
The 5-HT3A homomeric receptor desensitizes more slowly than most nAChRs 
(Ragozzino et a l, 1997; Gunthorpe et a l, 2000), but the heteromeric 5-HT3A/3B has a 
faster rate of desensitization compared to the homomeric receptor (Dubin et al,
1999). Single residues have been demonstrated to be important for the 
characteristics of desensitization of the 5-HT3A receptor including Leu286 in the M2 
domain (Yakel et al, 1993) and Ser248 in the Ml domain (Lobitz et a l, 2001).
1.5.S Conductance
All the nAChRs have relatively large single-channel currents that can be resolved 
with outside-out patch-clamp recording. The conductances range from 5 to 55 pS 
(Papke et a l, 1989; Role, 1992). Some of the receptors have more than one 
conductance state which can be clearly seen in single-channel recordings, for 
example chick a402 (22.3±1.0 and 41.8±1.5 pS; Ragozzino et a l, 1997). Although 
the single-channel conductance should be an intrinsic characteristic of the protein 
there are some differences seen when comparing receptors expressed in Xenopus 
oocytes as compared to mammalian cell lines. For example chick a l  has a single­
channel conductance of 45 pS in Xenopus oocytes, but two conductance levels are 
observed in mammalian cell lines and the largest measured conductance was only 32 
pS (Ragozzino et a l, 1997).
The homomeric 5-HT3A receptor has a low sub-pS single-channel conductance 
(Brown et a l, 1998) that cannot be resolved with single-channel recordings. The
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single-channel conductance can be estimated by noise analysis of the current during 
agonist application (Traynelis and Jaramillo, 1998). In contrast to the homomeric 5- 
HT3A receptor, the heteromeric 5-HT3A/3B receptor has a conductance of 16 pS 
(Davies et al., 1999b) which is comparable to the nAChRs. Adding to previous 
studies which attributed the characteristics of the single-channel current to the ion 
channel (Imoto et al., 1988), it has been demonstrated that residues in the large 
cytoplasmic loop determine the size of the single-channel conductance of both the 
a l  (Chapter 3, Section 3.6.3) and the 5-HT3R subunits (Kelley et al., 2003).
1.5.6 Calcium permeability
The calcium permeability of a receptor can have important effects on the host cell. 
Many cellular processes are dependent on the specific levels of calcium in a closely 
localized area, for example modulation of neurotransmitter release at synapses, 
regulation of calcium sensitive ion channels or control of calcium sensitive second 
messenger systems. The nAChRs are permeable to both monovalent and divalent 
cations. Different subtypes of the nAChRs have different calcium permeabilities, 
with Pf values ranging from 1.5% for the a4p4 nAChR (Lax et al., 2002) to 70% 
calculated in a murine cochlear cell line where AChRs are thought to contain the a9 
subunit (Jagger et al., 2000). Considering that the a9  homomeric receptor does not 
desensitize very rapidly (Section 1.5.7.1), depending on the receptor density, a large 
amount of calcium could enter the cell on ACh release. Muscle nAChR subtypes 
have a significant calcium permeability although generally less than most neuronal 
nAChRs (Fucile et al., 2004). They have Pf values comparable to some neuronal 
subtypes, and in fact murine a lp le S  has a greater Pf than the human a4(34 subtype 
mentioned above (Pf = 4.1%, Ragozzino et al., 1998).
The range of calcium permeabilities of nAChRs allows them to have varied roles 
within the cell. Many subunit combinations have not been measured yet, but so far it 
seems that the heteromeric combinations a4p2, a4p4 and cx3|34 have lower calcium 
permeability than the homomeric a l  and a9  or the a 9 a l0  receptors (review, Fucile 
et al., 2004). There are much more complex subunit combinations, and it has been 
shown that when a5 is incorporated into a number of heteromeric receptors, one of 
the consequences is an increase in calcium permeability (Gerzanich et al., 1998). A
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mutation found in some patients suffering from a rare form of epilepsy replaces a 
serine residue in the M2 region of the a4 subunit with phenylalanine and results in a 
receptor with virtually no calcium permeability (Kuryatov et a l, 1997). Thus 
calcium influx through at least the a4 containing receptors seems to be important for 
normal brain function.
The homomeric 5-HT3A receptor was thought to be impermeable to calcium (Eisele 
et al., 1993) however direct visualisation of calcium influx upon agonist application 
indicated that there was some permeability to divalent cations (Hargreaves et a l, 
1994; Reeves and Lummis, 2000). As discussed above, co-expression of 5-HT3Aand 
5-HT3B subunits result in a receptor with a much greater single-channel conductance. 
However there is evidence that the calcium permeability is drastically reduced 
(Stewart et al,. 2003), although another publication showed significant calcium 
influx comparable to that of the homomeric receptor (Dubin et al., 1999). At present 
the calcium permeability of the heteromeric 5-HT3 receptors remains uncertain.
1.5.7 Comparison of native to recombinant receptors
In many cases the characteristics of recombinant receptors are very similar to native 
nAChRs, but there are important differences. This implies that either the subunit 
combination of the recombinant receptor, or the environment of the host cell do not 
match that of native receptors. For example, the native Torpedo nAChR is in 
dimeric form with two receptor cross-linked at the 6 subunit, but when the Torpedo 
nAChR subunits are expressed in Xenopus oocytes only single pentameric receptors 
are formed (Sumikawa et al., 1981; DiPaola et al., 1989). This demonstrates the 
differences in host cell environment can affect the biochemical properties of the 
receptor.
1.5.7.1 Homomeric nAChRs
The a l,  a8 and a9  subunits are able to form homomeric receptors when expressed 
in Xenopus oocytes and some mammalian cell lines. However, there have been 
some questions as to whether these subunits form homomeric or heteromeric 
receptors in the brain. Neuronal a-BTX binding receptors have been proposed to be 
homomeric a l  receptors (Chen and Patrick, 1997; Drisdel and Green, 2000).
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However, homomeric recombinant and native a l  nAChRs have been demonstrated 
to have similar but non-identical pharmacological properties in the chick brain. For 
example, native a l  receptors have a 50 fold lower affinity for cytisine compared to 
recombinant homomeric receptors expressed in Xenopus oocytes (Anand et al.,
1993). Also, the EC50 for ACh and nicotine differs between native and recombinant 
a l  and a8 nAChRs (Gotti et al., 1994).
The different properties of native a l  nAChRs when compared to recombinant 
homomeric receptors may be due to the assembly of a l  with other nicotinic subunits 
(Virginio et al., 2002). The a l  subunit has been proposed to form heteromeric 
receptors with the a5 subunit (Yu and Role, 1998a; Cuevas et al., 2000), the (33 
subunit (Palma et al., 1999), the (32 subunit (Khiroug et al., 2002) and the a8 subunit 
(Keyser et al., 1993). The a5 subunit may affect the single-channel conductance of 
a l  nAChRs (Yu and Role, 1998a). The (32 subunit has been demonstrated to co- 
assemble with a l  and cause the resultant receptor to have a slower rate of 
desensitization (Khiroug et al., 2002). Alternatively the a l  nAChRs may indeed be 
homomeric, but may undergo post-translational modification only in native cell 
lines, providing them with specific pharmacological and functional characteristics 
(Blumenthal et al., 1997).
It has been shown that the biophysical characteristics of the a 9 a l0  heteromeric 
receptor, compared to the a9 homomeric receptor, are more similar to those of some 
of the nAChRs found in the cochlea (Elgoyhen et al., 2001). For example the rate of 
desensitization is much faster for some native and a 9 a l0  receptors, compared to the 
homomeric a9 receptor.
1.5.7.2 Heteromeric nAChRs
A number of paired combinations of nAChR subunits have been tested in 
recombinant systems, but the characteristics do not account for all native nAChRs. 
Subsequently, three, four and even five subunit combinations have been tested 
(Vernallis et al., 1993; Kuryatov et al., 2000). The inclusion of a5 into a3(32 and 
a3(34 receptors has produced characteristics that are more similar to the receptors in 
some areas of the brain (Wang et al., 1996; Gerzanich et al., 1998).
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1.5.7.3 Homomeric verses heteromeric 5 -HT3 receptors
The 5-HT3A subunit is able to form homomeric receptors in Xenopus oocytes 
(Maricq et al., 1991) and in mammalian cells lines (Hope et al., 1996). However, the 
functional and pharmacological properties of the homomeric receptor do not match 
those of the native channels (Briiss et al., 1999). Splice variants of the 5-HT3A 
receptor have some functional diversity, but is not sufficient to account for the 
differences observed between recombinant and native receptors (Hubbard et al., 
2000). For example, estimates of the single-channel conductance of some of the 
native receptors are much larger than that of the homomeric 5-HT3A (Hussy et al., 
1994; Gunthorpe et al., 2000) and the efficacies of 2-Me5-HT and mCPBG are 
greater at native 5-HT3 receptors (van Hooft et al., 1997a).
Recently the 5-HT3B subunit was cloned, and can form a heteromeric receptor with 
the 5-HT3A subunit (Davies et al., 1999b). The recombinant heteromeric receptor 
has characteristics that are more similar to native 5-HT3 receptor, including a larger 
single-channel conductance (Davies et al., 1999b; Dubin et al., 1999; Hanna et al.,
2000). The 5-HT3B mRNA has been shown to be present in many cell lines that 
express endogenous 5-HT3 receptors (Hanna et al., 2000) but it should be noted that 
the neuroblastoma cell line, NB41A3, contains the 5-HT3B transcript but has 5- 
HT3RS with the characteristics of the homomeric receptor (Stewart et al., 2003). 
When the 5-HT3B subunit is introduced by transient transfection, the 5-HT3 receptors 
expressed have the characteristics of the heteromeric receptor. Thus, it seems the 
NB41 A3 cells may not have sufficient 5-HT3B transcripts to produce the heteromeric 
5-HT3 receptor.
Three additional 5-HT3 subunits have been cloned (Dubin et al., 2002; Niesler et al.,
2003). The 5-HT3C has also been reported to associate with the 5-HT3A subunit and 
affect its function (Dubin et al., 2002). The transcripts for the 5-HT3D and 5-HT3E 
subunits have not been shown to be present in the nervous system (Niesler et al.,
2003).
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1.6 Function of nAChRs and 5 -HT3RS in the central nervous 
system
The nAChRs have been shown to have important roles outside the central nervous 
system. The muscle nAChR is essential for transmission from the nerve to the 
muscle. The a3 subunit has been demonstrated to be essential for survival in mice, 
as a3 knockout mice die during the first post-natal week. This is presumably 
because a3 nAChRs mediate fast transmission in the autonomic nervous system 
(Cordero-Erausquin et al., 2000). Nicotinic AChRs in the central nervous system are 
thought to be involved in cognitive functions such as learning and memory. 
Nicotine can improve memory in rats (Levin and Simon, 1998) however mice that 
lack the (32 subunit also have improved memory, but there is no improvement with 
nicotine (Jones et al., 1999; Cordero-Erausquin et al., 2000). This may implicate the 
|32-containing receptors in a dual role of inhibition memory formation, but mediating 
the positive effects of nicotine. The |32 and |34 subunits are also important for 
survival as knockout mice lacking both have retarded development and die young, 
(Cordero-Erausquin et al., 2000). This suggests that (34 probably can substitute for 
(32 in places necessary for development as these problems are not seen in the (32 only 
knock out mice (Picciotto et a l , 1995).
5-HT3 receptors have been shown to be involved in cardiac, intestinal and lung 
function in the body. The role of the 5-HT3 receptors in the central nervous system is 
not fully understood, but they may be involved in anxiety and cognition (Barnes and 
Sharp, 1999). In experiments with a 5-HT3A knockout mice, the lack of this subunit 
has an ambiguous effect upon anxiety, with differing results depending on which 
behavioural tests are used (Bhatnagar et al., 2004a/ However, mice that lack the 5- 
HT3A subunit show less of the sex differences that are seen in tests for anxiety 
(Bhatnagar et al., 2004b).
1.6.1 Pre and post-synaptic nAChRs
The primary role for nAChRs in the central nervous system is thought to be 
presynaptic modulation of neurotransmitter release resulting in regulation of synaptic 
transmission (Role and Berg, 1996; Wonnacott, 1997; Levin and Simon, 1998). The
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modulation of release can also occur through receptors that are not in the terminal 
region (preterminal) and this distinction can be shown by the blockage of modulation 
by tetrodotoxin (Wonnacott, 1997). The modulation of release of a number of 
neurotransmitters have been demonstrated, including dopamine, GABA, 
noradrenaline and glutamate (Role and Berg, 1996; Wonnacott, 1997). For example, 
a4|32 containing nAChRs are found on the terminals of dopamine neurones in the 
striatum, and modulation of dopamine release by (32 containing nAChRs has been 
demonstrated (Wonnacott, 1997; Wonnacott et al., 2000). The population of these 
receptors may be heterogeneous as some may also contain either or both of a5 and 
(33.
GABA synaptic transmission in the hippocampus is also modulated by nAChRs. 
This has been demonstrated to be due to a7-containing nAChRs located on the 
hippocampal interneurones (Alkondon et a l, 2000). The a l  agonist choline triggers 
action potentials in hippocampal interneurones, which are blocked by the a l  
selective antagonist MLA. Presynaptic nAChRs may also act as autoreceptors to 
modulate ACh release via a feedback mechanism. Release of ACh from the nerve 
terminal would activate the presynaptic nAChRs enhancing mobilisation of more 
ACh and thus aiding continual ACh release in situations of sustained nerve 
stimulation (Wonnacott, 1997).
Presynaptic nAChRs may have functions other than modulation of neurotransmitter 
release. The receptors could act to modulate other aspects of nerve terminal 
function, for example via calcium signalling. Nicotinic AChRs participate in 
regulating neurite outgrowth and pathfinding of growth cones (Role and Berg, 1996).
Postsynaptic nAChRs have been demonstrated to mediate fast transmission outside 
the central nervous system. The signal from the motor neurone to the muscle is 
transmitted by a homogenous population of nicotinic receptors on muscle cells. 
Nicotinic AChRs also mediate fast transmission at the Renshaw cell-motorneurone 
synapse (Dourado and Sargent, 2002), and the efferent synapses of the cochlea hair 
cells and within the autonomic ganglia (Role and Berg, 1996). Within the central 
nervous system few cases of fast nicotinic transmission have been documented,
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indicating that the primary role of nAChRs in the brain may be other than fast 
transmission. Fast transmission has been shown in the hippocampus and visual 
cortex (Jones et al., 1999), and possibly a few other areas (Role and Berg, 1996). 
Nicotinic AChRs occur in areas where there are no cholinergic projections to 
mediate fast transmission, and their role may instead be paracrine. This would be 
feasible for a l  containing receptors which are activated by physiological 
concentrations of choline, which is a metabolite of ACh (Alkondon et al., 1997). 
ACh is broken down by cholinesterase too quickly to mediate paracrine 
transmission, but choline is removed much more slowly.
1.6.2 Pre- and post-synaptic 5-HT3Rs
There is evidence for fast transmission which is mediated by cholinergic neurones in 
the amygdala (Sugita et al., 1992), in hippocampal interneurones (McMahon et al.,
1997) and the developing visual cortex (Roerig et al., 1997).). Also, postsynaptic 5- 
HT3 receptors are found on GABAergic interneurones in the central nervous system 
(van Hooft and Vijverberg, 2000).
There is also evidence of the presence of presynaptic 5-HT3 receptors in the CNS and 
they are thought to have a role in the modulation of neurotransmitter release. 
However, presynaptic 5-HT3 receptor modulation of neurotransmitter release has not 
been decisively proved (Lambert et al., 1995; van Hooft and Vijverberg, 2000). 
Presynaptic 5-HT3RS have been implicated in the modulation of release of a number 
of neurotransmitters including dopamine, 5-HT, GABA and cholecystokinin. 5- 
HT3R mediated 5-HT release has been investigated in the amygdala: the presence of 
presynaptic 5-HT3 receptors has been shown in synaptosomes from the amygdala by 
immunocytochemistry, and when the serotonerigic system is chemically lesioned the 
number of 5-HT3R is significantly reduced. However, there has been no 
demonstration of 5-HT3 receptor mediated 5-HT release in this system (van Hooft 
and Vijverberg, 2000). 5-HT3R mediated 5-HT release has been shown in other 
brain regions but the presence of presynaptic 5-HT3 receptor on these nerve terminals 
has not been confirmed.
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5-HT3 mediated dopamine release has been investigated in the nucleus acumbens. 
There is some evidence it occurs from in vivo studies but it has not been 
corroborated by in vitro experiments, and the exact location of the receptors is 
inconclusive (van Hooft and Vijverberg, 2000). There is conflicting evidence for 5- 
HT3 mediated dompaine release in the striatum (van Hooft and Vijverberg, 2000).
Thus, the 5-HT3 receptor has been implicated in mediating the release of a number of 
neurotransmitters, however the results remain ambiguous. There is little direct 
evidence for presynaptic 5-HT3 receptor influence on GABA release and the results 
on the influence on ACh and noradrenaline release vary from inhibition, to no effect, 
to enhancement (van Hooft and Vijverberg, 2000).
1.6.3 Tobacco dependence
Tobacco smoking has been demonstrated to be highly addictive, and the principal 
addictive component is nicotine (Jones et al., 1999). Both tobacco smoking and 
nicotine self administration in animals are associated with an increase in dopamine 
release in the nucleus accumbens (NAc) upon nicotine intake (Mansvelder and 
McGehee, 2002). These dopamine neurones are part of the mesolimbic 
dopaminergic pathway which is thought to be the primary area that reinforces the 
effects of natural rewards such as food. Drugs such as nicotine and cocaine are 
thought to exploit this pathway to result in an unnatural addiction (Jones et al.,
1999).
The principal dopaminergic projections to the nucleus accumbens come from the 
ventral tegmental area (VTA). The release of dopamine onto the NAc neurones is 
modulated by the nAChRs in the VTA rather than in the NAc (Nisell et al., 1994). 
In the VTA there are dopamine neurones, GABAergic neurones and glutamatergic 
presynaptic terminals that synapse onto the dopamine neurones (Mansvelder and 
McGehee, 2002). The glutamatergic excitatory inputs to the dopamine neurones 
may originate from the prefrontal cortex, and contain a  7 nAChRs (Mansvelder and 
McGehee, 2000). The GABAergic inhibitory inputs to the dopamine neurones 
originate from local interneurones, the NAcc and ventral pallidum, and these are 
likely to contain cx4|32 receptors (Mansvelder et al., 2002). The excitatory and
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inhibitory inputs contain different nAChRs and they respond differently to the low 
dose of nicotine that occurs upon smoking. This dose of nicotine has been shown to 
cause long term enhancement of glutamatergic transmission, due to long term 
potentiation and a lack of desensitization of the a l  nAChRs at this nicotine 
concentration (Mansvelder and McGehee, 2000). This long term potentiation of the 
glutamatergic synapse is aided by the activation of nAChRs (probably a4(32) on the 
dopamine neurone. This provides additional post synaptic activation to remove the 
magnesium block of the NMDA receptor and hence facilitate potentiation of 
excitatory transmission at these synapses. In p2 knockout mice there is no nicotine 
self-administration, and there is no long term activation as a result of nicotine 
application. This supports the idea that |32 containing nAChR activation in the 
postsynaptic dopamine neurone may be necessary for the induction of long term 
potentiation (Picciotto et al., 1998).
Long term depression of GABAergic transmission occurs as the a4p2 receptors 
desensitize rapidly at this concentration of nicotine (Mansvelder et al., 2002). As a 
result the dopamine neurones receive a net increase in excitatory input, which could 
explain the prolonged excitation of the mesolimbic dopamine system that is the 
result of a single application of nicotine (Mansvelder and McGehee, 2002).
The mechanism described above involves a single dose to a naive system that has 
had no previous exposure to nicotine. Most smokers maintain chronic levels of 
nicotine. Chronic exposure to nicotine has been shown to upregulate a number of 
nAChRs. There is increased [3H]-nicotine binding in postmortem brain tissue of 
smokers (Benwell et al., 1988) and in mice with continuous nicotine administration 
(Marks et al., 1992). The concentration of nicotine required to upregulate different 
subtypes of nAChRs differs, with only a4p2 upregulated at nicotine concentrations 
equivalent to the plasma concentration in smokers (Peng et al., 1997; Molinari et al.,
1998). The number of surface a4p2 receptors are also upregulated to a greater 
extent than a3 or a l  containing receptors (Peng et al., 1997). The concentrations of 
nicotine required to desensitize nAChRs also differ, as does the extent of the 
desensitization. The a3|32 containing receptors are much less sensitive to 
desensitization by nicotine than a4(32. The a3(32 receptors also are not fully
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desensitized even at high nicotine concentrations, compared to the full ablation of 
the a4|32 responses at nM concentrations (Hsu et al., 1996; Olale et al., 1997). 
These results suggest that only cx3|32 receptors would not be affected by the nicotine 
concentrations present in smokers.
1.6.4 Pathology
Nicotinic receptors have been implicated in a number of neurological disorders 
including epilepsy, Alzheimer’s disease, Parkinson’s disease, schizophrenia, anxiety 
and depression, Tourette’s syndrome and Lewy-body disease (Paterson and 
Nordberg, 2000; Picciotto and Zoli, 2002). Some of these are discussed in more 
detail below.
The hypersensitivity of the gastro-intestinal tract that is thought to cause the 
symptoms in irritable bowel syndrome may be mediated partially through 5-HT3 
receptors (Jones and Blackburn, 2002). The 5-HT3 receptor has not been specifically 
linked to neurological disorders, but antagonists to this receptor may prove useful for 
treatment for psychoses and anxiety (Jones and Blackburn, 2002).
1.6.4.1 Epilepsy
A number of specific mutations of nicotinic subunits have been identified in patients 
suffering from a rare form of epilepsy, autosomal dominant nocturnal frontal lobe 
epilepsy (ADNFLE) (Corcia et al, 2005). These mutations involve the a4 and |32 
subunits. A misssense mutation in the M2 domain of the a4  subunit, at Ser247 that 
causes it to be replaced by a phenylalanine, is associated with ADNFLE (Steinlein et 
a l, 1995). When the mutant a4  subunit is expressed with (32 in Xenopus oocytes, 
the resultant a4|32 receptors desensitizes faster and recover from desensitization 
more slowly than with the wild type receptors (Weiland et al., 1996). The mutant 
receptor also has a higher EC50, less inward rectification, virtually no calcium 
permeability and loses the larger of two single-channel conductance states (Kuryatov 
et al., 1997). The overall result is a decrease in function for this receptor. This 
could result in epilepsy if the receptor is part of an inhibitory circuit, for example 
modulating a GABA synapse. Other mutations that have been identified in a4  also 
cause a loss in function, whereas two mutations in the |32 subunit cause a gain of
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function (Corcia et al., 2005). Other loci containing other nicotinic subunits have 
also been linked to ADNFLE but no specific mutations have been identified (Corcia 
et al., 2005)
1.6.4.2 Alzheimer’s disease
The loss of nicotinic binding sites has been seen in a number of neurodegenerative 
diseases including Alzheimer’s disease (Picciotto and Zoli, 2002) and 
anticholinesterases have been used with some success to treat this disease (Racchi et 
al., 2004). The a4|32 nAChR has been implicated, as it is the major subtype lost in 
Alzheimer’s disease (Paterson and Nordberg, 2000). Radioligand binding and 
immunoblotting in the temporal cortex show a decrease in [3H]-epibatidine binding 
and a4  protein levels, but no difference in cx3 or a l  protein levels (Martin-Ruiz et 
al., 1999). (3-Amyloid has been shown to modulate a l  activity (Pym et al., 2005) 
and it has been reported that activation of a l  nAChRs may mediate the protective 
effect of nicotine against p-Amyloid induced neurotoxicity that occurs in 
Alzheimer’s disease (Kihara et al., 2001).
1.6.4.3 Parkinson’s disease
Parkinson’s disease is linked to the decrease in dopamine neurones in the substantial 
nigra, but there is also a decrease in the number of cholinergic neurones (Whitehouse 
et al., 1983) and a loss of nAChR binding sites in the cortex (Whitehouse et al., 
1988). There is evidence that nicotine may have a protective effect against 
Parkinson’s disease (Morens et al., 1995; Quik and Kulak, 2002), and that the a6 
subunit may be an important new drug target (Quik and Kulak, 2002).
1.6.4.4 Schizophrenia
This is a complex condition that is still not well understood. It is reported that the 
percentage of smokers in the schizophrenic population is much higher than normal 
(Paterson and Nordberg, 2000), however this may be due to patients compensating 
for the deficits induced by the antipsychotic drugs used for treatment (Lena and 
Changeux, 1998). Schizophrenia has been linked to a polymorphism at chromosome 
15ql4 which is the locus of the a l  gene (Paterson and Nordberg, 2000). A decrease 
in the expression of a l  nAChRs in the hippocampus has been reported for
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schizophrenic patients (Freedman et al., 2000). It has been reported that the cx 7 
receptor mediates inhibition of the response to repeated auditory stimuli, and loss of 
this inhibition, through loss of the a l  receptor, may cause the sensory gating 
disturbances seen in schizophrenic patients (Freedman et al., 2000).
1.6.4.5 Anxiety and depression
Nicotine has been reported to have an effect on both anxiety and depression, 
however the effects are complex as they can be anxiolytic or anxiogenic (Picciotto et 
al., 2002). The a4p2 receptor and the a l  subunit have been implicated in anxiety 
through mutant mice studies and the action of specific agonists (Picciotto et al., 
2002). These two nAChRs have also been linked to depression through increased 
levels of cytosine binding in animal models and linkage studies to the a l  subunit 
gene (Picciotto et a l, 2002).
1.6.5 Therapeutic potential
The involvement of nicotinic receptors in a number of disorders (described above) 
place them in an important position as a potential target for drug treatments. The 
protective nature of smoking against disorders such as Parkinson’s disease points to 
therapeutic potential of nicotinic agonists. Nicotine has been reported to have 
beneficial effects upon memory and thus could aid patients with cognitive 
dysfunction (Levin and Simon, 1998). Agonists to the a l  receptor could increase 
neuroprotection against P-Amyloid induced neurotoxicity (Geerts, 2005). Alternative 
nicotinic agonists could play an important role in helping patients with smoking 
cessation.
5-HT3 antagonists, for example ondansetron, have revolutionised the treatment of 
cancer by inhibiting the emesis caused by chemotherapy and radiotherapy (Jones and 
Blackburn, 2002). The 5-HT3 receptor has not been directly linked to many 
disorders or diseases. However 5-HT3 antagonists have been reported to have 
beneficial effects in preclinical trials for psychoses, cognitive dysfunction and 
anxiety disorders (Barnes and Sharp, 1999; Jones and Blackburn, 2002). No benefit 
has been shown in clinical trials as yet.
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1.7 C o-assem b ly  and cross-p h arm acology  o f  the nA C hR s and the 
5 -H T 3R
The co-assembly of recombinant 5-HT3A and nicotinic subunits has been reported. 
The 5-HT3A subunit has been shown to co-assemble with the a4 nicotinic subunit 
and form a heteromeric receptor that has increased calcium permeability in HEK 
cells, and a distinct sensitivity to block by the nicotinic antagonist d-tubocurarine in 
Xenopus oocytes (van Hooft et a l, 1998). The a4  subunit forms part of the lining of 
the ion channel pore in these heteromeric receptors when expressed in Xenopus 
oocytes (Kriegler et al., 1999). The (32 subunit has also been reported to associate 
with the 5-HT3A subunit, but the association with the 5-HT3A subunit does not enable 
the a4  or |32 subunit to be detected on the surface of HEK cells (Harkness and 
Millar, 2001). These results are ambiguous and functional significance of the co­
assembly remains unclear. A study of the porcine brain indicated that nicotinic 
subunits are not part of native 5-HT3 receptors (Fletcher et al., 1998), so it remains 
uncertain whether native cx4 and 5-HT3A do co-assemble and form heteromeric 
receptors (Nayak et al., 2000). There has been no indication that the 5-HT3A subunit 
co-assembles with other nicotinic subunits.
There is some pharmacological cross-reactivity between the nAChRs and the 5-HT3 
receptors, with opposing effect of ligands. Nicotinic agonists including ACh and 
nicotine act as competitive antagonists at the 5-HT3 receptor (Gurley and Lanthorn, 
1998). 5-HT has been demonstrated to antagonise a l  receptors (Palma et a l, 1996b) 
and the 5-HT3 antagonist tropisetron is a potent and selective a l  nAChR partial 
agonist (Macor et a l,  2001). However, some ligands have been identified that act in 
the same way upon the a l  and 5-HT3 receptors. PSAB-OFP is an agonist (Broad et 
a l,  2002) and 5-hydroxyindole potentiates the currents produced by agonists (van 
Hooft et a l, 1997b; Zwart et a l, 2002) at both these receptors.
1.8 A im  o f  th is study
The nAChRs and the 5-HT3RS are widely expressed in the nervous system, and the 
importance of these receptors in brain function has been highlighted by the number 
of neurological disorders in which they are implicated. One aim of this study was to
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gain a better understanding of the structural and functional properties of the a l  
nAChR and the 5-HT3A receptor, which show a number of similarities. Recombinant 
subunits were expressed in HEK cells to compare differences between the a l  and 5- 
HT3A receptors. The 5-HT3A subunit efficiently forms functional receptors, however 
the a l  subunit does not, so chimeras of these two subunits were constructed to 
investigate which domains caused this difference. The functional differences 
between the 5-HT3A and a l  subunits were examined using the chimeras, again to 
identify which regions of the subunit determine these differences.
The a l  subunit is able to form functional receptors in some expression systems and 
recently the RIC3 protein has been shown to enable the a l  subunit to form a-BTX 
binding sites. Another aim of this study was to examine whether these binding sites 
represented functional receptors, and how RIC3 affected other receptors including 
the 5-HT3A receptor and the a8  and a3|32 receptors. Part of the work on RIC3 in 
Chapter 4 has been published (Lansdell et a l, 2005).
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CHAPTER 2 
MATERIALS AND METHODS
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2.1 Materials
All chemicals were obtained from BDH unless otherwise specified. All restriction 
enzymes with buffers were obtained from Promega unless otherwise stated. A 
Biofuge 13 (Heraeus Instruments) was used to centrifuge samples unless otherwise 
specified.
2.1.1 Original plasmid constructs
Rat a l  nAChR subunit cDNA in pcDNAlneo (Invitrogen) was obtained from Dr. 
Jim Patrick (Baylor College of Medicine, Houston) and excised and subcloned into 
the Hindlll/Xhol sites of pZeoSV2(+) (Invitrogen). Human a l  and chick a8 nAChR 
subunit cDNAs (Peng et al., 1994; Schoepfer et al., 1990) were obtained from Dr 
Jon Lindstrom (University of Pennsylvania, PA., USA). Human a l  subunit cDNA 
was subcloned into pcDNA3neo (Invitrogen) in this laboratory by Dr Sandra Cooper 
(Cooper, 1998). Chick a8  subunit cDNA was subcloned from pBluescript SK(-) 
(Stratagene) and subcloned into pcDNA3neo in this laboratory by Dr Sandra Cooper 
(Cooper, 1998).
Murine 5-HT3a(l) subunit cDNA in pCDM6xl (Maricq et al., 1991) was obtained 
from Dr David Julius, (University of California) and subcloned into both 
pZeoSV2(+) and pRK5 in this laboratory by Dr Sandra Cooper (Cooper, 1998) and 
Dr Elizabeth Baker (Baker, 2003) respectively. Human 5-HT3A in pcDM8 was 
obtained from Ewen Kirkness (Institute for Genomic Research, Rockville, 
Maryland).
The C. elegans RIC3 cDNA was obtained from Millet Treinin (Hebrew University, 
Israel) and was subcloned into pcDNA3 in this laboratory by Dr Stuart Lansdell. 
Human and Drosophila RIC3 cDNA were cloned into pcDNA3neo in this laboratory 
by Dr Stuart Lansdell and Dr Anne Doward (Doward, 2005).
The properties of the plasmid expression vectors used in this project are summarised 
in Table 2.1. All subunit cDNAs or chimeric constructs were in the expression 
vector pZeoSV2(+) for experiments in Chapter 3. For experiments in Chapter 4, 
chick a8, human a l  and all RIC3 constructs were in pcDNA3neo. Rat a3 and (32
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were in pRK5. Rat a l  was in pcDNAlneo. Murine 5-HT3A was in pRK5. Human 
5-HT3A was in pcDM8 .
Table 2.1 Summary o f  the plasmid expression vectors used in this study
Expression
Vector
Promotor Inducible/
Constitutive
Poly-A
Signal
Selection
pcDNAlneo CMV Constitutive SV40 Kanamycin 
SupF* (amp/tet)
pcDNA3neo CMV Constitutive Bgh Kanamycin
Ampicillin
pRK5 CMV/SP6 Constitutive SV40 Ampicillin
pcDM8 CMV/SP6 Constitutive SV40 SupF* (amp/tet)
pZeoSV2(+) SV40 Constitutive SV40 Zeocin
Abbreviations: amp -  ampicillin, Bgh -  bovine growth hormone, CMV -  
cytomegalovirus, tet -  tetracycline, poly-A -  polyadenylation, SV40 -  Simian virus 
* SupF: Plasmids with the SupF gene require growth in a bacterial strain that 
contains the P3 episome (MCI061; Invitrogen). The P3 episome contains ampicillin 
and tetracyclin selectable markers which contain amber mutations that are 
complemented by the SupF transfer RNA.
2.2 Subcloning techniques
2.2.1 Polymerase chain reaction (PCR)
Polymerase chain reaction amplification was performed in a peltier thermal cycler, 
PTC-225 (MJ Research) (PCR). Typical reactions were carried out in 30-50 pi and 
contained 10-200 ng of plasmid DNA, 0.05-0.5 pM forward and reverse primers 
(synthetic oligonucleotide primers were obtained from Genosys), 250 pM dNTPs, lx 
polymerase buffer plus MgCh (for Taq only) or MgSC>4 (for KOD only), and 2.5 U 
of a DNA polymerase enzyme. One of three enzymes were used, Taq (Promega), 
Pfu (Stratagene) or KOD (Novogen). Taq only has 5’to 3’ exonuclease activity 
whereas the other two enzymes also have 3’ to 5’ exonuclease activity. As a 
consequence, Taq has a lower DNA synthesis fidelity and was only used for standard 
diagnostic PCR reactions, or to add TA overhangs onto Pfu or KOD PCR products.
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2.2.2 Agarose gel electrophoresis
PCR products, digested plasmid DNA fragments and excised DNA inserts were 
separated by molecular weight by electrophoresis through a 1% agarose gel. 
Electrophoresis-grade agarose (Invitrogen) was dissolved in TAE buffer (Tris- 
acetate: 0.04 M Tris-acetate, 0.0001 M EDTA) and 0.3 pg/ml of ethidium bromide 
was added. DNA samples were run along-side DNA size markers either, 1 pg of 
Hindill digested Lamda (k) DNA (Invitrogen) or PCR markers (Promega). This 
enabled estimation of the size of the sample DNA. Samples and markers were 
loaded in IX blue/orange loading dye (Promega). DNA was visualized by means of 
a UV transilluminator (UVP).
When DNA was required for subsequent purification, low melting point agarose was 
used (Invitrogen) and DNA fragments were excised after electrophoresis using a 
sterile scalpel. DNA was extracted from the agarose gel using the Wizard™ DNA 
clean up system (Promega). The agarose gel was melted in a hot block and mixed 
with 1 ml of Wizard™ DNA-binding resin. DNA was isolated from the resin using a 
Wizard™ clean up column and washed with 2 ml of 80% isopropanol. The 
isopropanol was removed from the column by centrifugation and evaporation. The 
DNA was then eluted with 50 pi of sterile pre-warmed milli-Q water and centrifuged 
for 1 minute at 13,000 rpm. 5 pi of this DNA was run on a diagnostic agarose gel to 
estimate the yield.
2.2.3 Restriction digestion of DNA
All restriction enzymes and reaction buffers were obtained from Promega unless 
specified otherwise. Reactions were carried out in 30 pi, containing 1-2 pg of DNA, 
5-10 U of restriction enzyme in the appropriated buffer. The reaction was incubated 
at an appropriate temperature (typically 37°C) for 1-2 hours. For “double digests” in 
which the DNA was digested with two restriction enzymes requiring incompatible 
buffers, the first reaction was performed as above. The reaction was then made up to 
100 pi in the preferred digestion buffer and incubated with the second enzyme for 1- 
2 hours. After plasmid DNA was digested it was run on an agarose gel along side 
uncut DNA to ensure that the restriction enzyme had cut the DNA as expected. For 
double digests of plasmid vectors, plasmid DNA was digested by each enzyme
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singly with the same protocol and run along side on an agarose gel to ensure that 
both enzymes had cut the DNA as expected.
2.2.4 Dephosphorylation of DNA
When subcloning involving digestion with a single restriction enzyme or two 
enzymes that had compatible overhangs, 5’ phosphate groups were removed using 
calf intestinal alkaline phosphatase (CIP) (Promega). This was done to prevent re­
ligation of the plasmid DNA. CIP (2-3 U) was added to the restriction digest 
reaction. This was incubated at 37°C for 30 minutes and then another 2-3 U of CIP 
was added to the mixture and incubated at 37°C for a further 30 minutes.
2.2.5 DNA ligation
Ligation was carried out in a volume of 10 pi, and contained a molar ratio of vector: 
insert of 1:3, 0.5 U of the T4 DNA ligase (Roche) and lx T4 DNA ligase buffer. 
Background re-ligated vector was determined by performing a ‘control’ ligation 
which contained no insert. Ligation reactions were incubated overnight at 14°C.
2.2.6 Competent cells for transformation
The XL 1-blue strain of Escherichia coli (E. coli) bacteria (Stratagene) were prepared 
as follows: from a frozen glycerol stock, cells were streaked onto a Luria-Bertani 
(LB) agar plate and grown overnight at 37°C. A single colony was picked and used 
to inoculate 20ml of LB medium (10 g/1 bacto-tryptone, 5 g/1 Bacto-yeast extract, 10 
g/1 NaCl, adjusted to pH 7.0 with NaOH) and grown overnight at 37°C with shaking 
at 225 rpm. The culture was transferred to 500ml of SOB (20 g/1 bacto™-peptone 
(DIFCO, Becton Dickinson), 5 g/1 bacto-yeast extract, 0.5 g/1 NaCl, 2.5 mM KC1, 10 
mM MgCh). The culture was then incubated at 37°C with shaking at 225 rpm until 
the optical density measured at 550 nm was 0.5-0.55. The culture was then 
centrifuged at 2500 rpm (using a Beckman J2-M1 centrifuge, JA-14 rotor), for 15 
minutes at 4°C. The supernatant was poured off and the cells resuspended in 20 ml 
of ice-cold RF1 (100 mM RbCl (Sigma), 50 mM MnCl2.4H20 (Sigma), 30 mM 
potassium acetate, 10 mM CaCl2.2H20, 15% w/v glycerol (Sigma), pH adjusted to
5.8 with 0.2 M acetic acid, filter sterilized (0.22 pM)) and incubated on ice for 15 
minutes. This was then centrifuged at 2500 rpm for 9 minutes at 4°C, the
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supernatant poured off and the pellet resuspended in 3.5 ml of ice-cold RF2 (10 mM 
RbCl, 10 mM MOPS (3-N-morpholinopropanesulphonic acid) (Sigma), 75 mM 
CaCl2.2H20, 15% w/v glycerol, pH adjusted to 6.8 with 0.2 M acetic acid, filter 
sterilised (0.22 pM)). The cells were incubated on ice for 15 minutes. Aliquots 
were fast frozen in a dry ice/ethanol bath and stored at -80°C.
2.2.7 Bacterial transformation
Bacterial transformations were performed using 50 pi frozen stocks of competent 
E.coli cells prepared as described in Section 2.1.6. 1-20 ng of plasmid DNA, or 2-4 
pi of ligation mixture was gently mixed with the cells in a Falcon 352005 
polypropylene tube (Becton Dickinson) and incubated on ice for 30 minutes. The 
cells were then subjected to a heat shock at 42°C for 90 seconds and then placed on 
ice for 2 minutes. 500 pi of SOC (SOB with 20 mM glucose from Sigma) was 
added and this was incubated at 37°C with shaking at 225 rpm for 1 hour to allow 
expression of the antibiotic resistance gene. Aliquots of this were plated on to LB- 
agar plates containing inhibitory concentrations of the appropriate antibiotic (50 
pg/ml ampicillin (Sigma) or 25 pg/ml Zeocin from Invitrogen).
2.2.8 Preparation of plasmid DNA
2.2.8.1 Small scale preparation of plasmid DNA by alkaline lysis 
extraction
LB medium (2 ml) containing the appropriate antibiotic was inoculated with a single 
bacterial colony. This was grown at 37°C overnight with shaking at 225 rpm. The 
bacterial culture was then centrifuged at 13,000 rpm for 30 seconds and the 
supernatant aspirated off. The cells were resuspended in 100 pi of ice-cold solution I 
(50 mM glucose, 25mM Tris.HCl -  pH 8, 10 mM EDTA (Sigma) -  pH 8) with 
vortexing. 200 pi of Solution II (0.2 NaOH, 1% SDS) was added and carefully 
mixed by inversion. 150 pi of ice cold solution III (3 M potassium acetate, glacial 
acetic acid) was added and mixed carefully by inversion and stored on ice for 5 
minutes. This mixture was then centrifuged at 13,000 rpm for 5 minutes and the 
supernatant transferred to a new eppendorf. 400 pi of Phenol/chlorophorm 
(Amresco) (1:1) was added and mixed with vortexing to extract the protein from the 
sample. This was then centrifuged at 10,000 rpm for 2 minutes. The top layer of
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liquid was transferred into a tube containing 800 i^l of 100% ethanol, vortexed and 
centrifuged at 13,000 rpm for 5 minutes. The supernatant was aspirated off and the 
pellet washed with 70% ethanol. The remaining ethanol was evaporated off by 
placing the tube into a hot block for a few minutes. The DNA was then resuspended 
in 20 pi of MQ water containing 50 p,g/ml RNAse A (Roche).
2.2.8.2 Large scale preparation of plasmid DNA
Plasmid purification kits from Qiagen (Qiagen Plasmid Maxi Kit and Qiagen 
HiSpeed™ plasmid Midi Kit) were used according to the manufacturers instructions. 
LB medium (250 ml -  maxi, or 50 ml - midi) of was inoculated with a single colony 
or a stab from a glycerol stock and grown overnight at 37°C with shaking at 225 
rpm. Cells were harvested by centrifugation at 6,000 rpm (using a Beckman J2-M1 
centrifuge, JA-14 rotor) for 15 minutes at 4°C. The pellet was resuspended in ice 
cold buffer PI (50mM Tris.Cl (pH 8.0), 10 mM EDTA, lOOp-g/ml RNAse A) by 
vortexing. Buffer P2 (200mM NaOH, 1% SDS) was added and mixed gently by 
inverting, and incubated on ice for 5 minutes. Buffer P3 (3 M potassium acetate, pH 
5.5) was added and mixed gently by inverting, and incubated on ice for 10-15 
minutes (room temperature for the midi kit). Different volumes of buffers were used 
for the two kits, 10 ml of buffers P I-3 were used for the maxi kit, and 6 ml for the 
midi kit.
Centrifugation was used to isolate the DNA in the maxi kit protocol. The mixture 
was centrifuged at 13,000 rpm (using a Beckman J2-M1 centrifuge, JA-14 rotor) for 
30 minutes at 4°C. The supernatant was added to a Qiagen tip, previously 
equilibrated with 10 ml QBT (750mM NaCl, 50mM MOPS, 15% isopropanol, 
0.15% Triton X-100). The supernatant moved through the tip by gravity flow, then 
the tip was washed twice with 30 ml of QC (1 M NaCl, mM MOPS, 15% 
isopropanol), and the DNA eluted with 15 ml of QF (1.25 M NaCl, 50 mM Tris.HCl 
(pH 8.5), 15% isopropanol) into a glass tube. The DNA was precipitated with 0.7 
volumes of room temperature isopropanol and this was centrifuged at 10,500 rpm 
(using a Beckman J2-M1 centrifuge, JA-17 rotor) for 30 minutes at 4°C. The 
supernatant was then poured off and the pellet washed with 5 ml of room
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temperature 70% ethanol, and then air-dried for 10-15 minutes. The pellet was then 
resuspended in 1 ml of TE buffer (10 mM Tris.Cl, ImM EDTA, pH 8.0).
The HiSpeed midi kit (Qiagen) used filtration to isolate the DNA. The cell lysate 
was forced gently through a QIAfilter cartridge and into a Qiagen tip that was 
previously equilibrated with 4 ml QBT. When this had passed through by gravity 
flow the tip was washed with 20 ml of QC, and the DNA eluted with 5 ml of QF. 
The DNA was precipitated with 0.7 volumes of room temperature isopropanol and 
incubated at room temperature for 5 minutes. The precipitated DNA was then forced 
through a QIA precipitator with a syringe, and the QIA precipitator was washed with 
2 ml of 70% ethanol. Air was then forced through repeatedly to dry the membrane 
of the QIA precipitator. The DNA was then eluted with 600 pi of TE buffer.
The yield of the DNA preparation was determined using ether a BIORAD 
SmartSpec™ 3000 spectrophotometer or a Beckman Coulter DU 800 
spectrophotometer. The absorbance at 260 nm (A260) and 280nm (A280) was 
measured. The DNA concentration was determined from the absorbance measured 
at 260 nm. A solution containing 50 pg/ml of double-stranded DNA has an 
absorbance of 1 at 260 nm, calculated assuming that the mass of a nucleotide pair in 
DNA is 660 daltons. The purity of the DNA was determined from the value of 
A260/A280, with approximately 1.8 indicating pure DNA. The DNA preparation was 
also run on an agarose gel to visualize the DNA.
2.2.9 Site-directed Mutagenesis used to construct a 7 1TM-5 HT3A 
Site-directed mutagenesis (SDM) was performed using the QuikChange™ site- 
directed mutagenesis kit (Stratagene) to the manufacturers instructions. Two 
complimentary oligonucleotide primers (typically of length 25-45 bp) were designed, 
containing the desired. Oligonucleotide primers were designed so that the GC base 
content (%GC) was a minimum of 40%, the melting temperature (Tm) was greater 
than or equal to 78°C using the equation:
Tm=81.5+0.41(%GC) - 657/N -% mismatch
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Where N is the primer length in bases. Primers were designed to end in G or C to 
ensure then ends of the primer hybridise to the template DNA. Primers were 
purified by polyacrylamide gel electrophoresis by the supplier (Genosys).
Site-directed mutagenesis reactions were performed in a volume of 50 pi containing 
50 ng of template, 125 ng of each of the two oligonucleotides, 1 pi of dNTP mix 
from kit, lx reaction buffer and 1 pi of P/wTurbo DNA polymerase (2.5 U/pl). The 
reaction was heated to 95 °C for 30 seconds and then the thermocycling reaction was 
performed for 12-18 cycles as follows:
95°C for 30 seconds (denaturation)
55°C for 1 minute (annealing)
68°C for 1/ minute per kilobase of plasmid length (extension).
The reaction mixture was then cooled on ice for 2 minutes and then 1 pi of the 
restriction enzyme Dpnl (10 U/pl) was added to digest the methylated, non-mutated 
parental template DNA. DNA was incubated with Dpnl at 37°C for 1 hour. 
Bacterial cells were then transformed with the DNA product. 1 pi of digested DNA 
was mixed with 50 pi of XL 1-blue supercompetant E. coli cells in a chilled Falcon 
2059 polypropylene tube (Becton Dickinson) and incubated on ice for 30 minutes. 
The cells were then heat shocked at 42°C for 45 seconds, put on ice for 2 minutes 
and then incubated in 500 pi of NZY+ broth (10 g/1 of NZ amine (casein hydrosylate 
enzymatic, Invitrogen), 5 g/1 yeast extract, 5 g/1 NaCl -  pH 7.5, 12.5 ml/1 of 1 M 
MgCL, 12.5 ml/1 of MgS04  and 10 ml/1 of 2 M glucose) for 1 hour with shaking at 
225 rpm. 250 pi of this transformation mix was plated onto LB agar plates 
containing the appropriate antibiotic and incubated at 37°C overnight.
The mutation was verified by nucleotide sequencing, and in cases where mutagenesis 
created a novel restriction enzyme site, by restriction enzyme digestion.
2.2.10 Nucleotide sequencing
Fluorescent-based cycle sequencing was carried out using the ABI Prism® BigDye ™ 
Terminator Cycle Sequencing Ready Reaction Kit 1.0 and 1.1 (ABI Applied 
Biosystems, Applera UK) according to the manufacturer’s instructions. The reaction
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was carried out in a volume of 20 pi and contained 200-500 ng of template DNA, 3.2 
pmol of primer and 8 pi of Terminator Ready Reaction Mix (dye-labelled ddNTP 
terminators, unlabelled dNTPs, AmpliTaq DNA polymerase, MgCl2 and buffer). 
The thermocycling reaction was performed for 25 cycles as follows:
96°C for 30 seconds (denaturation)
50°C for 15 seconds (annealing)
60°C for 4 minutes (extension)
DNA was precipitated by the addition of sodium acetate (2 pi, pH 5.2) and 99% 
ethanol (50pl) per 20pl of reaction. This was incubated on ice for 15 minutes and 
then centrifuged at 13,000 rpm for 15 minutes. The supernatant was aspirated off 
and the pellet washed in 500pl of 70% ethanol. The remaining ethanol was 
evaporated off by placing the tube in a hot block for a few minutes, and then 
resuspended in 10 pi of formamide. Samples were sequenced using an ABI Prism® 
3100-Avant Genetic Analyzer (ABI Applied Biosystems). Fluorescent DNA 
fragments were run on a 50 cm capillary array using POP 6 polymer (ABI Applied 
Biosystems) and the data was extracted using HOO-Avant Data Collection Software 
Version 1.0 (ABI Applied Biosystems). Sequences were analysed using either 
SeqEd™ (ABI Applied Biosystems) or Mac Vector™ 7.2.2 (Accelrys).
2.3 M am m alian  cell line and transfection
A subclone of the human embryonic kidney (HEK) 293 cell line, tsA201 cells, were 
obtained from Dr William Green (University of Chicago, IL, USA). This HEK cell 
line stably expresses an SV40 temperature sensitive T antigen.
2.3.1 Cell culture
Human embryonic kidney tsA201 cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) (Gibco-Invitrogen) in a humidified incubator containing 
5% C 0 2 at 37°C. DMEM contains 2 mM L-GlutamaxTM (Gibco-Invitrogen), 10% 
heat inactivated foetal calf serum (FCS) (Sigma), 100 units/ml penicillin and 100 
pg/ml streptomycin (Gibco-Invitrogen).
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2.3.2 Transient transfection
Cells were transfected using the Effectene™ Transfection Kit (Qiagen) according to 
the manufacturer’s instructions. Cells were trypsinised and re-plated the day before 
transfection, and then again 4-6 hours before transfection to 25-30% confluency. The 
cells were left for 4-6 hours to allow them to adhere to the bottom of the plate, and 
then media was removed to make the appropriate volume. For radioligand binding, 
western blotting and calcium-influx assays, 10 cm plates (Corning) were used 
containing 3 ml of medium. To transfect a 10 cm dish, 0.6 pg of plasmid DNA was 
added to 120 pi of Buffer EC in a sterile microfuge tube. 4.8 pi of Enhancer (DNA 
condensing enhancer solution) was added and incubated for 5 minutes. 13 pi of 
Effectene (non liposomal lipid formulation which coats condensed DNA with 
cationic lipids) was added and incubated for 10 minutes. 600 pi of growth medium 
was added and this mixture was dropped onto the cells making a final volume of 
approximately 3.7 ml. After 16 hours, 7 ml of growth medium was added.
For electrophysiological studies and enzyme-linked assays, cells were plated onto 13 
mm glass cover slips (VWR international) coated with collagen (10 pg/ml) and 
poly lysine (Sigma) (10 pg/ml) in a 3.5 cm dish (Falcon, Becton Dickinson) 
containing 1 ml of medium. The same procedure was used as above with 0.2 pg 
DNA, 1.6 pi of Enhancer, 4.3 pi of Effectene and 200pl of growth medium. Cells 
were used 38-48 hours after transfection.
2.4 R adio ligand  binding
Radioligand binding was were used to estimate the amount of expressed receptor. 
Binding was performed on either intact cells (to determine levels of receptor 
expressed on the cells surface) or permeabilised cells (to determine the level of total 
cellular receptor). All calculations were performed using Microsoft Excel.
2.4.1 Iodinated a-bungarotoxin ([125I]a-B T X ) binding
The radioligand [125I]a-bungarotoxin ([125I]a-BTX; specific activity 200 Ci/mmol) 
was purchased from Amersham. Cells were rinsed and harvested with Hanks’ 
buffered saline solution (HBSS; 1.26 mM CaCb, 0.49 mM MgCl2.6H20, 0.41 mM
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M gS04.7H20 , 5.33 mM KC1, 0.44 mM KH2P 04, 137.9 mM NaCl, 0.34 mM 
Na2H P04.7H20 , 5.56 mM D-Glucose) and split into two samples for total and 
whole-cell binding. For total binding, cell membranes were prepared by 
freeze/thawing and were resuspended in phosphate buffer containing protease 
inhibitors (4 pg/ml pepstatin, 8 pg/ml leupeptin, 8 pg/ml apoprotinin) and 2.5% 
bovine serum albumin (BSA) (Sigma). Membranes were incubated with 15 nM 
a-B TX  radioligand (5 nM [125I]a-BTX and 10 nM unlabelled a-BTX , 
Calbiochem) for 2 hours on ice. Non-specific [ I]a-BTX  binding was determined 
by adding 1.25 mM nicotine (Sigma) and 1.25 mM carbamylcholine-chloride 
(Sigma). Samples were harvested onto Whatman GF/A filters pre-soaked in 0.5% 
w/v polyethylene-imine (Sigma) with a Brandel cell harvester (Model M36, Semaat, 
UK) and assayed in a gamma counter. To assay cell-surface [125I]a-BTX binding, 
cells were incubated and harvested at room temperature as described above for cell 
membranes using HBSS instead of phosphate buffer.
The values obtained using the gamma counter (counts per minute, cpm) were 
converted into fmol of ligand bound using the following equation:
10Specific counts per minute/(E x S x 2.2 x 10' )
Where the specific counts per minute is equal to the total counts minus the non­
specific counts, E is the efficiency of the counter and S is the specific activity of the 
radioligand in Ci/mmol. This value was then converted into fmol per mg of protein 
or fmol per 106 according to the amount of protein or number of cells per assay tube 
(see section 2.4.3). Cells were counted using a haemocytometer.
2.4.2 Tritiated radioligand binding
The radioligand [3H]GR65630 (specific activity 75 Ci/mmol) was purchased from 
Perkin Elmer. This radioligand is membrane permeable and was therefore used for 
binding to permeabilised cells. Cell membranes were prepared by freeze/thawing 
and were resuspended in phosphate buffer containing protease inhibitors (4 p,g/ml 
pepstatin, 8 p,g/ml leupeptin, 8 (ig/ml apoprotinin). Membranes were incubated with 
radioligand (10 nM [3H]GR65630) for 2 hours on ice. Non-specific binding of
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[3H]GR65630 was determined by adding 12.5 mM 5-hydroxytryptamine (5-HT) 
(Sigma). Samples were harvested onto Whatman GF/B filters pre-soaked in 0.5% 
w/v polyethylene-imine with a Brandel cell harvester, and assayed by scintillation 
counting. The values obtained using the scintillation counter (disintegrations per 
minute, dpm) were converted into fmol of ligand bound using the equation:
1 9Specific disintegrations per minute/(S x 2.2 x 10' )
Where specific disintegrations per minute is equal to the total disintegrations minus 
the non-specific disintegrations, and S is the specific activity of the radioligand in 
Ci/mmol. There is no need to include the efficiency of the counter as the 
scintillation counter was set to give the disintegrations per minute, which is equal to 
the counts per minute divided by the efficiency of the counter.
2.4.3 Protein assay and cell counting
The protein concentration of cell membrane preparations was determined using a 
BioRad DC protein assay according to the manufacturer’s instructions. Typically, 
20 pi of diluted sample (1/10) or bovine serum albumin (BSA) standard was added 
to a semi-microcuvette (Starstedt) and mixed with 100 pi of Reagent A (alkaline 
copper tartrate solution). 800 pi of Reagent B (a dilute Folin Reagent) was added 
and mixed with vortexing. This was incubated at room temperature for 15-30 
minutes. Protein concentration was determined by measurement of the absorbance at 
750 nm with a spectrophotometer. Samples were compared to BSA standards at 
concentrations of 0.1, 0.2, 0.4, 0.8, 1.0, 1.2 mg/ml.
2.5 C ell surface enzym e-linked  an tib od y assay
The antibody pAbl20 (Spier et al., 1999) was used to label the extracellular N- 
terminal domain of the 5-HT3A subunit and the 5-HT3A3’4Loop'a7 chimera. The 
primary antibody pAbl20 was used at 1/750 and the secondary antibody goat-anti- 
rabbit was used at 1/2000. Cells transiently transfected onto 13 mm glass cover slips, 
were washed with HBSS supplemented with 25 pM MgCb and 25 pM CaCh 
(HBSS++).
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Non-specific binding was blocked by incubation in HBSS^ with 2% BSA 
(BLOCK). Cells were incubated with the primary antibody in BLOCK and 10% 
FCS for 1 hour in a humidified chamber. Cells were then washed five times in 
HBSS and fixed using 3% paraformaldehyde (Sigma) for 15 minutes. Cells were 
incubated in the secondary antibody conjugated to horseradish peroxidase (HRP) in 
BLOCK and 5% FCS for 1 hour in a humidified chamber. Cells were washed five 
times and then incubated in 750 pi of a liquid HRP substrate (3,3’,5,5’- 
tetramethylbenzidine, Amersham) to quantify antibody binding. The density of the 
colour change was measured with a spectrophotometer at 655 nm
2.5.1 Total cell receptor enzyme-linked antibody assay
The assay was performed essentially as described above but with the following 
changes: Cells were first fixed using 3% paraformaldehyde and permeabilised with 
0.1% Triton-XlOO, and then non-specific binding was blocked. The BLOCK 
solution contained 2% BSA, 10% FCS, 5% milk and 0.1% Triton-XlOO. 0.1% 
Triton-XlOO was also included in the wash solution.
2.5.2 Immunofluorescent microscopy
The protocol used for immunofluorescent labelling was very similar to that described 
for the enzyme-linked assay (Section 2.4). Cells were transfected as described in 
Section 2.2.2. Rhodamine a-B TX  (Molecular Probes) was used to visualize 
receptor localization in the cell. Cells were first fixed using 3% paraformaldehyde 
and permeabilised with 0.1% Triton-XlOO, and then non-specific binding was 
blocked. The BLOCK solution contained 2% BSA. The cells were incubated with 
250 nM rhodamine a-BTX in BLOCK for 1-2 hours in a dark humidified chamber 
then washed five times with HBSS++ and then once in water. The glass cover slips 
were mounted onto glass slides (BDH) in FluorSave (Calbiochem), and examined 
with a Zeiss Axiophot microscope using a Plan-Apochromat 100X 1.4 oil-immersion 
objective.
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2.6 In tracellu lar calcium  assay
Cells were re-plated into dark-walled 96-well tissue culture plates (Falcon, Becton 
Dickinson) 12-16 hours after transfection. The assay was performed 40-48 hours 
after transfection. The medium was removed from the cells which were then 
incubated in the membrane-permeable ratiometric calcium-sensitive dye Fluo 4 
acetoxymethyl ester (1 pM) plus 0.02% Pluronic® F-127 (Sigma) in HBSS at room 
temperature for 1 hour. The cells were then washed 2-3 times in HBSS and then 
incubated in an appropriate buffer, either HBSS or high calcium (HCA). The 
composition of the HCA buffer is as follows: 35 mM sucrose, 75 mM CaCh, 25 mM 
Hepes pH 7.4). The response of the cells to agonist was then assayed using a 
fluorometric imaging plate reader (FLIPR) (Molecular Devices, Winnersh) 
(Schroeder and Heagle, 1996). Cells were excited by light of 488 nm from a 4 W 
argon-ion laser and the emitted fluorescence passed through a 510 to 570 nm 
bandpass interference filter before detection with a cooled ‘charge coupled device’ 
camera (Princeton Instruments). A range of concentrations of agonist were prepared 
in a separate 96-well plate (Nunclon) for each assay, such that each column had a 
different concentration. The agonist was added to the cells and, after the continued 
presence of the agonist for 2 minutes, 2 pM iononmycin (Sigma) was applied to the 
cells. Ionomycin permeablilsed the cell membranes and allows calcium to enter.
The data was exported and analysed using Microsoft Excel. The background level of 
fluorescence was calculated for each well using the average of the values and time 
points before agonist application. The fluorescence value at each time point was 
divided by the backgound level to normalise the data. Each 96-well plate had at least 
two rows of mock transfected cells. Data averaged from these cells were used as a 
negative control. To calculate the actual response of each well of transfected cells, 
the values at each time point of the mock transfected cells were subtracted from the 
values of the transfected cells at equivalent agonist concentration applications within 
the same 96-well plate. There were two to four rows of cells transfected with the 
same DNA, and the results of these were averaged.
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The size of the peak of the response was plotted against the concentration of agonist 
used to produce concentration-response curves. The data was imported into 
SigmaPlot, which was then used to fit the data with the Hill equation:
R=Rmax x (AnH/(AnH + ECso""))
Where R is the response to agonist, R max is the maximum response to agonist, A is 
the concentration of agonist, nH is the Hill coefficient and EC50 is the concentration 
that evokes the half maximal response.
2.7 Electrophysiological recording
HEK tsA201 cells, grown on glass cover slips coated in collagen and polylysine, 
were co-transfected with pEGFP-C2 (Clontech), encoding green fluorescent protein, 
and plasmids containing either wild type or chimeric subunit cDNA in the ratio of 
1:20 .
2.7.1 W hole-cell patch-clamp recording
Whole-cell recordings were performed at room temperature, 38-48 hours after 
transfection. All chemicals listed in this section were obtained from Sigma. 
Recording solution contained (in mM): 110 NaCl, 5.4 KC1, 0.8 MgCh, 1.8 CaC^, 25 
glucose, 0.9 NaH2PC>4, 44 NaHCC>3 equilibrated with 95% O2 and 5% CO2. 
Borosilicate glass pipettes (Harvard GC150F-7.5) of resistance 2-8 MQ contained 
(in mM) 140 CsCl, 10 Hepes, 10 EGTA, 0.5 CaCb, 29.53 CsOH, pH adjusted to 
7.26, osmolarity 283 mOsm/Kg H2O. The series resistance and the whole cell 
capacitance were measured, and for all cells patched they were 28±0.4 MQ and 33±3 
pF respectively («=388). For cells transfected with 5-HT3A the series resistance was 
compensated by at least 80 %. Unless otherwise specified, the holding potential was 
-60 mV. Fast cell superfusion was achieved with a theta-barrelled application 
pipette made from 1.5 mm diameter borosilicate glass theta tubing (Harvard AH-30- 
0114), which was moved laterally using a stepper motor.
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Agonist evoked currents were recorded using an Axopatch 200B amplifier. These 
were stored on magnetic or digital audio tape for subsequent analysis or digitised 
online at 10 kHz using WinEDR (Strathclyde Electrophysiology Software; 
www.strath.ac.uk/Departments/PhysPharm) after filtering and further amplification 
to provide a low-gain DC, 2 kHz record that was used to measure the agonist- 
induced mean current.
2.7.2 Antagonist block and time course o f recovery
Whole-cell responses were blocked by the appropriate antagonist (Chapter 4). 
Antagonist was applied by exchanging the recording solution flowing through the 
bath for recording solution plus antagonist. The theta-barrelled application pipette 
was moved away from the cell to allow antagonist to wash on between agonist 
applications. Once a block of the responses was achieved the bath flow was 
changed back to recording solution alone to wash off the antagonist. The time 
course of recovery from block was examined for receptors that gave repeatable 
whole-cell responses every 10 seconds. The percentage of block of the response (as 
compared to the size of the response before the block) was plotted against time and 
the data fitted with an exponential equation:
C=Cmax X
Where C is the percentage block, Cmax is the maximum block, t is the time after the 
antagonist was removed and x the decay time constant for recovery from block. This 
allowed the estimation of the time constant, x, of recovery.
2.7.3 Reversal potential and rectification analysis
Rectification was investigated over the voltage range from -60 to +40 mV in 10 mV 
steps using three 500 ms agonist applications at 10 second intervals every minute. 
The size of agonist responses were verified at -40 and -60 mV after the final 
response at +40 mV. The data points were then fitted with a polynomial equation 
and the reversal potential (Erev) was calculated from the solved equation. The 
rectification was then quantified as follows:
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Rectification Index=[l4o/(40 -Erev)]/[I-6o/(-60-Erev)]
Where I40 is the current at +40mV, L60 is the current at -60 mV.
2.7.4 Desensitization analysis
The kinetics of desensitization were analysed on 20 second agonist applications for 
most constructs. For rat a  7 subunit, shorter (500 ms) agonist applications were used 
because of the rapid and complete desensitization of this receptor. Responses were 
inverted and fitted with single or double exponential functions:
I=SS+Imax x e'(t/x) (single) or I=SS+Imaxi x e'(t/xl) + ImaX2 x e'(t/x2) (double)
Where I is the whole cell current, Imax is the peak of the whole cell current, SS is the 
steady state current, t is the time after the peak of the whole cell current and x is the 
time constant of desensitization. The fit of a single or double exponential was fitted 
by eye. Thus the time constants (x) and relative amplitude for double exponential 
function and the steady state desensitization were obtained. Where a double 
exponential fit was used, a weighted time constant was calculated by multiplying 
each time constant by the proportion of its’ starting amplitude.
2.7.5 Conductance estimation from noise analysis
A high-gain band pass (2 Hz -2  kHz) record was recorded for variance and spectral 
density analysis. Both this high gain AC recording and the low gain DC recording 
were divided into segments of 0.82 seconds duration and edited to remove any 
segments with obvious artefacts.
2.7.5.1 Noise variance analysis
The relationship between the variance and the single-channel current can be derived 
from the binomial theorem, assuming that channels open independently from one 
another (Traynelis and Jaramillo, 1998). For a cell with N channels that have a 
single-channel current of i, the mean current (I) is equal to:
I=iNp
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where p is the probability that the channel is open. The current variance (o 21) is 
equal to:
or2 r=i2Np(l-p)
When this is rearranged and N is substituted for: 
aVilOp)
This means that when p is small (<0.1) then the variance is directly proportional to 
the mean current, with the single-channel current as the constant of proportion. The 
variance of each high gain AC segment was determined and plotted against the mean 
current of the equivalent low gain DC segment. This was then fitted with a straight 
line by linear regression and the single-channel conductance derived from the slope 
of the line (i), divided by the holding potential of the recording (-60mV in this case).
2.7.5.2 Noise power spectral density analysis
The relationship between the variance of the current fluctuations and the kinetics of 
receptor activation was examined by generating a power spectrum. The objective 
was to show how energy (amplitude squared per frequency) is distributed across the 
frequencies of the variance. A 10% cosine taper window was applied to each 
segment and the single-sided spectral density computed by fast Fourier transform 
and averaged over 16-32 logarithmically spread frequency ranges. The mean 
background spectrum was subtracted from the mean spectrum in the presence of the 
agonist to give the net agonist-induced noise spectrum. The single-channel 
conductance was calculated from the integration of the net power spectrum fitted 
with a single or the sum of two lorentzian components as judged by eye (Dempster 
2001);
S=S(0/(l+ (f/fc)2 (single) or S= S«,)i/(l+(f7fci)2+ S(0)2/(l+(f/fc2)2
Where S is the spectral density, S(o> is the asymptotic spectral density at zero 
frequency, f  is the frequency of the variation and fc is half power frequency. The
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time constant T=l/(2jtfc) is an estimate of the mean single channel open time 
(reviewed Traynelis and Jaramillo, 1998). For two-component spectra a weighted 
noise time constant was calculated from xw = x\A\ + T2A 2 where A\ and A2 are the 
relative areas of each Lorentzian component. The number of lorenztian equations 
used to fit the data does not reflect the number of conductance states. The single 
channel conductance, y, was calculated from;
Y=S(0)/ 4Im(V-Vrev)
Where Im is the mean current, V is the holding potential and Vrev is the reversal 
potential of the receptor.
2.8 S tatistical analysis
All statistical analysis was performed on Microsoft Excel, with a minimum 
significance level of /K0.05. For most comparisons in Chapter 3 and all in Chapter 
4, an F test was performed to examine whether data had the similar variances. If the 
variances were not significantly different a student’s t-test was performed. In cases 
where the variances were significantly different a modified Z test was performed. 
For the binding data in Chapter 3 Section 3.3.2 a 1-way analysis of variance and 
subsequent Tukey’s test was performed to determine whether any sample were 
significantly different.
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CHAPTER 3 
a7/5-HT3A Subunit Chimeras
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3.1 Introduction
The nAChR a l  subunit was first cloned in 1990 and, although it has been shown to 
generate functional homomeric receptors when expressed in Xenopus oocytes 
(Couturier et al., 1990a; Campos-Caro et al., 1997), considerable difficulties have 
been encountered in attempts to generate functional nAChRs by heterologous 
expression of a l  in a range of mammalian cell types (Cooper and Millar, 1997; 
Kassner and Berg, 1997; Rangwala et al., 1997; Zhao et al., 2003). In contrast, such 
difficulties have not been encountered in heterologous expression of homomeric 5- 
hydroxytryptamine (5-HT; serotonin) type 3 receptors (5-HT3RS). Heterologous 
expression of the 5-HT3A subunit results in efficient formation of functional 5-HT3RS 
in all cell types which have been examined (Maricq et al., 1991; Hargreaves et al., 
1994; Cooper and Millar, 1997; Gunthorpe et al., 2000).
A subunit chimera containing the extracellular domain of the a l  subunit and the 
transmembrane and intracellular domains of the murine 5-HT3A subunit generates 
high levels of functional cell-surface receptors in all cell lines tested, including cells 
in which a l  fails to do so, for example human embryonic kidney (HEK) cells (Eisele 
et al., 1993; Blumenthal et al., 1997; Rangwala et al., 1997; Cooper and Millar, 
1998). These findings have suggested that inefficient folding, assembly or 
trafficking of the a l  subunit can be attributed to regions other than the N-terminal 
domain (transmembrane and intracellular regions). This conclusion is supported by 
studies conducted with chimeras of a l  and 5-HT3A (Campos-Caro et al., 1996; 
Dineley and Patrick, 2000; Valor et al., 2002) and chimeras containing other nAChR 
subunits fused with a l  (Campos-Caro et al., 1997) or with parts of the 5-HT3A 
subunit (Cooper and Millar, 1998; Cooper et al., 1999; Harkness and Millar, 2001).
In the present study a series of subunit chimeras were constructed. The aim of this 
project was to identify which domains of the nAChR a l  subunit and the 5-HT3A 
subunit are important for folding, assembly or trafficking of these receptors. By 
heterologous expression of these chimeras in HEK tsA201 cells, domains have been 
identified which markedly influence folding, assembly, cell-surface expression and 
ion-channel conductance.
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3.2 Construction of chimeras
A number of chimeric subunits (Figure 3.1) were constructed containing regions of 
the rat nAChR a l  subunit (Seguela et al., 1993) and the murine 5-HT3A subunit 
(Maricq et al., 1991). All constructs were verified by nucleotide sequencing.
The a 7 (V201)/5-HT3A chimera (here referred to as a 7v201-5-HT3A) has been described 
previously (Eisele et al., 1993; Cooper and Millar, 1998). Three further a7/5-HT3A 
subunit chimeras (a7 S235-5-irnA a7 D265-5-HT3A a 7G301‘5‘HT3A) each of which
contained an N-terminal a l  domain and a C-terminal 5-HT3A domain have also been 
described previously (Cooper, 1998).
Chimeras in which the Ml and M2 domains of a l  were replaced by the 
corresponding regions of the 5-HT3A subunit (a72™'5'HT3A), and M l-M3 domains of 
a l  were replaced by the corresponding regions of the 5-HT3A subunit (a73™'5'HT3A), 
have been described previously (Cooper, 1998). Additional subunit chimeras were 
constructed, details of which are in the subsequent Sections (Section 3.2.1-3.2.7).
3.2.1 a 71TM-5HT3A
A chimera was constructed, in which the Ml domain of a l  was replaced by the 
corresponding region of the 5-HT3A subunit (a7 1TM'5'HT3A). A BspEl site was 
introduced into the a 7v201-5-HT3A chimeric DNA after Ml (at Ser235) by amplification 
using PCR with olignucleotides OL694(+) and OL695(-> The resulting fragment was 
subcloned into a Hindlll site (in the 5’ end of the multiple cloning site) and a BspEl 
site (introduced by site directed mutagenesis at Ser235) in a l.
Oligonucleotides used to amplify a7 V201'5'HT3A fragment:
OL694(+) 5’ CGA CTC ACT ATA GCG AGA CCC AAG CTT GCT A G 3'
Hindlll
OL695(.) 5' CTT GAA AGA GAC TCT CTC TCC GGA GTC CG 3'
BspEl
83
Ml M2 M3
n n ni n  h i
m —n—i ii n i
i n n i
a 7 V201-5HT3A
I II II I 
I M II I
a 7 S235-5HT3A
a 7 D265-5HT3A i—n—i
I II I I I  
L JJ-IL I
a 7 G301-5HT3A
I u u i
.
I Sa 7  3-4Loop-5HT3A nrrm
i n ii i
*a 7 1TM-5HT3A
I II II I 
I II II I
a 7 2TM-5HT3A
a 7 3TM-15HT3A
I II II I
a 7 4TM-5HT3A
I II II I
a 7 1/4TM-5HT3A
I II II I 
I II ll I
a 7 1/2/4TM-5HT3A
M II I
I II I
a 7 1/3-4TM-5HT3A
5 H T  3A 3"4Loop"a^
u u u
al □ al S
5HT3A ■ 5HT3A ■
Figure 3.1 Diagram of a7/5-HT3A chimeras.
The a l  and 5-HT3A domains are shown are shown, see keys. The four 
transmembrane (M1-M4) domains are indicated by the dashed boxes. TM- 
transmembrane domain. Loop -  M3 to M4 cytoplasmic loop. * indicates 
constructs nreoared bv the author.
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Oligonucleotides used for the site directed mutagenesis of cx7:
OL692c  5 GCT GCC TGC AGA CTC CGG AGA GAA AAT CTC TCT TG G 3'
BspEl
OL693(., 5' CCA AGA GAG ATT TTC TCT CCG GAG TCT GCA GGC AGC 3'
BspEl
3.2.2 a 7 4™ '5'HT3A
A chimera was constructed in which the M l-M3 and M4 domains of a l  were 
replaced by the corresponding regions of the 5-HT3A subunit (a74™'5'HT3A). This 
was achieved by annealing complementary PCR fragments amplified from a 7 3™’5' 
HT3A (region up to just before M4) and 5-HT3A (M4 to the end), and DNA 
polymerase I was used for elongation resulting in a change from a l  (at Val443) to 5- 
HT3a (at Val433). This fragment was then subcloned by digestion with Nhel and Sail 
into pZeo at the Nhel and Xhol sites in the multiple cloning site.
Oligonucleotides used to amplify the a 73™-5-HT3A fragment:
T7(+) 5 ATT AAT ACG ACT CAC TAT AGG G 3
OL292( )5 CAG CAG CCT GTC CAG CAC GCA GGC TCG AAA CTT CCA T 3
5-HT3A | al
Oligonucleotides used to amplify 5-HT3A fragment:
OL29i(+) 5 TTT GCA GCC TGC GTG CTG GAC AGG CTG CTG TTC CGC A 3
al | 5-HT3A
OL276(.) 5 - AAG CTG CAA TAA ACA AGT TGG GC 3
3 2 3 q  ^3-4Loop-5-HT3 A
A chimera was constructed in which the M3-M4 intracellular loop of a l  was 
replaced with the corresponding region of 5-HT3A (ay3-4100?-5^ ™ ), An Xbal site 
was introduced into the a 7G301-5-HT3A chimeric DNA (at Leu419) by amplification 
using PCR with olignucleotides T7 and OLso9(-)- The resulting fragment was 
subcloned into a BamEE site and an Xbal site in the multiple cloning site of pRK5 
(pRK5G301*).
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Oligonucleotides used to amplify a 7G301-5’HT3A fragment:
T7 - as shown above in Section 3.2.2
OL509(-) 5' GCA GCC TG TCTAGAA CGT ATC CCA C 3
Xbal
An Xbal site was introduced into the a l  cDNA (at Val444) by amplification using 
PCR with olignucleotides OL5o8(+) and SP6(.). The resulting fragment was subcloned 
into an Xbal site in pRK5G301*. As pRK5G301* was cut with a single restriction 
enzyme, to prevent religation the linearized plasmid was dephosphorylated by 
treatment with calf intestinal phosphatase (Chapter 2 Section 2.1.4).
Oligonucleotides used to amplify the a7(M4) fragment:
OL308(+) 5' CTG CTG TCT AGA CCG CTT GTG CC T3'
Xbal
SP6(.)5' TCT AGC ATT TAG GTG ACA CTA TAG 3l
3.2.4 5-HT3A3’4Loop"a7
A chimera was constructed in which the M3-M4 loop of 5-HT3A was replaced with 
the corresponding region of a l  (5-HT3A3“4Loop"“7). A section of the a 74™-5-HT3A
• 9 7 1chimera was subcloned from an Accl site at the position Val to an Apal site in the 
3’ end of the multiple cloning site, into an Accl site at Val286 to a Apal site after the 
3’ end of the cDNA in 5-HT3A subunit.
3.2.5 a 7 1/4™-5HT3A
A chimera was constructed in which the Ml and M4 domains of a l  were replaced 
with the corresponding regions of the 5-HT3A subunit (a 7 1/4™-5-HT3A) a  B stZ lll 
site was introduced into the a 7 ™ -5-HT3A chimeric DNA (at Val443) by amplification 
using PCR with oligonucleotides T7iong and OL745(.). The resulting fragment was 
subcloned into an EcoRl site (at the 5’ end of the multiple cloning site) and a
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BstZMl site in the a 74™-5-HT3A (introduced by site directed mutagenesis at a l  Val443 
making V443I, by Sebastian Kracun, this laboratory).
Oligonucleotides used to amplify the a 7 1TM-5-HT3A fragment:
T7iong(+)5 GAA ATT AAT ACG ACT CAC TAT AGG GAG 3’
OL745(.) 5 CGG TCC AGTATACAG GCT GC 3’
BstZMl
Oligonucleotides used for site directed mutagenesis of a 74™-5-HT3A
OL59i(+)5GGA AGT TTG CAG CCT GTA TAC TGG ACA GGC TGC TGT TCC GC3
BstZMl
OL592(-)5 GCG GAA CAG CAG CCT GTC CAG TAT ACA GGC TGC AAA CTT CC3
BstZMl
3.2.6 a 7 "2/4TM-5-HT3A
A chimera was constructed in which the M l-M2 and M4 domains of a l  were 
replaced with the corresponding regions of the 5-HT3A subunit (a 7 1/2/4™-5-HT3A) 
Exactly the same method was used as described for the a 7 1/4™-5-HT3A chimera in 
section 3.2.5, but using a fragment of the a 72™-5-HT3A chimera instead of the a 7 1TM'
5-HT3A c J1jm e r a
3.2.7 a 7 ^ - 4TM-5-HT3A
A chimera was constructed in which the Ml and M3-M4 domains of a l  were 
replaced with the corresponding regions of the 5-HT3A subunit (a 7 1/3-4™-5-HT3A) a  
Kpnl site was introduced into the a 7 ,TM-5-HT3A chimeric DNA between M2 and M3 
(at a position equivalent to Ser266 in a l)  by amplification using PCR with 
oligonucleotides T7iong and OLi69(-> The resulting fragment was subcloned into an 
EcoBl site (in the 5’ end of the multiple cloning site) and a Kpnl site in the a 7 D265'5' 
HT3A chimera (at a l  Ser266).
Oligonucleotides used to amplify a 7 1TM-5-HT3A fragment:
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T7iong - as shown above in section 3.2.5
OLi69(.)5' GGG GGT ACC ATC AGA TGT TGC TGG CAT GAT CTC3' 
Kpnl
RESULTS
3.3 Radioligand binding to assay correctly folded receptor protein
3.3.1 The a 7 VJ01 5 HT3A chimera
Human embryonic kidney tsA201 cells were transiently transfected with plasmid 
expression vectors encoding either the nAChR a l  subunit or a previously described 
subunit chimera, a 7V201-5-HT3A (Cooper and Millar, 1998). The subunit chimera 
a yV20i-5-HT3A contains N-terminal extracellular domain of the nAChR a l  subunit 
together with the C-terminal (intracellular and transmembrane) domain of 5-HT3A.
19SRadioligand binding was performed with [ I]a-BTX on transfected cells (as 
described in Chapter 2, Section 2.4). A Student’s t-test was used to test for 
significant differences. As has been reported previously (Eisele et a l, 1993; 
Blumenthal et a l, 1997; Rangwala et al., 1997; Cooper and Millar, 1998), high
1 9 Slevels of [ I]a-BTX binding were detected on the surface of cells transfected with 
a 7v20i-5'HT3A subunjt chimera (3.0±0.4 pmol/mg protein, n= 12; Figure 3.2), which 
were significantly different from background (p<0.001) and from the levels of 
binding seen with cells transfected with a l  (p<0.005). High levels of [,25I]a-BTX 
binding were also detected in permeabilised cells (3.4±0.7 pmol/mg protein, n= 11, 
significantly above background/K0.001). In contrast, no significant specific binding
p c
of [ I]a-BTX was detected on the surface of cells (0.01±0.01 pmol/mg protein) or 
in permeabilised cells (0.01 ±0.01 pmol/mg protein) transfected with the a l  subunit. 
These findings are in agreement with previous studies (Cooper and Millar, 1997) 
which have demonstrated that the lack of specific [125I]a-BTX  binding is a 
consequence of an inability of the a l  subunit to assemble efficiently into an 
appropriately folded nAChR in this host cell environment.
These and previous findings have clearly implicated regions within the C-terminal 
region of the a l  subunit in inefficient assembly of functional nAChRs (Eisele et al.,
88
1993; Blumenthal et a l, 1997; Rangwala et al., 1997; Cooper and Millar, 1998). 
Similar conclusions have been made from studies conducted with similar subunit 
chimeras which contain the N-terminal region of other nAChR subunits (e.g. a4  and 
|32 subunits) fused to the C-terminal region of 5-HT3A (Cooper et al., 1999; Harkness 
& Millar, 2001).
3.3.2 Additional a7/5-H T 3A chimeras
With the aim of identifying more precisely subunit domains influencing nAChR 
folding and assembly, several further a7/5-HT3A subunit chimeras were constructed 
as described in Section 3.1 (Figure 3.1) and the statistical significance was tested 
using an analysis of variance and a subsequent Tukey’s test. Chimeric subunits were 
expressed in tsA201 cells and examined for their ability to form a high-affmity 
binding site for [125I]a-BTX. As illustrated in Figure 3.2 and 3.3, no specific 
binding of [125I]a-BTX was detected in cells transfected with a7/5-HT3A chimeras 
containing an N-terminal a  7 subunit domain which terminated after transmembrane 
region Ml (a7S235-5'HT3A), M2 (a7D265'5-HT3A), or M3 (a7G301*5-HT3A). It would 
appear, therefore, that a l  sequences within the region of Ml (i.e. contained in 
a yS235-5-HT3A put absent jn a7 v20i-5-HT3A^  &re imp0rtant jn regulating efficient subunit
folding and assembly. A similar conclusion was made by a previous study of a7/5- 
HT3a chimeras (Dineley and Patrick, 2000).
Additional a7/5-HT3A subunit chimeras were constructed which contained the entire 
a l  sequence, except for selected transmembrane domains and in between 
transmembrane domains derived from the analogous regions of 5-HT3A (a7 1TM'5' 
HT3A, a 7 2™ - 5-HT3A, a 7 3TM-5-HT3A a 7 4TM-5-HT3A p i g u r e  3  ^  chimeras containing the
Ml region of 5-HT3A (a7 1TM’5’HT3A), Ml and M2 plus M l-M2 intracellular loop of 5- 
HT3a (a 72™-5-HT3A) or the M l, M2 and M3 plus the M l-M2 intracellular and M2- 
M3 extracellular regions (a 73™-5-HT3A) showed little or no specific [125I]a-BTX  
binding on the cell surface or within the cell (Figure 3.2). Replacement of the Ml 
domain of a l  alone with the analogous region of 5-HT3A is, therefore, not sufficient 
to permit efficient folding of a l.  Expression of a chimera (a74™'5'HT3A), which 
contained all four of the predicted transmembrane domains and the M l-M2 and M2- 
M3 regions from 5-HT3A, but containing the N-terminal and the large M3-M4
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Figure 3.2 Specific surface [125I]a-BTX binding of a7 and a7/5-HT3A 
chimeras in transiently transfected tsA201 cells.
Cells were counted and protein was assayed for each experiment to give (A), 
specific binding in pmol per 106 cells and (B), specific binding in pmol per mg 
of protein. n=6-12. The results were tested for significant differences using an 
analysis of variance and a subsequent Tukey’s test. * p<0.05 and ** /xO.Ol 
when compared to all other samples except a 7V201'5HT3A and a74™'5HT3A
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Figure 3.3 Specific total [  I]a-BTX binding o f a l  and al/5H Tu chimeras 
in transiently transfected tsA201 cells.
(A) Binding was done on the same cells as for whole cell binding, but cells 
were permeabilized, see methods section 2.3.1. n=6-12. The results were tested 
for significant differences using an analysis of variance and a subsequent 
Tukey’s test. ** /?<0.01 when compared to all other samples except a7 V201'
5HT3A and a l4TM-5HT3A Saturation binding in cells transfected with (B) the
a l V201-5HT3a and (C) the a l 4TM-5HT3a, n=2. Data was fitted with the Hill
equation in SigmaPlot. Kd values of 4.1±0.5 nM, 6.1±0.6 nM, and nH values of 
1.3±0.1, 1.3±0.3 respectively.
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intracellular loop of a7, resulted in high levels of specific [125I]a-BTX binding on 
the cell surface (2.6±0.4 pmol/mg protein, n=6; Figure 3.2, /?<0.001) and with 
permeablilsed cells (3.5±0.7 pmol/mg protein, «=6; Figure 3.3, /?<0.001). These 
values are not significantly different from those of the a 7v201-5-HT3A chimera. 
Saturation binding was performed on the a 7v201-5-HT3A ancj a 74TM-5-HT3A 
determine the concentration of [125I]a-BTX that would provide a fair comparison of 
the levels of binding of these two chimeras. There was no significant difference in 
the size of the dissociation constant or the hill coefficient tested (student’s t-test). 
The proportion of the receptors on the cell surface can be determined by dividing the 
cell surface binding by the total (permeabilised) cell binding. There was no 
significant difference between the two constructs that showed specific radioligand 
binding (a 7V20'-5-HT3A 73±6%, a 7 « M . 5-HT3A 85±19%, student’s t-test). This suggests 
that the subunit sequence within both the Ml and M4 regions are critical in 
regulating efficient subunit assembly and subsequent export to the plasma 
membrane.
To examine whether the transmembrane domains other than Ml and M4 are 
necessary for correct subunit folding and assembly, additional chimeras were made 
containing the entire a7  sequence except for the Ml and M4 of 5-HT3A (a 7 1/4™'5' 
HT3A) the M l, M2, M l-M2 intracellular region and M4 of 5-HT3A (a 7 1/2/4™-5’HT3A) 
and the M l, M3, M3-M4 intracellular loop and M4 of 5-HT3A (a 7 1/3-4™-5-HT3A)> 
None of these chimeras showed significant specific [125I]a-BTX  binding on the cell 
surface or within the cell (n=4, Figures 3.2 and 3.3).
These findings demonstrate that efficient subunit folding and assembly (as assayed 
by [125I]a-BTX binding) is possible in tsA201 cells only for those subunits 
examined which contain the region from the beginning of Ml to the end of M3, and 
including M4 from 5-HT3A (a 7V201-5-HT3A and a74™'5'HT3A). Replacement of the 
large intracellular loop of a 7V201-5-HT3A with that of the a l  subunit (a 74™-5-HT3A) did 
not have a significant effect on levels of [125I]a-BTX  binding (Figures 3.2 and 3.3). 
To examine further the influence of the large intracellular loop, two additional 
chimeras ( a 7 3'4LooP-5‘HT3A ancj 5-HT3A3*4Loop‘a7) were constructed (Figures 3.1). No 
[125I]a-BTX binding was detected in cells transfected with a 73-4Lo°p-5-HT3A (Figures
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3.2 and 3.3). High levels of specific binding of the 5-HT3A receptor ligand 
[3H]GR65630 (a membrane-permeable ligand) were detected in permeabilised cells 
transfected with 5-HT3A3’4Loop’a7 (0.47±0.14 pmol/mg protein, n=4; Figure 3.4A). 
When this construct was compared with the 5-HT3A subunit (0.30±0.09 pmol/mg 
protein, «=4; Figure 3.4A) there appeared to slightly greater specific binding with 
the 5-HT3A3’4Loop’a7 chimera, however this was not a statistically significant 
difference (student’s t-test). These findings are consistent with the conclusion that 
only those subunit chimeras containing regions from the beginning of Ml to the end 
of M3, and including M4 of 5-HT3A fold and assemble efficiently in tsA201 cells. 
These findings also provide further evidence that efficient or inefficient subunit 
folding is not determined by sequences present within the large intracellular loop 
region.
3.3.3 Enzyme-linked assay to determine cell surface receptors
As the serotonergic radioligand [ H]GR65630 is membrane permeable, it was not 
possible for it to be used selectively to detect cell surface receptors. For this reason 
an enzyme-linked assay was used with tsA201 cells transfected with the 5-HT3A 
subunit and the $_HT3A3’4Loop’a7 chimera to examine levels of cell surface receptor. 
The antibody pAbl20, which is immuno-reactive to the extracellular N-terminal 
domain of the 5-HT3A subunit (Spier et al., 1999), was used with the protocol 
described in Chapter 2, Section 2.5, for both intact cells (w=7) and permeabilised 
cells («=5) and either a student’s t-test or modified z-test has been used to test 
significance. As expected, the 5-HT3A subunit showed a significant signal above 
background for cell surface receptors (p<0.005) and total cell protein (p<0.005) 
(Figure 3.4). The 5-HT3A3‘4Loop’a7 chimera showed significant total cell protein 
(p<0.01), in agreement with data from radioligand binding. Again, this appeared to 
be greater than with the 5-HT3A subunit, but was not a statistically significant 
difference. With intact cells there was also a significant signal (p<0.005), however 
this was consistently higher in cells transfected with the 5-HT3A3’4Loop'a7 chimera 
compared to the 5-HT3A subunit (/?<0.01). Thus it seems that the 5-HT3A3'4Loop’a7 
chimera is more efficiently expressed at the cell surface than the 5-HT3A subunit. It 
was not possible to compare the cell surface to total cell signals, because the 
background levels of antibody binding in permeablilsed cells was much greater than
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A B C
Figure 3.4 Surface and total expression o f  5-HT3A and the 5-HT3A3'4Loop~a7 
chimera transiently transfected in tsA201 cells.
(A), specific total [3H]GR65630 binding in permeabilised cells n=4. Enzyme- 
linked assay on (B) permeablilsed, n=4 and (C) whole cells, n=7. The results 
were tested for significant differences using a student’s t-test or a modified Z 
test, **p<0.01.
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with intact cells, thus probably masking some of the 5-HT3A N-terminal protein 
levels.
3.4 Intracellu lar calcium  assay
The experiments described provide strong evidence for the role of discrete subunit 
domains as determinants of the ability of subunit proteins to form correctly folded 
ligand-binding sites and to be expressed on the cell surface. However, they do not 
address the question of whether these subunit chimeras are able to generate 
functional agonist-gated ion channels. To examine this question, the chimeras that 
showed significant cell surface radioligand binding were assayed for function using 
an intracellular calcium assay with a population of cells. HEK tsA201 cells were 
transiently transfected with either the 5-HT3A subunit or one of the three chimeric 
constructs that showed significant radioligand binding in Section 3.4 (5-HT3A3*4Loop' 
<l7,a7v201'5'HT3A and cx74™'5'HT3A). The cells were re-plated into 96-well plates and a 
fluorescent calcium-sensitive dye was used as described in Chapter 2, Section 2.6. A 
fluorometric imaging plate reader (FLIPR) was used to measure in the influx of 
calcium upon agonist application. The agonist was added to the wells 35 seconds 
into the trace (indicated with a red arrow) after which time the cells are constantly 
bathed in the agonist. Agonist-induced elevations of intracellular calcium were 
detected in cells transfected with the 5-HT3A subunit, as would be expected (Figure 
3.5A), and also the three chimeric subunits. As would be expected from the 
presence of the N-terminal region of 5-HT3A, the 5-HT3A3"4Loop’(x7 chimera responded 
to 5-HT3 receptor agonist (mCPBG), Figure 3.5B. The agonist mCPBG was chosen, 
as it is a more potent ligand at the homomeric 5-HT3A receptor than 5-HT ( E C 5 0  0.8 
pM, Mair et a l,  1998). Similarly, nicotinic agonists (DMPP and nicotine) induced 
elevations of intracellular calcium were detected in cell transfected with the a7 v201'5' 
HT3A and a 74™-5-HT3A chimeras, which have the a l  N-terminal regions (see Figure
3.5 C and D). More consistent increases in intracellular calcium were detected with 
DMPP compared to nicotine, where the increase in calcium did not always relate to 
the concentration of nicotine used. Thus, the chimeras that showed binding also 
showed significant calcium influx upon application of agonist. This was interpreted 
as showing function of these constructs.
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Figure 3.5 Agonist-induced calcium responses in tsA20J cells transiently 
transfected with 5-HTu and a7/5-HT3A chimeras.
(A), 10 jiM CPBG applied to cell transfected with 5HT3A subunit. (B), 10 pM 
CPBG applied to cells transfected with 5HT3A3'4Loop‘a7 chimera. (C), 17 pM 
DMPP applied to cells transfected with the a7V201'5HT3A chimera. (D), 1.8 pM 
DMPP applied to cells transfected with the a74™'5HT3A chimera. The red line 
indicates when the agonist was applied.
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Agonist concentration-response curves were determined using a 96-well FLIPR 
assay, to give a rough estimate of the potency of the agonists and the comparative 
size of the responses obtained. Each column of wells had a different concentration 
of agonist, and 2-4 rows of wells were transfected with each DNA contruct 
(including an “empty” vector as a control) thus giving an n number of 2-4 for each 
concentration. Two different buffers were used, Hank’s buffered saline solution 
(HBSS) and a high calcium buffer (HCA, see Chapter 2 Section 2.6). The HBSS 
buffer has physiological concentrations of calcium (1.26 mM), whereas the high 
calcium buffer has 75 mM CaCl, a very high level of calcium which may amplify the 
influx of calcium. The results shown are from a single transfection, and the results 
were fitted with the Hill equation using SigmaPlot (see Chapter 2 Section 2.6). For 
cells transfected with the 5-HT3A subunit, maximum calcium influx was achieved 
with 0.3 pM mCPBG in HBSS (Figure 3.6 A) and 10 pM mCPBG in HCA(Figure 
3.7 A). The EC50 of this ligand with this subunit is 0.8 pM (Mair et a l , 1998), and 
the value obtained from this experiment is close at approximately 0.2 pM (HBSS) 
and 2.1 pM (HCA). When compared to the 5-HT3A3'4Loop’a7 chimera, it can be seen 
that this chimera responds by a greater amount to the same concentration of ligand. 
Thus, there are either more receptors per cell or the efficacy of this ligand is greater 
at this chimera than at the 5-HT3A subunit. According to the enzyme-linked assay 
experiments (Section 3.4.3) there was three times the amount of the protein on the 
cell surface in cells transfected with the 5-HT3A3’4Loop’a7 chimera when compared 
with the 5-HT3A subunit. This is sufficient to account for the greater response of the 
chimera in the calcium-influx assay. From the concentration-response curve for 
mCPBG with this chimera in Figure 3.6B and 3.7B the EC50 (0.3 pM HBSS, 1.3 pM 
HCA) is similar to that of the 5-HT3A subunit.
The concentration-response curves for the nicotinic ligand DMPP were obtained 
with the a 7V201-5-HT3A anci a74™‘5'HT3A chimeras (Figures 3.6 C and D, 3.7 C and D). 
It can be seen that the a 74™‘5'HT3A chimeras respond to a greater extent to the same 
concentration of ligand when compared to the a 7v201-5-HT3A chimera by 
approximately four times (at 50 pM DMPP). The level of surface radioligand 
binding was not significantly different between these two chimeras, thus the 
difference in the calcium influx may be due to differences in efficacy of this ligand
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Figure 3.6 Concentration-response relationship for agonist induced calcium 
responses from tsA201 cells in HBSS, transiently transfected with 5-HT3A and 
a7/5-HT3A chimeras.
From one experiment with (A), CPBG applied to cells transfected with 5-HT3A 
subunit. (B), CPBG applied to cells transfected with 5-HT3A3'4Loop'a7 chimera. 
(C) DMPP applied to cells transfected with the a 7 V201'5HT3A chimera. (D), 
DMPP applied to cells transfected with the a 7 4™ ' 5HT3A chimera.
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Figure 3.7 Concentration-response relationship for agonist induced calcium 
responses in tsA201 cells in high (75mM) calcium buffer transiently 
transfected with 5 -HT3A and a7/5-HTiA chimeras.
From one experiment with (A), CPBG applied to cells transfected with 5HT3A 
subunit. (B), CPBG applied to cells transfected with 5-HT3A3'4Loop‘a7 chimera.
(C) DMPP applied to cells transfected with the a7 V201’5HT3A chimera. (D), 
DMPP applied to cells transfected with the a74TM'5HT3A chimera.
99
between the two receptors. Alternatively, it is possible that a proportion of the 
surface receptors are non-functional in cells transfected with the a 7V201'5 Hr3A 
chimera. The EC50 values can only be estimated from the results in the HCA buffer, 
as it can be seen in Figure 3.6 C and D that the saturating concentration of ligand has 
not been reached in HBSS. The EC5o values in the HCA buffer were 4.87 pM for 
the a7 V201'5'HT3A chimera and 1.6 pM for the a7 4™'5 HT3A chimera.
3.5 Whole-cell responses
The chimeras that showed calcium influx on application of agonist were also tested 
for function by whole-cell patch-clamp recording in transiently transfected HEK 
tsA201 cells. The purpose of these experiments was to examine in more detail the 
functional properties in single cells as opposed to a population of cells. Cells were 
co-transfected with a receptor subunit or chimera and a GFP containing plasmid. It 
was confirmed that cells that express the GFP protein also express a chimeric protein 
when they are co-transfected (Figure 3.8).
A B C
Figure 3.8 HEK tsA201 cells co-transfected with o f™ -5-1*™ anj  pEGFP- 
C2, stained with rhodomine ctBTX.
(A) light micrograph and the same cells (B) showing GFP fluorescence and (C) 
rhodomine fluorescence. There is a good correlation between cells that show 
fluorescence in (B) and (C).
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In each case, functional responses to rapid agonist application were obtained at -60 
mV holding potential (unless stated otherwise), as illustrated in Figure 3.9. Either a 
student’s t-test or modified z-test was used to test for significance when comparing 
either the size or the functional characteristics of the responses. The 5-HT3A and 5- 
HT3A3’4Loop’a7 receptors responded to 5-HT3 receptor agonists (mCPBG and 5-HT) 
with inward currents. 5-HT was chosen to be used for the subsequent experiments as 
it is less potent than mCPBG, and it was desirable to have responses less than 2 nA. 
The average response of the 5-HT3A receptor to different concentrations of 5-HT 
were as follows: 0.139±0.039 nA to lpM  5-HT (n=6) and 1.28±0.439 nA to 4 pM 5- 
HT (n=4). The 5-HT3A3'4Loop'a7 chimera had significantly larger responses at 1 pM 5- 
HT (1.3±0.5 nA >7=10, p<0.05). This is an order of magnitude greater than the 5- 
HT3A responses to this concentration. This cannot be solely accounted for by the 
approximately three fold greater amount of protein on the cell surface (Figure 3.4). 
A number of responses were obtained from this chimera at a higher concentration (2 
pM 5-HT), with an average response of 0.8±0.2 nA (n=6). This is not significantly 
different from the responses at 1 pM 5-HT, suggesting that 1 pM is equal to or 
greater than the maximally effective concentration. The E C 5 0  of 5-HT on the 
homomeric 5-HT3A receptor is 2.6 pM (Hubbard et al., 2000), thus 5-HT seems to be 
more potent at the 5-HT3A3"4Loop*a7 chimera compared to the 5-HT3A subunit assuming 
that this E C 5 0  is equal to that of the homomeric 5-HT3A receptor in these 
experiments.
The a 7V20,-5-HT3A ancj a y4TM-5-HT3A responded to the nicotinic agonist
DMPP (Figure 3.9 C and D, 400 pM and 100 pM respectively). Three 
concentrations of DMPP were applied to the a 7V201-5-HT3A chimera, and there was no 
significant difference in the size of the response, (100 pM, 287±117 pA, n=6; 200 
pM, 245±54 pA, n=5; 400 pM, 295±121 pA, n=5) it was therefore concluded that 
100 pM is equal to or greater than the maximally effective concentration. 
Concentrations below 100 pM were tried but the responses were not reliable. In 
contrast to the a7 v201"5"HT3A chimera, the a 74™'5*HT3A chimera showed responses at 
concentrations as low as 20pM DMPP. The average response at 20 pM DMPP 
(372±94 pA, n=l) was not significantly different from the responses of the a7 V201'5' 
HT3A chimera at 100 pM DMPP. A higher concentration of DMPP was applied to
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Figure 3.9 Whole-cell responses in tsA201 cells transiently transfected with 
5-HT3a and a7/5-HT3A chimeras.
The bar above the responses indicates a 500 ms application of agonist with (A), 
4 pM CPBG applied to a cell transfected with the 5-HT3A subunit. (B), 4 pM 
CPBG applied to a cell transfected with 5HT3A3'4Loop'a7 chimera. (C), 400 pM 
DMPP applied to a cell transfected with the a 7 V201'5HT3A chimera. (D), 100 pM 
DMPP applied to a cell transfected with the cx7 4™ ' 5 H T 3a  chimera. Holding 
potential was -60 mV.
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cells expressing the a 74™_5’HT3A chimera (lOOpM DMPP, 439±64 pA, n—4), but 
there was no significant difference between responses to 20 pM and 1 OOpM. Thus, 
it seems that 20 pM may be greater or equal to the maximally effective concentration 
for the a 74™-5'HT3A chimera. As there are approximately equal numbers of receptors 
on the cell surface (see Figure 3.2), the differences between the two chimeras may be 
due to either a greater number of functional receptors on the surface of cells 
transfected with the a 74™-5'HT3A chimera, or DMPP is a more potent agonist at the
a 7 4TM-5-HT3Ar e c e p t( )r s  ^  ^  a 7 V201-5-irr3A
All of the subunits for which radioligand binding was detected, and for which 
functional expression has been confirmed (5-HT3A, 5-HT3a3’4Loop'(i7, a 7V201'5'HT3A 
and a74™'5'HT3A), contain identical hydrophobic transmembrane domains (Ml, M2, 
M3 and M4) from 5-HT3A, but different N-terminal and large cytoplasmic loop 
domains (either a7  or 5-HT3a). The homomeric a7  and 5-HT3A receptors have some 
significantly different functional properties including desensitization, rectification 
and single-channel conductance, and it was therefore decided to examine these 
properties in the a7/5-HT3a chimeras transfected in a HEK tsA201 cell line.
3.5.1 Reversal potential and rectification properties
The reversal potentials for the a7 and 5-HT3A subunit receptors are not significantly 
different from each other (Puchacz et al., 1994; Hubbard et al., 2000), however there 
is a large difference in the rectification properties. The reversal potential and 
rectification of the subunits were investigated by obtaining triplicate responses at 
holding potentials from -60 to +40 mV (an example of a cell transfected with the 5- 
H t3a3-4Loop-«7 chimera, with brief (500 ms) agonist applications shown in Figure 
3.10). There were no significant differences in these two functional characteristics 
between the four subunits. The reversal potentials for the 5-HT3A subunit and the 5- 
HT3A3'4Loop'a7, a7 v20l'5'HT3A and a 74™‘5~HT3A chimeras were 1.15±1.25, 5.83±2.62, 
4.78+2.55 and 3.64+2.40, mV respectively, similar to that previously described for 
the wild-type 5-HT3A subunit (-2.7mV; Hubbard et al., 2000) and the rat a l  subunit 
(OmV; Puchacz et al., 1994). The rectification profile for the four subunits showed 
little inward rectification, the rectification indices (see Chapter 2, Section 2.7.3) were
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Figure 3.10 Reversal potential and rectification o f whole-cell responses from  
tsA201 cells transiently transfected with 5 -HT3A and a?/5-HT '3.4  chimeras.
(A), an example of brief agonist applications done in triplicate to obtain 
current-voltage relation, with a cell transfected with the 5-HT3A3'4Loop‘ct7 
chimera. (B)-(E), mean current voltage relations for the 5-HT3A subunit (B), 
the 5-HT3A3'4Loop*a7 chimera (C), the a 7 V201' 5HT3A chimera (D) and the ctf4™" 
5HT3 a  chimera (E). The responses were normalised to the response obtained at - 
60 mV. «=5.
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0.93±0.09, 1.08±0.04, 0.94±0.08 and 1.01 ±0.15 respectively. These functional 
characteristics are more similar to those shown previously for the 5-HT3A receptor 
(Gunthorpe et al, 2000, Hubbard et al, 2000) as compared to the a l  subunit 
(complete inward rectification; Puchacz et a l, 1994, Zhao et al., 2003).
3.5.2 Desensitization properties
The homomeric a l  nAChR is known to desensitise rapidly, and the responses have a 
time constant of decay in the region of tens of milliseconds (e.g. 75 ms, Ragozzino et 
al, 1997). In comparison, the 5-HT3A subunit desensitises much more slowly with a 
time constant in the timescale of seconds (e.g. 2.13 s, Gunthorpe et al, 2000). The 
desensitization of the three chimeras and the 5-HT3A subunit were compared using 
long 20 second agonist applications (Figure 3.11 A). 1 pM 5-HT was applied to the 
5-HT3a subunit and the 5-HT3A3'4Loop'a7 chimera. This concentration is lower than 
the EC50 value of the homomeric 5-HT3A receptor, however the maximally effective 
concentration would produce very large responses that would not give reliable data. 
200 pM DMPP was applied to the a 7V201-5’HT3A ancj a y4TM-5-HT3A cijjmeraSj an(j ^ is
value should give the maximum whole-cell responses. The decay of the 
desensitization was fitted with an exponential equation. The time constant of decay 
could then be obtained (see Chapter 2 Section 2.7.4), see Figure 3.11 for examples of 
the decay fitted with an exponential equations for 5-HT3A and each of the chimeras. 
The steady state desensitization calculated from the curve fitted to 18 seconds of 
agonist application and expressed as a % (he final current divided by the peak 
current) was also compared.
There was a significant difference between the a 7V201'5-HT3A ancj a 74TM-5-HT3A 
chimeras, both activated by nicotinic agonists (denoted nicotinic subunits) as 
compared to the 5-HT3A3’4Loop'a7 chimeras and 5-HT3A subunit, activated by 
serotonergic agonists (denoted serotonergic subunits). However, the rate of decay 
was not determined from the maximally effective concentration of 5-HT, thus the 
nicotinic and serotonergic subunits cannot be directly compared. The time constant 
for decay for the two nicotinic subunits were 223±32 ms for a 7v201"5-HT3A ancj 
925±220 ms for a 74™-5-HT3A (Figure 3.13A). These values are smaller than 
previously published values obtained for the homomeric 5-HT3A receptor (2.13 s,
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Figure 3.11 Long agonist applications: whole cell responses from tsA201 
cells transiently transfected with 5-HT\ 4 and a?/5-HT3a chimeras.
(A), 1 pM CPBG applied to a cell transfected with 5-HT3A subunit. (B), 1 pM 
CPBG applied to a cell transfected with the 5-HT3A3‘4Loop'a7 chimera.
(C), 200 pM DMPP applied to a cell transfected with the a 7 V201*5HT3A chimera.
(D), 20 pM DMPP applied to a cell transfected with the cx7 4™ * 5 H T 3a  chimera. 
The black bar above the trace indicates the agonist application.
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Figure 3.12 Inverted whole-cell responses from tsA201 cells transiently 
transfected with 5 -HT3A and a7/5-HT3A chimeras, fitted with an exponential 
equation to detemine desensitization characteristics
20 second agonist applications were analysed to obtain the time constant of 
decay and the percentage of desensitization of the 5-HT3A subunit (A) the 
5-HT3A3"4Loop"c‘7 chimera (B) the a7 V201'5HT3A chimera (C) and the a74™'5HT3A 
chimera (D) see methods section 2.6.4. D, percentage desensitization; x, time 
constant of decay, n= 5. A single exponential was used to fit to the data in (A),
(B) and (C) and a double exponential was used to fit the data in (D).
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Figure 3.13 Desensitisation characteristics o f whole-cell responses from  
tsA201 cells transiently transfected with 5-HTsa and ol7/5-HT$a chimeras.
20 second agonist applications were analysed, to obtain the mean time constant 
of the decay of desensitization (A) and the mean percentage of desensitization
(B) in cells transfected with the 5-HT3A subunit and the 5-HT3A3'4Loop'a7, a7- 
V201-5m3Aand a,74™'5HT3Achimeras. *=6-8.
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Gunthorpe et al, 2000). This indicates that the N-terminal extracellular domain may 
play a role in determining the rate of desensitization.
There was a significant difference between the a 7V20,-5-HT3A an(j a y4TM-5-HT3A 
chimeras (223±32 ms and 925±220 ms respectively, p<0.02), which suggests that the 
large intracellular loop can also affect the rate of desensitization. However, the time 
constant for decay of the 5-HT3A3 4Loop"a7 chimera (7067±878 ms) was not 
significantly different to that measured for the 5-HT3A subunit, despite having 
different intracellular loops.
The steady state percentage desensitization estimated from the exponential fitting 
was also determined for the four constructs. This was greater for the two 
serotonergic subunits when compared to the nicotinic subunits (70.8±3.2% for
a 7 V20l-5-HT3A ^  6 4  6 ± 2  9 0/0 f o r  9 0  7 ± 0  9 o/o  f o r  ^
84.1±7.1% for 5-HT3A, Figure 3.13B, n=6-8, p<0.05), despite the serotonerigic 
agonist not being at maximally effective concentration. There was no significant 
difference between the two nicotinic subunits, or between the serotonergic subunits.
3.5.3 Estimate of the single-channel conductance from noise analysis
Previous studies have reported that homomeric 5-HT3A receptors, produced by the 
heterologous expression of 5-HT3A, exhibit very small (sub-pS) single-channel 
openings (Hussy et al., 1994; Kelley et a l, 2003) in contrast to the homomeric rat a l  
subunit that have been shown to have a significantly larger single-channels of 72 and 
87 pS when expressed in Xenopus oocytes (Fucile et a l,  2002), although it should be 
noted that the conductance for chick a l  is lower in mammalian cell lines (18.5 and
31.5 pS; Ragozzino et a l, 1997) when compared to Xenopus oocytes (45 pS; Revah 
et al, 1991). Historically the single-channel properties of nAChRs have been 
attributed to the M2 transmembrane domain (Imoto et a l, 1986; Leonard et a l, 
1988).
Surprisingly, considerable differences were apparent in the noise variance of 
functional responses obtained with these chimeras with long agonist applications
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(Figure 3.10), suggesting that regions outside of the four proposed transmembrane 
domains exert an influence upon ion channel properties.
Consistent with previous studies (Hussy et al., 1994; Kelley et al., 2003) tsA201 
cells expressing 5-HTsa generated whole-cell responses with little detectable noise 
during agonist application (Figure 3.10A). Noise analysis of responses obtained 
with 5-HT3A was used to estimate a single-channel conductance of 0.7±0.1 pS, («=8; 
Figures 3.14 and 3.15). There was no significant difference in the values obtained 
by the noise analysis variance method compared to the noise power spectral density 
estimate (student’s t-test). Surprisingly, the 5-HT3A3’4Loop'a7 chimera, in which the 
M3-M4 cytoplasmic loop of 5-HT3A was replaced with that of the a l  subunit, 
generated receptors with a single-channel conductance of 9.6±1.9 pS («=11), which 
was significantly higher than that of 5-HT3A (/?<0.05). Analysis of whole-cell 
responses recorded from cells transfected with the a 7V201-5-HT3A chimera revealed an 
average single-channel conductance of 2.2±1 pS (n=9), but this was not significantly 
different from the sub-pS conductance observed with 5-HT3A. (0.7±0.1 pS). This was 
because 4/9 of the cells had low single-channel conductances. Their average of 
0.8±0.1 pS was the same as the 5-HT3A receptors. The average of the other 5 cells 
was 2.4±0.9 pS and was significantly different from 5-HT3A subunit (/?<0.05). Cells 
transfected with the a 74™-5-HT3A chimera expressed receptors with a single-channel 
conductance of 21.5±2.4 pS (n=8). This was significantly larger (p<0.05) than the 
conductance of receptors generated by the 5-HT3A3'4Loop’w7 chimera. These results 
indicate that replacement of the two domains, the extracellular N-terminal domain 
and the M3-M4 cytoplasmic loop of 5-HT3A with that of a l  lead to a significant 
increase in channel conductance.
The noise power spectrum can also be used to estimate the of the mean single­
channel open time from the x value obtained from the lorentzian fit. There was no 
significant difference in the x values estimated for the 5-HT3A subunit (24.2±4.3 ms, 
n=8), the a 7V20,-5-HT3A chimera (18.0±5.3 ms, n=9) and the a 74™-5-HT3A chimera 
(18.6±6.8 ms, n=8). The x value for the 5-H T 3A3'4Loop'a7 chimera was significantly 
greater than the other constructs (38.0±3.3 ms, n=l l,p<0.05).
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Figure 3.14 Estimation of single-channel conductance using the noise 
analysis variance method to analyse whole-cell responses from tsA201 cells 
transiently transfected with 5-HTsa and a7/5-HT3A chimeras.
20 second agonist applications were analysed to obtain the single channel 
conductance of the 5-HT3A subunit (A) the 5-HT3A3'4Loop'a7 chimera (B) the a7- 
V20i-5HT3A cj1jmera (q  and the a74™'5HT3A chimera (D) see methods section 
2.6.5.1. «=8-ll.
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Figure 3.15 Estimation o f single-channel conductance using the noise power 
spectral density method to analyse whole-cell responses from tsA201 cells 
transiently transfected with 5-HTsa and a7/5-HT3A chimeras.
20 second agonist applications were analysed to obtain the single channel 
conductance of the 5-HT3A subunit (A) the 5-HT3A3^ Looi>a7 chimera (B) the a7- 
v2oi-5ht3a c hjm em  ( Q  and the a74™'5HT3A chimera (D ) see methods section 
2.6.5.2. x, estimate of mean single-channel open time, y, estimate of single­
channel conductance . «=8-l 1. A double lorenztian was used to fit the data in 
(A) and (B) and a single lorentzian was used to fit the data in (C) and (D).
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3.6 D iscussion
Difficulties in the efficient expression of functional a l  nAChRs in many 
heterologous expression systems have been a considerable hindrance to their detailed 
study. Evidence that subunit chimeras containing the extracellular domain of the 
nAChR a l  subunit fused to the C-terminal domain of the 5-HT3R subunit 5-HT3A 
(Eisele et a l, 1993) has been widely exploited by several research groups as a means 
of circumventing difficulties in heterologous expression of a l  (Eisele et al., 1993; 
Blumenthal et al., 1997; Rangwala et a l, 1997; Cooper and Millar, 1998). In a 
previous study aimed at identifying subunit domains influencing the folding and 
assembly of the a l  it was concluded that inefficient folding and assembly could be 
attributed, in part, to regions close to the Ml hydrophobic transmembrane domain 
(Dineley and Patrick, 2000). In this study we provide evidence that transmembrane 
domains other than Ml have an equally profound influence upon the efficiency of 
subunit folding. Only subunit chimeras in which the regions of a l  from the 
beginning of Ml to the end of M3, and including M4 were replaced with the 
corresponding regions from the 5-HT3A subunit were found to fold efficiently into a 
conformation, which exhibited specific high affinity binding of the nicotinic 
radioligand [125I]a-BTX. No binding was seen if the construct contained the M l, 
M2, M3 or M4 of cx7.
Differences in the efficiency with which a l  and 5-HT3A subunits are able to generate 
functional cell-surface receptors might have been predicted to be influenced by 
regions such as their large cytoplasmic M3-M4 domain. This region of nAChR 
subunits has been shown to interact with a range of intracellular proteins (Maimone 
and Enigk, 1999; Jeanclos et al., 2001; Lin et a l, 2002) and to influence receptor 
targeting (Williams et a l, 1998). Our findings suggest that it is not this region of a l  
that is responsible for inefficient folding, assembly and cell-surface expression. In 
fact when the intracellular loop of 5-HT3A was replaced with that of a l  there was a 
statistically significant increase in the amount of receptor protein on the cell surface 
(Figure 3.5C).
The chimeras that showed significant binding have also been shown to be functional 
with two different methods. Using a calcium-influx assay, consistent responses were
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obtained that were dependent on agonist concentration. This method can be used in 
the future to examine in more detail the concentration-response relationship, 
however there are some reports of variability in values such as the EC50 when 
comparing calcium-influx assays to whole-cell patch-clamping, with a difference of 
nearly ten fold (Feuerbach et a l, 2005). This may be due to different concentrations 
of agonist required to give the maximal calcium response compared to the whole cell 
reponse. Alternatively, as the EC50 for the calcium assay is lower, it may be that this 
method is more sensitive thus will register responses as low concentrations that elicit 
no visible response in whole cell recording.
By using whole-cell patch-clamp recording, it was possible to examine various 
functional properties of the functional chimeras and compare them, directly to the 
homomeric 5-HT3A subunit, and indirectly to values reported previously for the 
homomeric a l  subunit. The rectification values of the chimeras were not 
significantly different to that with the 5-HT3A subunit. This is as may be expected as 
the rectification has been attributed to the M2 channel domain of these receptors 
(Forster and Bertrand, 1995), and this is the region that the three chimeras have in 
common with the 5-HT3A subunit.
The results of desensitization characteristics were less clear cut. Chimeras that 
contained the N-terminal of the a l  subunit desensitise faster than expected for the 
homomeric 5-HT3A subunit thus the N-terminal domain may be important 
determinant of the rate of desensitization. The N-terminal domain has been reported 
to be important for desensitization of the (32 and (34 subunit nAChRs (Bohler et a l , 
2001; Francis et a l, 2000). There were also significant differences in the rate of 
desensitization for the two chimeras that had the same a l  N-terminal domain. The 
a yV20i-5-HT3A an(j a y4TM-5-HT3A cijimeras had different large cytoplasmic M3-M4
domains, thus this domain may also determine the speed of desensitization. The rat 
a l  subunit and the mouse 5-HT3A have different potential phosphorylation sites in 
the M3-M4 domain (Seguela et a l, 1993; Maricq et a l,  1993), which may contribute 
to differing properties of desensitization as phosphorylation has been proposed to be 
a mechanism of regulation of desensitization (Quick and Lester, 2002). It should 
also be mentioned that these two chimeras had desensitization characteristics that
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were different to the homomeric a l  receptor. This implies that the channel domain 
is also important in determining the rate of desensitization.
The steady state percentage desensitization was estimated from the exponential 
fitting of responses to a 20 second agonist application. The a7 v201'5'HT3Aand a74™' 
5-HT3A c j1-m e r a s  s h o w e ( j a steady state level of activation of approximately 30%. The 
homomeric 5-HT3A receptor showed significantly less activation (only 9.3±0.9%), 
and the homomeric rat a l  receptor is know to fully desensitize within a few seconds 
(see Chapter 4, Section 4.). Thus it seems that the equilibrium between the open and 
desensitized states of these two chimeras is different from both the 5-HT3A and 
homomeric a l  subunit receptors.
An unexpected finding to emerge from this study was evidence that subunit domains 
other than the putative transmembrane regions have a significant influence upon 
single-channel conductance. Extensive experimental evidence exists to suggest that 
the M2 domain of ligand-gated ion channels lines the channel pore and exerts a 
direct influences upon ion channel properties. Residues within the M2 region of the 
Torpedo nAChR can be photo affinity labelled by channel blockers (Giraudat et al., 
1986; Hucho et al., 1986). The influence of residues within the M2 domain upon ion 
channel properties has been demonstrated by construction of subunit chimeras 
(Imoto et al., 1986) and by site-directed mutagenesis (Imoto et al., 1988; Leonard et 
al., 1988; Charnet et al., 1990; Villarroel et al., 1991).
This study provides evidence obtained from the series of subunit chimeras to 
demonstrate that single-channel conductance is influenced by regions other than the 
predicted transmembrane regions. The result that the cytoplasmic M3-M4 loop 
domain of the nAChR a l  subunit can influence channel conductance agrees with a 
recent investigation of the human 5-HT3 receptor channel conductance which 
examined chimeras constructed between the 5-HT3A and 5-HT3B subunits (Kelley et 
al., 2003). This study identified three arginine residues within the amphipathic helix 
in the large M3-M4 cytoplasmic loop as being critical in influencing 5-HT3 receptor 
single-channel conductance. These arginine residues are present in the 5-HT3A but 
not the 5-HT3B. A mutated 5-HT3A subunit without these arginine residues has a
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greater single-channel conductance (25.1 ±0.8 pS) than the wild type homomeric 
receptor (0.76±0.22 pS). The murine 5-HT3A subunit also has these arginine 
residues, which the rat a l  subunit lacks. The results in this study confirm that 
constructs that contain a M3-M4 cytoplasmic loop without these arginine residues 
have a greater signal channel conductance. In terms of the 3-dimensional receptor 
struture the large intracellular loop may form part of a cage-like structure beneath the 
inner mouth of the ion channel that is seen by electron microscopy (Figure 1.5). 
Residues in the structure may act to control the flow of ions into the channel. In this 
case the positively charged arginines may form an electrostatic barrier making it 
harder for cations to enter the channel, resulting in a smaller conductance compared 
to cation channels without these positive residues.
In addition, evidence has been obtained that conductance can be influenced by the 
extracellular N-terminal domain of ligand-gated ion channels. When the 5-HT3A N- 
terminal domain is replaced by that of a7, the single-channel conductance estimate 
increases about two fold. This could be an intrinsic characteristic of the protein, or 
dependent on the interaction of a specific type of ligand with the protein. It would 
be difficult to determine more precisely which region of the N-terminal is 
responsible as changes in the ligand-binding domain could easily effect agonist 
binding and result in a chimera that was not functional. Recently a compound 
(PSAB-OFP) has been described which is an agonist of both the a l  and the 5-HT3A 
subunits (Broad et al., 2002). It would be interesting to use this to examine the 
conductance in the functional chimeras from this study.
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CHAPTER 4 
RIC3 affects functional expression of multiple 
nAChR subtypes and the 5-HT3A receptor.
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4.1 Introduction
The a l  nAChR subunit has been shown to form functional receptors in Xenopus 
oocytes (Couturier et al., 1990a) and some mammalian cell lines (Puchacz et a l, 
1994; Gopalakrishnan et a l, 1995). However, no evidence of functional expression 
of a l  nAChRs can be detected when the a l  subunit is expressed in a number of 
other mammalian cell lines, for example HEK cells (Cooper and Millar, 1997; 
Sweileh et a l , 2000). There has also been difficulty expressing functional chick a8 
receptors in this cell line (Cooper and Millar, 1998) despite the ability of a8  to form 
functional nAChRs in Xenopus oocytes (Gerzanich et a l, 1994; Gotti et a l, 1994). 
This implies that the host cell environment may be important for the correct subunit 
folding, assembly and cell surface expression of these ligand-gated ion channels. A 
number of nAChR-interacting proteins have been identified and have been shown to 
enhance the expression of nAChRs. Calnexin and BiP are involved in the assembly 
of muscle nAChRs (Gelman et a l,  1995; Blout and Merlie, 1991), and chaperone 
protein 14-3-3r] has been shown to increase the levels of a4|32 receptors (Jeanclos et 
a l, 2001). Until recently, no factors have been identified which facilitate the 
functional expression of a l  or a8  subunits in HEK cells.
A recent study with Caenorhabditis elegans has identified a protein encoded by the 
gene ric-3 (Halevi et a l,  2002). Mutations of this protein cause the intracellular 
accumulation of nicotinic receptors, suggesting that this protein has a role in the 
maturation of nAChRs (Halevi et a l,  2002). Co-expression of C. elegans RIC3 with 
the C. elegans nAChR DEG-3/DES-2 in Xenopus oocytes revealed an enhancement 
of the nAChR function (Halevi et a l,  2002). This enhancement was not restricted to 
C. elegans nAChRs, and has also been observed with homomeric rat a l  receptors 
expressed in Xenopus oocytes (Halevi et a l,  2002). The RIC3 protein has been 
shown to have no effect on functional expression of some other ligand-gated ion 
channels, for example the GABA, glutamate and glycine receptors (Halevi et a l, 
2002; Halevi et a l,  2003). However RIC3 has been reported to reduce functional 
expression of the murine 5-HT3A receptor expressed in Xenopus oocytes (Halevi et 
a l, 2003).
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Vertebrate and invertebrate homologues of the C.elegans RIC3 protein have been 
cloned and this family of proteins are predicted to have two transmembrane domains 
separated by a proline-rich spacer region (Halevi et al., 2003). The C. elegans RIC3 
is predicted to have two coiled-coil domains after the second transmembrane 
domain, whereas all the other RIC3 genes examined (Ostertagia ostertagi, 
Drosophila melanogaster, Danio rerio, Xenopus leavis, murine and human; Figure 
4.IB) have one predicted coiled coil domain (Halevi et al., 2003). The proposed 
topology of this protein places the N-terminal and C-terminal on the cytoplasmic 
side of the membrane (Figure 4.1 A; Halevi, et al., 2003).
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Figure 4.1 Structure and topology o f the RIC3 proteins 
The C. elegans RIC3 protein is predicted to have two transmembrane domains 
separated by a proline rich domain, followed by two coiled coil domains 
(predicted by Halevi et al., 2002; Halevi et al., 2003). (A) shows the predicted 
topology of the C.elegans RIC3 protein. (B) is adapted from Halevi et al., 
2003 and shows the structure and conservation within the RIC3 gene family.
The human RIC3 homologue has been reported to enhance the function of the a  7 
nAChR (both the human and rat), but reduce the function of the heteromeric a4(32
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and a3|34 nAChRs and the murine 5-HT3A receptor when expressed in Xenopus 
oocytes (Halevi et al., 2003). Human and C. elegans RIC3 have also been co­
expressed with the a l  subunit in HEK cells, to investigate whether this would result
11Sin correctly folded a l  receptors in this cell line. A significant level of [ I]a-BTX 
binding (Lansdell et al., 2005) and fluorescent labelled a-BTX (human RIC3 only 
Williams et al., 2005) has been reported on the surface of these cells that is not 
detected when the a l  subunit is expressed alone. The human RIC3 protein has been 
demonstrated to associate with the human a l  subunit (Williams et al., 2005, human 
RIC3 only; Lansdell et al., 2005). There is also a significant increase in cell surface 
radioligand binding when RIC3 was co-expressed with either the chick a8 subunit or 
one of a number of heteromeric nAChR subunit combinations (a3p2, a3|34, a4|32 
and a4|34; Lansdell et al., 2005). It is not clear what effect RIC3 has upon 5-HT3A, 
as there are differences depending on the assay used and the species of the 5-HT3A 
subunit and the RIC3 protein expressed (Doward, 2005).
This chapter examines whether nAChR subunits can form functional receptors when 
co-expressed with RIC3 in a HEK cell line (tsA201). Although not known at the 
time this part of the current project was performed, data published subsequently 
(Williams et a l , 2005), has reported that the human a l  forms functional receptors in 
HEK cells when co-expressed with human RIC3. For this chapter whole-cell patch- 
clamping has been used to examine the effect of RIC3 when co-expressed in HEK 
cells with the following nAChRs: human and rat a l ,  chick a8  and rat a3p2 subunits, 
thus results with all but one of these combinations are novel. In addition the effect 
of RIC3 upon the functional expression of the 5-HT3A subunit was also examined.
RESULTS
4.2 Functional a  7 receptors formed when co-expressed with RIC3
As has been discussed previously (Cooper and Millar, 1997) difficulties have been 
reported in attempts to detect functional homomeric a l  nAChRs in transfected HEK 
cells. In the present study, HEK tsA201 cells were transfected with the a l  subunit 
alone and examined by whole-cell patch-clamping. None of the cells examined 
showed a response to ACh (n=ll, Figure 4.2). These results are consistent with
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B a l  alone + Ce RIC3 + hRIC3 +dRIC3
Human a l 0/9 9 / u 13/17 5/5
Rat a l 0/8 6/7 8/8 4/6
Number of cells that responded / t o t a l  num ber o f ce lls  ch a llen ged
with 2 0 0  n.M ACh
Figure 4.2 Mean size o f whole-cell responses o f a l  co-expressed with RIC3 
in tsA201 cells..
(A) Mean size of responses in cells transfected with either the human or rat a l  
subunit, and either C.elegans RIC3, human RIC3 or Drosophila RIC3. (B) 
The table indicates the fraction of cells that responded to 200 |uM ACh. The n 
number for the calculated mean is in larger type. The differences between 
groups were tested for significance with using either a student’s t-test or a 
modified Z test. * indicates p<0.05
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previous studies that show that no significant a-BTX binding can be detected on the 
surface of transfected HEK cells when the a7  subunit is expressed alone (Cooper 
and Millar, 1997). HEK tsA201 cells were transfected with the a  7 subunit (human 
or rat) and RIC3 (C. elegans, human or Drosophila), which has been shown 
previously to allow significant a-BTX binding to be detected on the cell surface 
(Lansdell et al., 2005; Williams et al., 2005). Cells were examined by whole-cell 
patch-clamping and challenged with 200 jxM ACh to determine whether functional 
a l  nAChRs could be detected.
4.2.1 Whole-cell responses in cells co-expressing a 7 and RIC3
When the a l  subunit was co-expressed with RIC3, a large proportion of cells 
examined show significant whole-cell responses upon application of ACh. It should 
be noted that all cells transfected with 5-HT3A subunit cDNA gave whole cell 
responses when challenged with 5-HT. This implies that the a l  subunit is still no as 
efficient as the 5-HT3A subunit at forming functional receptors even when expressed 
with RIC3. All combinations of the a l  nAChR subunit (human or rat) and the RIC3 
protein (C. elegans, human or Drosophila) tested showed function in most cells 
examined (examples of whole-cell responses in Figures 4.3 and 4.4). Of the cells 
transfected with human a l  subunit and a RIC3 protein, 27/33 gave whole-cell 
responses when challenged with ACh. Similarly, most cells transfected with rat a l  
subunit and a RIC3 protein gave whole-cell responses (18/21). The whole-cell 
responses ranged from 20 to 300 pA. There was no significant difference in the size 
of the responses between the human and rat a l  subunit transfections (Figure 4.2). 
There was also no significant difference in the size of the responses of cells 
transfected with the human a l  subunit, although it did appear that cells co­
expressing the human a l  subunit with the Drosophila RIC3 had smaller responses 
(Figure 4.2). There was no significant difference between the size of the responses 
in cells with the rat a l  subunit co-expressed with either C. elegans or human RIC3, 
but the responses were significantly smaller in cells co-expressing the rat a l  subunit 
and Drosophila RIC3 (Figure 4.2, p<0.05). These data show that the RIC3 protein 
enables the a l  subunit to fold correctly and form functional receptors. This occurs 
with mammalian a l  subunits and human, C. elegans or Drosophila RIC3 proteins, 
although this appears less efficient with the Drosophila RIC3.
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Figure 4.3 Whole-cell responses o f human a.7 co-expressed with R1C3 in 
tsA201 cells.
Examples of whole-cell responses in cells transfected with the human a7 
subunit either with (A) C.elegans RIC3, (B) human RIC3 or (C) Drosophila 
RIC3. The lower black bar indicates the application of 200 pM ACh, the upper 
line indicates the bath application of 100 nM ML A. The right hand column 
shows responses after the antagonist was washed off.
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Figure 4.4 Whole-cell responses o f rat a l  co-expressed with RIC3 in tsA201 
cells.
Examples of whole-cell responses in cells transfected with the rat a l  subunit 
either with (A) C.elegans RIC3, (B) human RIC3 or (C) Drosophila RIC3. 
The lower black bar indicates the application of 200 pM ACh, the upper line 
indicates the bath application of 100 nM ML A. The right hand column shows 
responses after the antagonist was washed off.
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4.2.2 Inhibition of whole-cell responses with an a l  nAChR antagonist
A reversible block of whole-cell responses to ACh was observed on application of 
the antagonist methyllycaconitine (MLA). ACh (200 pM) was applied for 500 ms 
every 10 seconds. After stable and reproducible responses were observed, 100 nM 
MLA was washed into the bath. A fast block of the response was seen, and once full 
block was achieved, the MLA was washed off and a slow recovery from the 
inhibition was observed (example of one cell shown in Figure 4.5A). It was not 
possible to accurately measure the on-time course of the MLA inhibition, as in most 
cases the inhibition reached 100% in less than three ACh applications. The loss of 
inhibition was measured over time for both the human and rat a l  nAChRs, and the 
recovery was fitted with an exponential equation (Figure 4.5 B and C) to calculate 
the time constant (x=l/k_i). There was no significant difference between the time 
constants calculated for the human (189±26 s, n=6) and rat (204±16 s, n=6) a l  
nAChRs. These values agree with those published for MLA block of the human a l  
nAChR (Palma et a l, 1996a). It can be estimated that the rate constant for the 
association (k+i) of MLA must be equal to or greater than 3xl07 s^M '1, as full block 
occurred in the presence of 2 nM within 30s. This value agrees with the value of 
2.7x107 s^M '1 published by Palma et al. (1996). Thus, the dissociation equilibrium 
constant can be estimated (Lj/k+i) to be approximately 0.2nM. This value is slightly 
smaller than that estimated by radioligand binding (Davies et al., 1999a), however 
this was done on homogenised rat brain membranes which may not have contained 
only homomeric a l  nAChRs.
4.3 Functional a 8  receptors formed when co-expressed with RIC3
The chick a8 subunit shows close sequence similarity to the a l  subunit (Schoepfer 
et al., 1990). This subunit can form functional homomeric nAChRs when expressed 
in Xenopus oocytes (Gerzanich et al., 1994, Gotti et al., 1994), and is blocked by the 
antagonists a-BTX and MLA. Just as with the a l  subunit, there have been problems 
expressing functional a8  receptors in cell lines such as tsA201 (Cooper and Millar, 
1998). It has been shown that when the a8 subunit is co-expressed with RIC3, 
significant [125I]a-BTX binding can be detected on the cell surface (Lansdell et al., 
2005). Surprisingly, when the a8 subunit was expressed alone in tsA201 cells
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Figure 4.5 MLA inhibition o f  response to ACh in tSA201 cells transfected 
with a l  andRIC3.
(A) An example of responses to brief (500 ms) agonist applications (200 pM 
ACh) every 10 seconds, from a cell transfected with the the human a l  subunit 
and C.elegans RIC3. (B) and (C) plot of % of inhibition with time during wash 
off of MLA for (B) the human a l  subunit co-expressed with RIC3 (n=6) and 
(C) the rat a7subunit co-expressed with RIC3 (n=5). % of inhibition was 
calculated by comparing the reponses on recovery to the average of 3 
responses before antagonist application.
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and examined by whole-cell patch-clamping, a small number of cells (3/11) showed 
functional responses evoked by brief applications of 100 pM ACh. The a8 subunit 
was then co-transfected with RIC3 (C.elegans or human) DNA. Cells were 
examined by whole-cell patch-clamping and challenged with 100 pM ACh to 
determine the functional level of a8 nAChRs.
4.3.1 Whole-cell responses in cells co-expressing a 8 and RIC3
When the a8 subunit was co-expressed with RIC3 (C. elegans and human), almost 
all cells showed rapid whole-cell responses upon brief application of 100 pM ACh 
(examples of whole-cell responses in Figures 4.6). There was no significant 
difference in the size of the responses between the a 8 subunit transfected alone 
(72±26 pA, n= 3), and with human RIC3 (124±24 pA, n= 14). However, there was a 
significant difference in the number of cells that responded to agonist (Figure 4.7). 
All cells that had been transfected with the a8 subunit and human RIC3 responded 
when challenged with lOOpM ACh (n= 14), compared with only 3/11 cells 
transfected with the a8 subunit alone. Cells transfected with a8 and C. elegans 
RIC3 gave significantly bigger responses than the a8 subunit alone, and the a8 
subunit with human RIC3 (356±103pA, «=14, /K0.05). Thus, the RIC3 protein 
appears to enhance the ability of the chick a8 subunit, as well as the a l  subunit, to 
form functional receptors. In this case the C. elegans RIC3 seems to increase the 
functional expression by a greater amount than the human RIC3. This could be due 
to a greater number of functional receptors, which is in agreement with greater 
amount of [125I]a-BTX binding with the a8  subunit and C. elegans RIC3.
4.3.2 Inhibition of whole-cell responses with nicotinic antagonists
MLA was used to block whole-cell responses in cells transfected with a8 and RIC3, 
but in most cases there was no recovery from this inhibition during the length of the 
recording. Concentrations as low as 2 nM blocked the response and no recovery was 
seen with 11/12 cells, even after 25 minutes in one case. The nicotinic antagonist, d- 
tubocurarine was used as an alternative antagonist that is known to be reversible. 
Four cells showed reversible block with this antagonist (10 pM, examples of this can 
be seen in Figure 4.6). The nicotinic antagonist a-BTX (10 nM) was also applied to
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Figure 4.6 Whole-cell responses o f chick a8 co-expressed with R1C3 in 
tsA201 cells.
Examples of whole-cell responses in cells transfected with the chick a8 
subunit either with (A) C. elegans RIC3 or (B) human RIC3. The lower black 
bar indicates the application of 100 pM ACh, the upper line indicates the bath 
application of 10 pM d-TC. The right hand column shows responses after the 
antagonist was washed off.
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Figure 4.7 Mean size o f whole-cell responses o f  chick a8 co-expressed with 
RIC3 in tsA201 cells.
Mean size of responses in cells transfected with the chick a8  subunit either 
alone or with C. elegans RIC3 or human RIC3. The table below indicates the 
fraction of cells that responded to 100 pM ACh. The n number for the 
calculated mean is in larger type. The differences between groups were tested 
for significance with using either a student’s t-test or a modified Z test.. * 
indicates /?<0.05
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two cells that showed some recovery in only a few minutes after washing, implying 
that this antagonist may be quickly reversible at the chick a8 receptor, unlike the a  7 
receptor. This rapidly reversible block of a8  with a-BTX has not previously 
reported. Because the a8 receptor was slower to recover from desensitization than 
the a l  receptors, it was more difficult to obtain the data required to examine the time 
course of recovery with this concentration of agonist. The recovery from 
desensitization was almost as slow as the recovery from block. For this reason there 
is no analysis on the time course of recovery of antagonist on cells expressing the a8 
receptor.
4.4 Functional <x3p2 receptors formed when co-expressed with 
RIC3
Functional expression of rat a3p2 has been reported in Xenopus oocytes (Boulter et 
al., 1987; Luetje and Patrick, 1991; Fenster et al., 1997; Covernton and Connolly, 
2000), however there are no reports in mammalian cells. Specific radioligand 
binding of [3H]epibatidine has been reported to cells transfected with the rat a3 and 
|32 subunits, but this level of binding is low compared to other nAChR subunit 
combinations. Co-expression of the rat a3 and p2 subunits with human RIC3 
significantly increases the level of binding over four fold (Lansdell et al., 2005). 
When the rat <x3 and P2 subunits were transfected into tsA201 cells and examined by 
whole-cell patch-clamping, only a few cells showed functional responses (2/10) to 
400 pM ACh. The a3 and P2 subunits were also transfected with RIC3 (C. elegans 
or human) and again cells were examined by whole-cell patch-clamping and 
challenged with 400 pM ACh to determine the functional level of a3p2 nAChRs.
4.4.1 Whole-cell responses in cells co-expressing a 3 p 2  and RIC3
When the a3 and p2 subunits, and RIC3 were transfected together, all the cells 
patched showed whole-cell responses upon application of ACh («= 18, example 
traces of responses from cells expressing the a3 and p2 subunits and RIC3 are 
shown in Figure 4.8). Cells transfected with the a3 and p2 subunits and RIC3 
showed significantly larger responses than cells expressing the receptor subunits
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Figure 4.8 Whole-cell responses o f  rat a3/32 co-expressed with R1C3 in 
tsA201 cells.
Examples of whole-cell responses in cells transfected with rat a3 and (52 
subunit either with (A) C. elegans RIC3 or (B) human RIC3. The lower black 
bar indicates the application of 100 pM ACh, the upper line indicates the bath 
application of 10 pM dTC. The right hand column shows responses after the 
antagonist was washed off.
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Figure 4.9 Mean size o f whole-cell responses o f  rat a3/32 co-expressed with 
RIC3 in tsA201 cells.
Mean size of responses in cells transfected with the rat a3 and |32 subunits 
either alone or with C. elegans RIC3 or human RIC3. The table below 
indicates the fraction of cells that responded to 400 pM ACh. The n number 
for the calculated mean is in larger type. The differences between groups were 
tested for significance with using either a student’s t-test or a modified Z test.. 
** indicates /?<0.01
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alone (19±3pA, n=2, /?<0.01). The mean response with C. elegans RIC3 was 
112±27pA (n= 9), and with human RIC3 was 86±12pA (n=9). There was no 
significant difference in the size of the responses in cells transfected with the a3 and 
(32 subunits with C. elegans RIC3 compared to human RIC3. Thus co-expression of 
RIC3 increases the number of cells expressing functional rat a3|32 receptors and also 
increases the size of the response (Figure 4.9).
4.4.2 Inhibition of whole-cell responses with a nicotinic antagonist
Whole-cell responses were reversibly blocked by the nicotinic antagonist d- 
tubocurarine (examples shown in Figure 4.8). A complete block of responses to ACh 
was obtained with 10 pM d-tubocurarine. As with the chick a8 receptor, the rat 
a3|32 receptor did not recover from desensitization as quickly as the a l  receptor. For 
this reason, only two responses were made every minute, which made it more 
difficult to examine the time course of the recovery from block.
4.5 Functional level of 5-HT3A receptors co-expressed with RIC3
The 5-HT3A subunit belongs to the same ligand-gated ion channel family as a l ,  
however it is able to form functional receptors in the cell lines in which no functional 
a l  receptors can be detected (Cooper and Millar, 1997; Gunthorpe et a l, 2000). The 
murine 5-HT3A subunit has been co-expressed with human RIC3 in Xenopus oocytes, 
and this resulted in the loss of 5-HT-induced currents (Halevi et al., 2003). Human 
or murine 5-HT3A subunits were expressed alone in tsA201 cells, and examined by 
whole-cell patch-clamping. Large whole-cell responses were obtained upon 
application of 2pM 5-HT (see figure 4.10), a value close to the E C 5 0  for both the 
human and murine subunits (Brown et al., 1998; Hubbard et al., 2000). There was 
no significant difference in the size of the currents obtained with the murine and 
human 5-HT3A receptors (Figure 4.11). HEK tsA201 cells were transfected with the 
5-HT3A subunits (human or murine) and RIC3 (C. elegans or human). Cells were 
examined by whole-cell patch-clamping and challenged with 2 pM 5-HT to 
determine the functional level of 5-HT3 receptors.
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Figure 4.10 Whole-cell responses o f  5-HT3A receptors co-expressed with RIC3 
in tsA201 cells.
Examples of whole-cell responses in cells transfected with the human (A,B 
and C) or murine (D,E and F) 5HT3A subunit either alone (A and D) or with 
C. elegans RIC3 (B and E) or human RIC3 (C and F). The black bars indicate 
the 500 ms application of 2 pM 5HT.
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4.5.1 Whole-cell responses in cells co-expressing 5-HT3A and RIC3
When 5-HT3A is transfected with RIC3 there are different effects upon the level of 
function (enhancement versus reduction) depending on which species of 5-HT3A 
subunit and which species of RIC3 protein were examined (see Figure 4.10 and 
mean whole-cell responses in Figure 4.11). There was no significant difference in the 
size of currents in cells transfected with human 5-HT3A subunit alone (2069±397pA, 
«=10), or with human RIC3 (1750±558pA, n=9). When human 5-HT3A is 
transfected with C. elegans RIC3 the currents in response to 5-HT were significantly 
greater (5551±1109pA, n= 11, p<0.02). With cells transfected with human 5-HT3A 
subunit with or without RIC3, all cells tested responded to agonist.
When the murine 5-HT3A subunit was transfected with C. elegans RIC3, all cells 
gave whole-cell responses when challenged with ACh (2534±496 pA, n= 16), and 
responses were not significantly larger than those observed with the murine 5-HT3A 
subunit transfected alone (1651 ±3 59 pA, n= 14). In contrast to this and the result for 
the human 5-HT3A subunit, when the murine 5-HT3A subunit was transfected with 
human RIC3, the whole-cell responses obtained were significantly smaller (669±172 
pA, «=20, /?<0.05). Also, five of the twenty-five cells tested showed no response to 
agonist. These results agree with those obtained by using a calcium-influx assay 
(Doward, 2005). Thus, it seems that the RIC3 protein has differential effects that 
depend on the which species of the 5-HT3A subunit and the RIC3 protein are co­
expressed.
4.6 Functional ch aracteristics o f  a l  and 5-H T 3A expressed  w ith  
R IC 3
The effect on functional characteristics upon co-expression of RIC3 with the a l  and 
5-HT3A subunits was examined. It has been reported that interacting proteins can 
affect the functional characteristics of receptors, for example VILIP-1 and the a4|32 
nAChR (Lin et al., 2002) and calmodulin and NMDARs (Ehlers et a l, 1996; Rycroft 
and Gibb, 2002). The rat a l  subunit or murine 5-HT3A subunit was transfected with 
human RIC3 into HEK tsA201 cells. Rat a l  and murine 5-HT3A were chosen to be 
investigated as chimeras have been constructed from these two subunits (Chapter 3).
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Human RIC3 protein was chosen as it caused an increase in functional expression of 
the rat a l  receptor and a reduction in functional expression of the murine 5-HT3A 
receptor (Section 4.2 and 4.5). Rectification, desensitization and single-channel 
conductance were investigated as described in the Chapter 2, Section 2.7.
4.6.1 Rectification of a 7 and 5-HT3A expressed with human RIC3
Previous studies have demonstrated that there is no significant difference between 
the reversal potentials of the homomeric a l  and 5-HT3A receptors (Puchacz et al., 
1994; Hubbard et a l,  2000). In contrast, the a l  receptor has been shown to exhibit 
much greater rectification compared with the 5-HT3A receptor (Puchacz et al., 1994; 
Hubbard et al., 2000). The current-voltage relationship of the a l  or 5-HT3A subunits 
co-expressed with RIC3 was investigated by obtaining triplicate responses at holding 
potentials from -60 to +40 mV (see, for example, Figure 4.12A). The reversal 
potential and rectification were determined from the current-voltage relations (Figure 
4.12B and C). There was no significant difference in the reversal potential between 
the rat a l  subunit (8.1±2.4 mV, n=6) and the murine 5-HT3A subunit (9.0+3.0 mV, 
>7=5). Co-expression of RIC3 with murine 5-HT3A subunit caused no significant 
difference in the reversal potential compared to murine 5-HT3A subunit alone 
(1.2+1.3 mV, n=5). There was also no significant difference between the rat a l  
subunit and three cx7/5-HT3A chimeras ( a 7 v 2 0 1 5 ' H T 3A , 4.8+2.6 mV; a 7 4 ™ ' 5 ' H T 3A , 
6.6+2.4 mV; 5-HT3A3 4Loop'a7, 5.8+2.6 mV; >7=5, Chapter 3). Thus it appears that the 
RIC3 protein does not alter the reversal potential when expressed with the murine 5- 
HT3A receptor subunit.
The rectification characteristics of the murine 5-HT3a receptor were not affected by 
co-expression of RIC3. There was little or no rectification seen in the current- 
voltage relation for the 5-HT3A subunit expressed alone (Figure 3.10B) or with 
human RIC3 (Figure 4.12B). There was no significant difference in the coefficient of 
rectification (method of calculation in Chapter 2, Section 2.7.3) between the murine 
5-HT3A subunit expressed alone (0.93+0.08, n=5), or with human RIC3 (0.95+0.20, 
>7=5). As has been shown previously for the a l  receptor, the rat a l  receptor showed 
much greater rectification, that can be seen in the current-voltage relationship 
(Figure 3.10A and C). The coefficient of rectification was significantly lower with
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Figure 4.12 Current voltage relations o f  whole-cell responses from tsA201 
cells transiently transfected with 5-HT3a or a l  and R1C3.
(A), an example of brief (500 ms) agonist applications (200 pM ACh) done in 
triplicate to obtain current-voltage relation, with a cell transfected with the rat 
a l  subunit and human RIC3. (B) and (C) current-voltage plot for murine 
5HT3A co-expressed with human RIC3 (B) and rat a l  co-expressed with 
human RIC3 (C), The responses were normalised to the response obtained at - 
60 mV. n=5-6.
138
the a l  subunit (0.18±0.04, n=6, p<0.005), than observed with the 5-HT3A subunit 
(transfected with or without human RIC3), or any of the three cx7/5-HT3a chimeras 
( a 7 V 2 0 1 5 ' H T 3A , 0.94±0.08; a 7 4 ™ ' 5 ' H T 3 A , 1.01±0.15; 5-HT3A3'4I'00|>a7, 1.08±0.04; n=5). 
The large amount of rectification of the a l  receptor seen here is consistent with 
previously published results (Puchacz et a l , 1994). Thus is appears that the RIC3 
protein does not alter the rectification characteristics of the 5-HT3A receptor.
4.6.2 Desensitization o f a  7 and 5-HT3A expressed with human RIC3
The homomeric a l  and 5-HT3A receptors have very different desensitization 
characteristics. The a l  nAChR desensitizes much faster (within tens of ms) than the 
5-HT3A receptor (Ragozzino et al., 1997; Gunthorpe et al., 2000). 5-HT was applied 
for 20 seconds to the cells transfected with the 5-HT3A subunit and RIC3. ACh or 
DMPP were only applied for 500 ms to the cells transfected with the a l  subunit and 
RIC3 because the whole-cell responses fully desensitized within that time. The 
difference in the desensitization characteristics can be seen clearly in the whole-cell 
responses (Figure 4.13A and B), which confirm that the rat a l  receptor desensitizes 
much faster than the murine 5-HT3A receptor. The decay of the desensitization was 
fitted with an exponential equation from which time constant of decay could then be 
obtained (Chapter 2, Section 2.7.4). The steady state desensitization estimated from 
the single exponential fitting of a response from a 20 second agonist application for 
5-HT3A and 500 ms agonist application for a l  was also compared.
There was no significant difference in either the time constant of decay or the 
percentage of de sensitization of whole-cell responses between cells transfected with 
the murine 5-HT3A subunit alone, or with human RIC3. The time constant for decay 
for the murine 5-HT3A subunit with human RIC3 (6895±1682 ms, n=6, Figure 
4.13C) was not significantly smaller than the 5-HT3A subunit alone (9201±1345 ms, 
n=6). The steady state desensitization was approximately the same with murine 5- 
HT3A with RIC3 (91.7±3.2%) as with murine 5-HT3A alone (89.9±2.5%). It appears 
that the co-expression of the murine 5-HT3A subunit with human RIC3 does not 
affect the characteristics of desensitization of this receptor.
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Figure 4.13 Desensitization analysis o f whole-cell responses from tsA201 
cells transiently transfected with 5-HT3a or a l , and R1C3.
Whole cell responses were analysed to obtain the time constant of decay and 
the percentage of desensitization. (A) and (C): the murine 5-HT3A subunit co­
expressed with human RIC3, with a 20 second application of 1 pM 5-HT. (B), 
(D) and (E): the rat a7  subunit co-expressed with human RIC3, with 500 ms 
application of (D) 200 pM ACh and (E) 200 pM DMPP. (A) and (B) show 
examples of the redordings used for analysis. (C), (D) and (E) show examples 
of average of the responses from one cell («=3-5), inverted and fitted with an 
exponential equation to estimate the time constant of decay and the percentage 
of desensitization.
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Cells expressing the rat a l  subunit and human RIC3 gave whole-cell responses that 
had significantly faster time constants (ACh, 66.5±12.8 ms, «=8,/?<0.001) compared 
to values for the murine 5-HT3A receptor, from this study and previously published 
(Gunthorpe et al., 2000). DMPP was also used so that a l  could be compared with 
three a7/5-HT3A chimeras (Chapter 3, Section 3.6.1). The time constant for decay 
with DMPP (54.7±16.5ms, n=l) was not significantly different from that obtained 
from ACh applications, and was significantly smaller than the values obtained for 
the three a 7 /5 -H T 3A chimeras ( a 7 v2015'HTiA, 223.2±31.5 ms; aT 4™ '5'1" ,* , 924±220 
ms; 5-HT3A3'4Loop'a?, 7067±878 ms; n=6-8) (p<0.001). The values o f  the tim e 
constants of decay for the rat a l  receptor determined here are consistent with values 
previously published (chick a l , 75 ms; Ragozzino et a l, 1997).
The steady state desensitization of whole-cell responses was significantly greater for 
the rat a l  receptor compared to that of the murine 5-HT3A receptor. The 5-HT3A has 
been shown to completely desensitize (Gunthorpe et al., 2000) but in that study a 
much higher concentration of 5-HT was used. Only 1 pM 5-HT was used in the 
present study, and this value is smaller than the EC50 value, thus is sub-maximal and 
will not produce as much desensitization as 30 pM 5-HT.
For cells expressing functional a l  receptors the steady state desensitization with the 
agonist DMPP was 99.9±0.6% («=7) and with ACh was 99.5±0.03% («=8). The 
steady state de sensitization was significantly greater than values obtained with the 
same concentration of DMPP, from cell transfected with one of two a7/5-HT3A 
chimeras (a7V2015‘HV  70.8±3.2%; a 7 4™'5-HT,A, 64.6±2.9%; p<0.001). There was 
no difference in the steady state desensitization after 500 ms with ACh compared to 
DMPP. This complete de sensitization seen for the rat a l  receptor is consistent with 
responses reported previously (Gopalakrishnan et al., 1995).
4.6.3 Single-channel conductance of 5-HT3A expressed with human RIC3
Single-channel conductance was estimated for the murine 5-HT3A receptor using 
noise analysis. Due to the rapid desensitization of the rat a l  receptor it was not 
possible to obtain a reliable estimate. A very large number of responses (>100) 
would be needed per cell to perform the analysis as the responses are so short. The
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murine 5-HT3A receptor has been shown to have a small single-channel conductance 
of about 0.7±0.1 pS (Chapter 3, Section 3.6.3, Hussy et al., 1994; Kelley et a l, 
2003).
As with murine 5-HT3A subunit transfected alone, there was little detectable noise 
during agonist application in cells where the murine 5-HT3A subunit was co­
expressed with human RIC3 (Figure 3.14A). Noise analysis was performed on long 
responses (as described in Chapter 2, Section 2.7.5). There was no significant 
difference in the estimate of the single-channel conductance by the variance method 
for the murine 5-HT3A subunit alone (0.50±0.06 pS, n= 8) compared with the 5-HT3A 
subunit expressed with human RIC3 (0.62±0.15pS, n=6). Noise power spectral 
density analysis also showed no significant effect of RIC3 on single-channel 
conductance. The single-channel conductance of the 5-HT3A subunit expressed alone 
was 0.67±0.10pS («=8), and the 5-HT3A subunit expressed with RIC3 was 
0.81±0.13pS (w=6). Using the noise power spectral density method of analysis the 
kinetics of channel gating were characterized (see Chapter 2 Section 2.7.5.2). There 
was no significant difference between the mean single-channel open time of the 
murine 5-HT3A alone (x=24.2±4.3 ms, n=8) and with human RIC3 (t=36.9±1 1.4 ms, 
«=6). Thus, co-expression of human RIC3 does not appear to change the single­
channel conductance or the channel kinetics of the murine 5-HT3 a receptor.
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Figure 4.14 Noise analysis o f  whole-cell responses from tsA201 cells 
transiently transfected with 5 -HT3A and RIC3.
20 s e c o n d  a g o n is t  a p p l i c a t io n s  w e r e  a n a ly s e d  t o  o b ta in  th e  s in g le  c h a n n e l  
c o n d u c t a n c e  o f  t h e  5- H T 3A s u b u n it .  R e s u l t s  fo r  o n e  c e l l  a r e  s h o w n . ( A ) ,  A n  
e x a m p l e  o f  a  r e s p o n s e ,  t h e  b la c k  a b o v e  t h e  tr a c e  in d ic a t e s  th e  a g o n is t  
a p p l ic a t io n .  ( B ) ,  E s t im a t io n  o f  s i n g le  c h a n n e l  c o n d u c t a n c e  b y  th e  v a r ia n c e  
m e t h o d .  ( C ) ,  E s t im a t io n  o f  s i n g le  c h a n n e l  c o n d u c t a n c e  b y  t h e  n o i s e  p o w e r  
s p e c t r a l  d e n s i ty .
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4.7 D iscussion
There have been difficulties reported for the expression of functional a l  nAChRs in 
many heterologous expression systems. The a l  subunit protein can be detected, for 
example by immunoprecipitation, but neither specific binding with a-BTX nor 
conformationally sensitive antibodies were able to detect the appropriately folded 
protein (Cooper and Millar, 1997). It has, therefore been proposed that the a l  
subunit is incorrectly folded when expressed in such host cell types as HEK and 
Chinese hamster ovary cells (Cooper and Millar, 1997; Sweileh et al., 2000). 
Although the a l  subunit forms functional homomeric receptors in Xenopus oocytes 
(Couturier et al., 1990a) and some mammalian cell lines such as GH4C1 (Virginio et 
al., 2002), little is understood about how this protein folds into the correct 
conformation. The Torpedo and muscle nAChRs have been more extensively 
studied (Chapter 1, Section 1.3.1). Although the muscle nAChR forms receptors in 
many cell lines, this has been shown to be slow and inefficient (Merlie and 
Lindstrom, 1983, Wanamaker et al., 2003), with only 20-30% of synthesized 
subunits assembling into mature receptors.
Various factors are thought to aid assembly of non-a7 nAChR subunits. For 
example the endoplasmic reticulum chaperone calnexin has been shown to associate 
with nascent a l  subunits. This interaction decreases shortly before assembly with 
other subunits (Gelman et al., 1995) and calnexin has been shown to enhance surface 
expression of muscle nAChRs when they are co-expressed in HEK cells (Chang et 
al., 1997). BiP has also been shown to be involved in the assembly of muscle 
nAChR (Blount and Merlie, 1991; Forsayeth et al., 1992). The neuronal subunit a4  
interacts with the chaperone protein 14-3-3r), and this interaction significantly 
increases the steady state levels of a4j32 receptors (Jeanclos et al., 2001). Thus it 
was not unexpected to find a protein that, when co-expressed with the a l  subunit, 
increased cell surface expression and function of this nAChR.
The RIC3 protein has been shown to have an effect on nicotinic receptors of C. 
elegans (Halevi et al., 2002). RIC3 has also been shown to cause a functional 
upregulation of rat and human a l  receptors when expressed in Xenopus oocytes, 
indicating that it may interact with these receptors (Halevi et al., 2002; Halevi et al.,
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2003). These results suggest that the RIC3 protein may enable the a7  subunit to fold 
correctly in cells that are not normally permissive, allowing the formation of 
functional receptors. Radioligand binding and immunoblotting studies in HEK cells 
have shown that both human and rat a l  subunits, when co-expressed with human or 
C. elegans RIC3, form a-BTX binding sites on the cell surface (Lansdell et al., 
2005; Williams et a l, 2005). The human a l  subunit has been shown to co-assemble 
with the human RIC3 protein, as demonstrated by co-immunoprecipitation (Lansdell 
et al., 2005, Williams et al., 2005). These results support the idea that RIC3 
associates with a l  and helps the protein fold correctly. This chapter has investigated 
the effect of RIC3 upon the level of functional a l  receptors and some of the 
functional characteristics of the receptor.
4.7.1 RIC3 co-expressed with the a 7 nAChR subunit
In the present study, no functional human or rat a l  receptors could be detected in 
tsA201 cells transfected with only the a l  cDNA. When any of the three RIC3 
constructs (C. elegans, human or Drosophila) were co-expressed with the a l  
receptors, whole-cell responses were seen in response to ACh in a large proportion 
of the cells. Thus, in the presence of RIC3, not only is the a l  protein now folded in 
such a way that it allows a-BTX to bind, but the subunits assemble into functional 
receptors. The whole-cell responses that were obtained with ACh could be blocked 
with the a7/a8 selective antagonist MLA. The recovery from block by MLA 
displayed a time course that was consistent with data previously reported for a l  
(Palma et al., 1996a). The rat a l  receptors expressed with human RIC3 have 
functional characteristics that are typical for the a l  receptor. They show strong 
inward rectification, which has been reported repeatedly for a l  receptors (Puchacz et 
al., 1994; Forster and Bertrand, 1995). The a l  receptors are known to desensitize 
rapidly (Virginio et al., 2002; Ragozzino et al., 1997). The results from this thesis 
show clearly that, when expressed with human RIC3, the rat a l  also desensitizes 
rapidly, with a time constant of only tens of ms with both the natural agonist ACh 
and also in response to DMPP.
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Thus it seems that the RIC3 protein associates with the a  7 subunits, and allows the 
subunits to fold correctly or associate with each other correctly to form both the a- 
BTX binding site and a functional receptor. This agrees with the results of Castillo 
et al. (2005), who suggest that the RIC3 protein acts to both increase the number of 
mature or correctly folded receptors and also facilitate the transport of the receptor to 
the cell surface. As functional characteristics of the rat a l  receptor with RIC3 are in 
agreement with data already published in the literature (Puchacz et al., 1994; 
Gopalakrishnan et al., 1997; Ragozzino et al., 1997), it is possible that in all the 
expression systems where the a l  subunit is able to form functional receptors an 
endogenous RIC3 protein may be expressed. A Xenopus RIC3 homologue has been 
cloned (Halevi et al., 2003), and endogenous RIC3 transcripts have been identified 
in SH-SY5Y cells, a human neuroblastoma cell line (Lansdell et al., 2005), which 
expresses functional endogenous a l  receptors (Puchacz et al., 1994).
4.7.2 RIC3 co-expressed with other nAChR subunits
RIC3 has been reported to increase the levels of other nicotinic receptors. The a 8 
subunit gives no specific binding when expressed alone (Cooper and Millar, 1998), 
and the rat a3 and |32 subunits give low levels (Xiao and Kellar, 2004; Lansdell et 
al., 2005). Radioligand binding studies with the chick a 8 and rat a3j32 nicotinic
1 c  -i
receptors (with [ I] a-BTX and [ Hjepibatidine respectively) showed increased 
number of radioligand binding sites when co-expressed with RIC3 (Lansdell et al., 
2005). The effect of RIC3 upon the level of functional expression of these nicotinic 
receptors was investigated to determine if, as with the a l  receptor, co-expression of 
RIC3 increases the expression of functional receptors.
When the a 8 subunit was expressed alone, most cells examined by whole-cell patch- 
clamping gave no response to agonist, although 3/11 gave small whole-cell 
responses. Response in cells expressing only the a 8 subunit was unexpected 
because no specific binding has been detected with [125I]a-BTX when the a 8 subunit 
was expressed alone (Cooper and Millar, 1998). The absence of specific [125I]a- 
BTX binding could be due to only a very small number of cells expressing correctly 
folded and thus functional receptors, so small that it cannot be detected by 
radioligand binding. This conclusion is supported by the results that when cells are
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transfected with both the a 8 subunit and the RIC3 protein (C. elegans or human), 
there was a significant level of binding (Lansdell et al., 2005) and 28 out of 29 cell 
examined gave whole-cell responses when challenged with an agonist. The whole­
cell responses were blocked by the a7 /a8  selective antagonist MLA and recovery 
did not occur within the time of the whole-cell recording. There is no data published 
on the reversibility of the block by MLA on recombinant a 8 receptors. The nicotinic 
antagonist d-tubocurarine reversibly blocked the whole-cell responses. The 
antagonist a-BTX was also used to block the responses, but it was ambiguous 
whether this block was reversible. Thus it seems that the RIC3 protein allows more 
a  8 subunits to fold correctly or associate with each other correctly to form both the 
a-BTX binding site and a functional receptor.
When the rat a3 and |32 subunits were expressed together most cells patched gave no 
response to agonist, although 2/9 cells gave measurable whole-cell responses. This 
is in agreement with the low level of radioligand binding observed compared to other 
subunit combinations such as a3|34, which has a Bmax 150 times greater than a3|32 
(Xiao and Kellar, 2004). No data has been published on the function of rat a3|32 
receptors in mammalian cells. This is not surprising as the 2 out of 9 cells that did 
respond to agonist had very small responses to 400pM ACh, a concentration more 
than 2 fold greater than the EC50 obtained in Xenopus oocytes (two components: 
6.9±2.0pM and 170±120pM; Covernton and Connolly, 2000). Such a small number 
of cells producing functional receptors would make it difficult to examine function 
by whole-cell patch-clamping. When the rat a3 and (32 subunits were co-expressed 
with RIC3 (C. elegans or human) all cells that were challenged with agonist gave 
whole-cell responses, and the mean size of the responses was significantly greater 
than that of responses obtained in cells without RIC3. These responses were 
reversibly blocked with d-tubocurarine, a nicotinic antagonist.
The action of RIC3 is not restricted to the a  7 nAChR. RIC3 causes the functional 
upregulation of both chick a 8 and rat a3|32 receptors. In addition it has been shown 
that human RIC3 also increases the number of epibatidine binding sites and the 
calcium influx upon agonist application in cells expressing rat a3j34, a4|32 and 
a4|34, (Lansdell et al., 2005). Human RIC3 assembles with rat a4(32, shown by
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immunoprecipitation (Lansdell et a l, 2005). It has also been demonstrated that co­
expression of RIC3 has no effect on a 9 a l0  receptor expression in tsA201 cells 
(Lansdell et a l , 2005). Thus, RIC3 is a general nicotinic receptor-associated protein 
that can up regulate the functional expression of many but not all nicotinic subtypes.
4.7.3 RIC3 co-expressed with 5-HT3A receptors
The nicotinic receptors are not the only ligand-gated ion channels that are affected 
by RIC3. Human RIC3 has been shown to almost completely abolish function of the 
murine 5-HT3a receptor expressed in Xenopus oocytes (Halevi et a l , 2003). Human 
5-HT3a has also been shown to transiently interact with human RIC3 (Cheng et a l, 
2005). Radioligand binding studies conducted in a mammalian cell line have shown 
that the total number of 5-HT3 receptor binding sites is greater with co-expression of 
either C.elegans or human RIC3 (Doward, 2005). However use of an enzyme-linked 
antibody assay has revealed differences between the murine and human forms of 5- 
HT3a (Doward, 2005). There is no difference in the amount of murine 5-HT3a 
receptor detected on the cell surface with or without RIC3 (C. elegans or human), but 
a greater amount of human 5-HT3a receptor has been detected on the cell surface 
when co-expressed with RIC3 (Doward, 2005). In the present study the effect of 
RIC3 upon the level of functional expression of human and rat 5-HT3a receptors in 
tsA201 cells was investigated to determine if, as with the a  7 receptor, co-expression 
of RIC3 increases the level of functional expression. Radioligand binding assays 
show more 5-HT3a receptor on the cell surface with co-expression of RIC3, 
suggesting that the level of function expression should also be greater. However, the 
enzyme-linked antibody assay show no difference in the level of murine 5-HT3a 
subunit on the cell surface when it is co-expressed with RIC3, which suggests that 
level of functional expression of this receptor will be no different.
The 5-HT3a receptor (human or rat) gave whole-cell responses from all cells 
challenged with 5-HT. When C. elegans RIC3 was co-expressed with the murine 5- 
HT3a subunit no difference was detected in the size of the responses. In contrast 
there was an increase the mean size of the responses to 5-HT in cells expressing the 
human 5-HT3a subunit and C. elegans RIC3 compared to human 5-HT3a alone. 
When human RIC3 was co-expressed with the human 5-HT3A subunit it had no
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effect on the level of receptor function. This agrees with the results of Cheng et al., 
2005, who also showed that increasing the amount of RIC3 DNA used for 
transfection of cells caused an increase in the number of surface receptors and in 
receptor function in a concentration-dependent manner. Co-expression of human 
RIC3 with murine 5-HT3A caused a reduction in the magnitude of responses (mean 
response was decreased to 40% of the size of the response with murine 5-HT3A 
alone), and some cells showed no response at all. This reduction is not as great a 
decrease as seen in Xenopus oocytes (Halevi et al., 2003), which highlights again the 
differences that the expression system appears to exert. The functional 
characteristics of the murine 5-HT3A subunit when expressed with RIC3 are not 
significantly different from the murine 5-HT3A subunit expressed alone (Chapter 3, 
Section 3.6). The desensitization, reversal potential and rectification, and single­
channel conductance are all the same with and without the RIC3 protein.
The presence of an extracellular isoleucine (I218) just before the first putative 
transmembrane domain has been reported as responsible for the loss of functional 
murine 5-HT3A receptors in Xenopus oocytes, by hindering the transport of mature 
receptors to the cell surface (Castillo et al., 2005). However, in mammalian cells the 
human RIC3 protein causes a decrease in function (assayed by recordings of agonist- 
induced changed in levels of intracellular calcium and by whole-cell 
electrophysiological recording), but no change in the surface levels of the murine 5- 
HT3A receptor (Doward, 2005). These results seem contradictory, however these 
differences could be explained by a decrease in the agonist sensitivity of the 5-HT3A 
receptor. The alteration of agonist sensitivity of a nAChR has been shown 
previously with VILIP-1 and the a4|32 receptors (Lin et a l 2002). However the 
human RIC3 and the 5-HT3A subunit have been shown to interact only transiently 
(Cheng et al., 2005), so if RIC3 does affect the agonist sensitivity, this might require 
a long-lasting modification of the receptor that was retained after the two proteins 
separated. Alternatively, the human RIC3 protein might decrease the proportion of 
functional murine 5-HT3A receptors expressed on the cell surface, without affecting 
the total amount of subunit protein. This does not agree with the radioligand binding 
data, which suggests that there are more correctly folded 5-HT3A receptors on the 
cell surface when the subunit is co-expressed with RIC3.
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Further experiments with RIC3 need to be performed to investigate the discrepancies 
between the radioligand binding, enzyme-linked assays and functional assays and 
also to confirm the mechanism of action of RIC3 upon the subcellular trafficking and 
the resulting functional expression of the 5-HT3A subunit. Future studies can do be 
done to examine which regions of the subunits that have been shown to interact with 
RIC3 are needed for this interaction.
150
CHAPTER 5 
CONCLUSION
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5.1 Inefficien t fo ld ing o f  the a l  nA C hR  sub u n it
The folding and assembly of the muscle nAChR has been demonstrated to be 
inefficient, with only 30% of synthesized a  subunits assembling into receptors 
(Merlie and Lindstrom, 1993). The a l  subunit has been reported to form no 
functional recombinant receptors in some cell lines (for example HEK and COS) in 
which functional recombinant muscle nAChR, other neuronal nAChRs and 5-HT3RS 
are detected (Cooper and Millar, 1997; Sweileh et al., 1998; Gunthorpe et al., 2000). 
The a l  subunit is able to form functional receptors in Xenopus oocytes (Couturier et 
al., 1990a) and some neuronal cell lines (Puchaz et al., 1994; Cooper and Millar, 
1997; Virginio et al., 2002) and the protein is detected in HEK cells by antibodies to 
a linear epitope, but not by conformationally sensitive antibodies (Cooper and 
Millar, 1997). Thus, it has been suggested that some cell lines lack factors such as 
chaperones that are needed for the a l  subunit to fold correctly. Both the a l  subunit 
and the 5-HT3A subunit are able to form functional homomeric receptors in Xenopus 
oocytes, but despite forming similarly complex structures to make functional 
receptors, the 5-HT3A has been demonstrated to do this efficiently in all cell lines 
tested.
5.1.1 a7/5-H T 3A chimeras
A chimera with the N-terminal extracellular domain of a l  and the transmembrane 
and intracellular domains of the 5-HT3A subunit has been demonstrated to form 
functional receptors gated by ACh in HEK cells, where no a l  function is detected 
(Eisele et al., 1993; Cooper and Millar, 1997). The present study has extended the 
research previously published by narrowing down which regions within the 
transmembrane and C-terminal domains of the 5-HT3A subunit confer the ability to 
fold and assemble efficiently into functional receptors in HEK tsA201 cells.
A series of a7/5-HT3A chimeras was constructed replacing various domains of a l  for 
the equivalent 5-HT3A sequence (Chapter 3, Figure 3.1) and the cell surface 
expression of correctly folded receptors was established by radioligand binding and 
enzyme-linked assays. Chimeras showing cell surface expression were then tested 
for function using a calcium-sensitive dye in a FLIPR based assay and by whole-cell 
patch-clamp recording. In each case where surface expression was found, the
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receptors were functional suggesting only correctly folded (and hence functional) 
receptors are transported to the cell surface. All chimeras that contained the four 
transmembrane domains of 5-HT3A showed significant radioligand binding and were 
found to be functional. These results suggest that all four transmembrane domains 
of the 5-HT3A subunit are necessary for efficient expression of correctly folded 
functional receptors. The large cytoplasmic M3-M4 domain has been proposed to 
influence folding and assembly of neurotransmitter receptors as this region has been 
shown to interact with a range of intracellular proteins (Maimone and Enigk, 1999; 
Jeanclos et al., 2001; Lin et al., 2002). However, there was no detrimental effect on 
serotonergic radioligand binding when the 5-HT3A large cytoplasmic loop was 
replaced with the equivalent a 7 sequence. Additionally, when the a 7 intracellular 
loop was replaced with the 5-HT3A intracellular loop the receptor still formed no a- 
BTX binding sites. Thus, from the results obtained in this study, it was concluded 
that only the regions from just before Ml to the end of M3, and just before M4 to the 
end of the protein determine the efficiency of folding and assembly of these 
receptors.
5.1.2 The a  7 subunit co-expressed with RIC3
The wild-type a l  subunit is able to form functional receptors in some mammalian 
cell lines, for example in SH-SY5Y cells which contain endogenous a l  receptors 
and can express heterologous a l  receptors efficiently (Puchacz et al., 1994). Also 
GH4C1 cells which do not express endogenous a l  receptors, can express 
heterologous a7 receptors and (Virginio et al., 2002). This has been attributed to 
host-cell specific factors that aid the correct folding and assembly of a l  subunits in a 
small number of expression systems that include Xenopus oocytes. Recently the 
RIC3 family of proteins has been identified and implicated in the maturation of 
several nAChR subtypes, including the a l  nAChRs, when expressed in Xenopus 
oocytes (Halevi et al., 2002; Halevi et al., 2003). A correlation between the 
expression of RIC3 and the ability to express functional a l  receptors has been 
shown: the presence of RIC3 transcripts was demonstrated in SH-SY5Y cells that 
endogenously express a l  receptors, but no R1C3 transcript could be detected in HEK 
tsA201 cells, which are unable to express functional heterologous a l  receptors 
(Lansdell et al., 2005). Co-expression of a l  and RIC3 in HEK cells has been
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demonstrated to result in cell surface expression of an a l  nAChR capable of binding 
a-BTX (Williams et a l, 2005; Lansdell et al., 2005). The aim of this study was to 
examine how co-expression of RIC3 affected the level of functional expression of 
a l  nAChRs expressed in HEK tsA201 cells. This was investigated by whole-cell 
patch-clamp recording of cells transfected with cDNAs of different species of a l  
and of RIC3.
It has been demonstrated in this thesis that functional a l  nAChRs can be detected 
only when the subunit is co-expressed with RIC3 (Chapter 4, Section 4.2). Co­
expression of the human a l  subunit and human RIC3 resulted in functional nAChRs, 
as has also been demonstrated by Williams et al. (2005). The combinations of 
human or rat a l  subunit and human or C. elegans RIC3 all gave mean whole-cell 
responses of approximately the same size (Chapter 4, Section 4.2.1). Co-expressing 
the a l  subunit with Drosophila RIC3 also resulted in functional a l  nAChRs, but 
gave smaller whole-cell responses with human or C. elegans RIC3.
The functional characteristics of the rat a l  nAChR when co-expressed with human 
RIC3 were investigated by examining whole-cell responses. The reversal potential, 
rectification characteristics and desensitization (Chapter 4, Section 4.6) were all very 
similar to those reported previously for a l  receptors expressed in Xenopus oocytes 
or studied in native cells such as cultured hippocampal neurones (Mike et al., 2000). 
When expressed with human RIC3, both the human and rat a l  subunit formed 
receptors which were blocked by the antagonist MLA (Chapter 4, Section 4.2.2). 
The recovery from block had characteristics similar to those previously published for 
the a l  receptor (Palma et al., 1996a). These results indicate that the functional 
characteristics of the channel have either not been altered by co-expression with 
RIC3, or, that all other cells expressing functional a l  receptors also co-express 
RIC3. It is possible that the RIC3 protein may act by enhancing the efficiency of 
subunit folding, assembly. It has been proposed that RIC3 does not affect receptor 
trafficking as it has been reported that there was no difference in the amount of cell 
surface a l  subunit detected in the presence or absence of RIC3 (Williams et al., 
2005). However, it has also been suggested that the effect of RIC3 upon the a l  
subunit in Xenopus oocytes is mediated at two levels; an increase in the number of
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mature receptors and facilitation of transport to the plasma membrane (Castillo et a l , 
2005).
The RIC3 protein co-assembles with the a l  subunit, as demonstrated by 
immunoprecipitation (Doward, 2005; Williams et al., 2005); thus the action of RIC3 
upon the a l  subunit may be mediated directly through the association of these 
proteins. This may be a transient association as it has been demonstrated in Xenopus 
oocytes that labelling of the a l  subunit only coincides in some places with RIC3 
labelling (Castillo et al., 2005).
5.1.3 RIC3 co-expressed with other neurotransmitter receptor subunits
In this thesis it has been demonstrated that the RIC3 protein can affect the expression 
of nicotinic neurotransmitter receptor subunits other than a l  (Chapter 4, Section 4.3- 
4.4; Lansdell et al., 2005). When the a 8 nicotinic subunit was expressed alone in 
fibroblast cells, no a 8 receptor can be detected with radioligand binding (Cooper and 
Millar, 1998). However, when RIC3 is co-expressed in HEK with the a 8 subunit 
specific radioligand binding is detected (Lansdell et al., 2005). In this thesis, it was 
investigated whether the level of functional expression assayed by whole-cell patch- 
clamp recording, would increase with co-expression of RIC3. In cells expressing the 
cx8 subunit alone three out of 11 cells responded to ACh (Chapter 4, Section 4.3). 
This was unexpected as no specific radioligand binding with this subunit has been 
demonstrated previously (Cooper and Millar, 1997; Lansdell et a l , 2005). A much 
greater proportion of the cells tested showed functional expression when the a 8 
subunit was co-expressed with RIC3 and the responses were of greater magnitude 
(Chapter 4, Section 4.3.1).
Radioligand binding assays demonstrate that cell expressing the a3 and (32 subunits 
show low levels of specific binding in comparison to other subunit combinations 
such as a4|32 (Xiao and Kellar, 2004; Lansdell et a l , 2005). When a3 and |32 
subunits were co-expressed, only two out of ten cells showed small whole-cell 
responses (Chapter 4, Section 4.4). When RIC3 was co-expressed with the a3 and 
(32 subunits an increase in radioligand binding and an increase in calcium influx 
upon application of nicotinic agonist has been demonstrated (Lansdell et a l , 2005).
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When tested with whole-cell patch-clamp recording, the whole-cell responses were 
larger and a higher proportion of cells responded to agonist in the presence of RIC3 
(Chapter 4, Section 4.4.1).
Additionally, when co-expressed with RIC3, an increase has been reported in the 
number of radioligand binding sites, and in agonist-induced intracellular calcium 
influx in cells expressing a4(32, a4|34 or a3(34 nAChRs (Lansdell et al., 2005). 
These results and the results in this thesis indicate that RIC3 is a general nAChR 
associated protein that acts to increase the number of functional receptors. 
Previously reported nAChR-accessory proteins (Calnexin, BiP and 14-3-3r|) have 
been demonstrated to up-regulate only muscle nAChR (Chang et al., 1997; 
Forsayeth et al., 1992) and a4(32 receptors (Jeanclos et al., 2001).
The RIC3 protein also affects the functional expression of 5-HT3A receptors (Chapter 
4, Section 4.5). Co-expression of human RIC3 with murine 5-HT3Ahas been shown 
to result in the loss of functional expression of this receptor when expressed in 
Xenopus oocytes (Halevi et a l , 2002). In contrast, when this receptor is expressed in 
a mammalian cell line (HEK), there is an increase in radioligand binding (Doward 
2005) and cell surface receptors (Cheng et al., 2005) when the 5-HT3A subunit is co­
expressed with RIC3. There are differences in the effect of RIC3 upon the 
expression of 5-HT3A, depending on the species of RIC3, the species of 5-HT3A and 
the technique used to examine the levels of expression. For example, compared to 
expressing the subunit alone, co-expression of human 5-HT3A with human RIC3 
gave a greater number of surface receptors, but the same level of functional 
expression as assayed by agonist-induced calcium influx (Doward, 2005). There is 
no difference in cell surface receptor expression with murine 5-HT3A alone and with 
human RIC3 (Doward, 2005); however agonist-induced calcium influx is lower 
when human RIC3 is co-expressed with the murine 5-HT3A subunit (Doward, 2005; 
Chapter 4, Section 4.5.1). This thesis examines the functional expression of the 5- 
HT3A receptor by whole-cell patch-clamp recording as an alternative method to the 
calcium-influx assay.
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All cells expressing one of the 5-HT3A subunits (human or murine) responded to 5- 
HT (Chapter 4, Section 4.5). Upon co-expression of C. elegans RIC3, there was an 
increase in the size of whole-cell responses from cells expressing the human 5-HT3A 
subunit, but no difference in cells expressing the murine 5-HT3A subunit. In 
contrast, when human RIC3 was co-expressed with the human or murine 5-HT3A 
subunit there was no difference in the size of the whole-cell response from human 5- 
HT3 A receptors, but a decrease in response from the murine 5-HT3a receptor (Chapter 
4, Section 4.5.1). Thus this thesis shows that no generalization can be made about 
the action of RIC3 upon the 5-HT3A receptor. In the future it would be interesting to 
clone the murine RIC3 protein and see what effect it would have upon the murine 5- 
HT3A subunit. Also, since the cell line used in these experiments was of human 
origin, it would be interesting to investigate if there were any difference if a murine 
cell line was used.
It has been demonstrated that if the ratio of human RIC3 to the human 5-HT3A 
subunit is increased, the level of functional expression also increases (Cheng et al., 
2005). The RIC3 protein (when in sufficient quantities) may increase the level of 
functional expression of the human 5 -HT3A subunit, but may act differently at the 
murine 5-HT3A subunit. When expressed in Xenopus oocytes the lack of detectable 
functional murine 5-HT3A receptors when co-expressed with human RIC3 has been 
attributed to inhibition of export of the receptor to the plasma membrane. This 
requires an extracellular isoleucine close to the first transmembrane receptor domain 
(Castillo et a l , 2005). It would be interesting to see if loss of this isoleucine also 
abolished the effect of co-expression of human RIC3 in HEK tsA201 cells. As yet 
there is no hypothesis as to how RIC3 enhances the functional expression of human 
5-HT3A. By using the chimeric subunits described in Chapter 3, studies can be 
performed in the future to examine which part of the subunits are necessary for both 
the interaction with RIC3 and the resultant effect on function.
Human RIC3 has been shown to co-assemble with the cx3, a4, (32 and (34 nAChR 
subunits and the 5-HT3A subunit (Lansdell et a l , 2005; Williams et a l,  2005; Cheng 
et a l,  2005). This suggests that, as for the a l  subunit, the action of RIC3 upon these 
subunits may involve direct interaction with the RIC3 protein. The co-assembly of
157
human RIC3 and human 5-HT3A has been proposed to be transient as RIC3 and 5- 
HT3A co-immunoprecipitate only a few hours after metabolic labelling (Cheng et a l, 
2005). In this case RIC3 may promote some posttranslational modifications, for 
example palmitoylation (Drisdel et a l , 2004) that is required for forming the correct 
receptor structure or transport to the cell surface (Cheng et a l , 2005).
The RIC3 protein has been demonstrated to have multiple actions. It increases the 
number of nAChRs and their transport to the membrane, but also acts on the 5-HT3A 
subunit, and affects the level of functional expression. In the future, the chimeras 
constructed between the rat a  7 and murine 5-HT3A subunits can be co-expressed 
with RIC3 to identify which regions of the subunits are important for the association 
with RIC3 and the effect that RIC3 has upon the receptor subunit. It has been 
reported that amino acids in the putative amphipathic helix in the large cytoplasmic 
loop of the human a l  subunit are necessary for the positive effect of RIC3 upon the 
number of surface a-BTX binding sites (Castillo et a l, 2005). This intracellular 
loop region does not affect the efficiency of protein folding of the a l  subunit as 
demonstrated in Chapter 3 (Section 3.3.2), where exchange of the 5-HT3A and a l  
M3-M4 sequences did not effect the number of radioligand binding sites. However, 
this region may important for the mechanism by which RIC3 enables a l  to fold to 
form a-BTX binding sites.
5.2 Functional characteristics of the homomeric a 7  and 5-HT3A 
receptors
The a l  nAChR subunit and 5-HT3A subunit have approximately 33% sequence 
similarity, but they have very different functional properties, thus it was of interest to 
examine which of the sequence differences were important for function. Out of the 
thirteen chimeras constructed from the a l  and 5-HT3A subunits in this study, three 
were functional (5-HT3A3'4L°op'e'7) a 7 v201'5'HT3A and a7 ‘>™-5-HT3A) Jhe functional 
characteristics of these three chimeras were compared with the 5-HT3A receptor 
(Chapter 3, Section 3.6) and the a l  receptor (co-expressed with RIC3; Chapter 4, 
Section 4.6).
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5.2.1 Reversal potential and rectification
There was no significant difference in the reversal potential of the homomeric a l  
and 5-HT3A receptors, and the three chimeras also had similar reversal potentials. 
The a l  receptor shows much greater rectification then the 5-HT3A receptor, and the 
chimeras all resembled the 5-HT3A receptor. The 5-HT3A subunit and the three 
chimeras share only the four transmembrane domains. Thus the results in this thesis 
suggest that this is the region that determines the rectification characteristics of these 
receptors. Surprisingly, rectification is not affected by the large cytoplasmic loop, 
even though this region contains amino acids that affect the single-channel 
conductance (see below).
5.2.2 Desensitization characteristics
The a l  receptor desensitizes approximately 40 times faster than the 5-HT3A receptor. 
The 5-HT3A3'4Loop’a7 chimera had desensitization characteristics similar to the 5-HT3A 
receptor, but the a 7v201-5'HT3A ancj a y4TM-5-HT3A chjmeras rates 0f desensitization 
that were in between the a l  and 5-HT3A receptors. Also the rate of desensitization 
was significantly faster for the a 7V201-5-HT3A chimera, compared to the a 74™-5-HT3A 
chimera. These results demonstrate that multiple regions may determine the rate of 
desensitization. Both the a l  and 5-HT3A subunits and the 5-HT3A3"4Loop’a7 chimera 
desensitize to a greater degree than the a 7v201'5'HT3A an(j a 74TM-5-HT3A cj1imeraS; 
which had a high level of residual activation after desensitization (-30%). Having 
the N-terminal extracellular region of a l  but the transmembrane domains of 5-HT3A 
results in a receptor that does not fully desensitize even upon long agonist 
applications.
5.2.3 Single-channel conductance
The single-channel conductance of the a l  receptor is approximately 50 times greater 
than that of the receptor formed form 5-HT3A subunits. Previously the 
transmembrane domains, and particularly M2, have been postulated to determine the 
single-channel conductance of nicotinic receptors (Imoto et al., 1986). However the 
results of this thesis and also work published by Kelley et al (2003) suggest 
otherwise. Using noise analysis to determine the single-channel conductance, the 
three chimeras were shown to have significantly greater single-channel conductance
159
than the 5-HT3A receptor, despite all four constructs containing the same 
transmembrane domains. Inclusion of the large cytoplasmic loop of the a l  receptor 
(comparing 5-HT3A to 5-HT3a34Loop'°7, and a 7V20|-5-HT3A t0 aytTM-s-HTBA^  increased
the conductance ten fold, and inclusion of the N-terminal domain of a l  (comparing 
5-HT3A to a 7V2°'-5-HT3A 5 _ H X 3 A 3-4Loop-„7 t 0  a 7 4TM-5-HT3A)  increased the conductance
two fold. Thus, both the large cytoplasmic loop and the N-terminal domain are 
involved in determining the single-channel conductance of the a l  and 5-HT3A 
receptors. It has been demonstrated that the low conductance of the 5-HT3A receptor 
can be attributed to three arginine residues in the large cytoplasmic loop (Kelley et 
al., 2003), and the a l  sequence contains none of these arginine residues.
5.3 Sum m ary
The aim of this thesis was to further investigate structural domains responsible for 
the inefficient folding, assembly and functional expression of the a l  subunit. The 
exchange of a minimum of two domains of the a l  subunit cDNA sequence 
(including Ml to M3 and M4 to the end of the subunit) for that of the 5-HT3A 
subunit, created chimeras that were able to form functional receptors. Thus the 
domains that dictate the correct folding and assembly of these receptors have been 
narrowed down. It was also demonstrated that the transmembrane domains 
determine the rectification of the receptors and that the large cytoplasmic loop and 
the N-terminal domain determine the single-channel conductance.
The a l  subunit forms functional receptor in some mammalian cell lines, and this has 
recently been suggested to be due to the presence of the RIC3 protein. This thesis 
demonstrates that the a l  subunit forms functional receptors only when co-expressed 
with RIC3 in HEK cells. It has also been demonstrated that RIC3 increases the 
functional expression of other nicotinic receptors (a8 and a3(32), and influences the 
functional expression of the 5-HT3A receptor.
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